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General Introduction
1.1 
HISTORICAL OVERVIEW
On December 23, 1954, Ronald Herrick donated a kidney to his identical twin brother Richard 
who was dying of renal failure. The kidney transplant produced urine immediately and in 
February 1955, Richard Herrick was discharged from hospital. He survived for another nine 
years (at which time his kidney allograft failed from recurrent glomerulonephritis), married 
the nurse who attended him, became father of two children and returned to work as a radio 
and television engineer. His brother Ronald lived on for more than 50 years after donating 
his kidney.1-3
In the years following this first successful human kidney transplantation, several more 
kidney transplants were performed between identical twins. Most of these patients had a 
return of normal kidney function and survived for a considerable period of time.4 However, 
it was clear from previous experience that if kidney transplantation was to be extended 
successfully to genetically non-identical individuals, suppressing the recipient’s immune 
system was necessary in order to prevent acute rejection. Early after World War II, a small 
number of human kidney transplantations had been performed in Europe and the United 
States. The recipients had received no immunosuppression except for a few cases in which 
short courses of ACTH or cortisone had been given. Although some of these kidney allografts 
did function for a limited period of time -most likely as a result of profound uremia5- most 
of the transplanted kidneys were acutely rejected or destroyed as a result of thrombosis or 
infection, and none of the recipients survived for a long period of time.3,6-10
The first attempts at immunosuppression included sublethal total body irradiation. By use of 
this treatment, which achieved immunosuppression by producing profound bone marrow 
aplasia, several kidneys were transplanted successfully. However, many patients developed 
overwhelming infections and despite this heavy immunosuppressive treatment, acute 
rejection still occurred frequently. As a result, the large majority of these patients died from 
sepsis or renal insufficiency.3,11-13 Subsequently, total body irradiation was largely abandoned 
and the search for less toxic methods of immunosuppression continued. A major breakthrough 
came with the discovery of the immunosuppressive properties of 6-mercaptopurine in the 
late 1950s. Already in clinical use as an anticancer agent, 6-mercaptopurine was shown by 
Schwartz and Dameshek to suppress the immune response against human serum albumin in 
rabbits.14,15 In addition, the drug prolonged the survival of kidney allografts in dogs although 
the actual survival of the animals was rather poor.16,17 Shortly thereafter, 6-mercaptopurine 
and its pro-drug azathioprine (Imuran®), which was considered less toxic, were used in 
humans for the suppression of the immune response following kidney transplantation.13,18,19 
The initial results obtained with chemical immunosuppression were promising and in the 
words of Francis D. Moore, “gentle, feasible and practical” in comparison with the “tough, 
sledge-hammer medicine of whole body irradiation”.13
During the next fifteen years, azathioprine became the base immunosuppressant for the 
prevention of acute rejection after kidney transplantation. As such, it was mostly used in 
combination with glucocorticoids with or without the addition of cytotoxic agents (such as 
12
Chapter 1
cyclophosphamide), actinomycin C or the newly-developed antilymphocyte serum. Besides 
the development of pharmacological immunosuppression, the 1960s and 1970s were further 
characterized by improvements in dialysis technique and refinements in the management of 
patients with renal allografts, a better understanding of transplantation biology, advances in 
preservation and storage of organs, the clinical introduction of tissue typing and cytotoxicity 
assays, as well as the first attempts at transplanting liver, lung and heart.3,20-24 However, as 
the one-year kidney allograft survival rates increased to between 50% and 60% during this 
period, the downside of immunosuppression also became increasingly evident.21,22,25 Serious 
and often fatal and atypical infections developed frequently among transplant recipients.3,21 
The incidence of cancer among transplanted patients was much higher as compared with the 
general population. Finally, all immunosuppressive drugs had their specific toxicities which 
resulted in considerable morbidity and an impaired quality of life.3
In the early 1970s, new strains of fungi imperfecti were isolated as part of an antifungal 
screening program in the microbiology department of Sandoz Ltd., Switzerland, from soil 
samples from Wisconsin in the United States (Cylindrocarpon lucidum Booth) and from 
the Hardanger Vidda in Norway (Sandoz employees away on business trips or on holiday 
used to take along plastic bags for collecting such samples). The Norwegian strains were 
originally classified as Trichoderma polysporum (Link ex. Pers.) Rifai, but were later termed 
after their correct taxonomic name Tolypocladium inflatum Gams.26 Both strains turned 
out to produce unique metabolites that were called cyclosporins.26,27 After perfecting and 
scaling up the fermentation process of Tolypocladium inflatum Gams, sufficient quantities 
of the mixture of cyclosporins (designated as compound 24-556) were produced for the 
initial screening of its pharmacologic activity. Compound 24-556 possessed only limited 
anti-fungal and no anti-tumor activity but it was remarkably immunosuppressive and non-
toxic in rodents. Over the next few years, the major active metabolite of compound 24-
556, cyclosporine A, was isolated and chemically characterized and studied further for its 
immunosuppressive effects.26,28-30
The immunosuppressive actions of cyclosporine A [now named cyclosporin(e) or ciclosporin] 
were first described by Jean-François Borel and colleagues.31 They demonstrated that 
cyclosporine suppressed alloantibody formation, delayed skin allograft rejection in mice 
and graft-versus-host disease in mice and rats. In addition, the drug inhibited experimental 
allergic encephalitis and Freund’s adjuvant-induced arthritis in rats (animal models for 
multiple sclerosis and rheumatoid arthritis, respectively). Importantly, and in contrast to 
cyclophosphamide and azathioprine, cyclosporine was not myelotoxic in immunosuppressive 
doses.31 This classic study demonstrated that cyclosporine suppresses antibody- and cell-
mediated immunity, is highly selective for (T-) lymphocytes, is not lymphocytotoxic but 
affects the induction phase of lymphocyte proliferation. 
After the effectiveness of cyclosporine in preventing acute allograft rejection had been 
demonstrated further in several other animal experiments,32-34 Roy Y. Calne and colleagues 
in Cambridge were the first to use the drug in human renal transplant patients.35 In 1978, 
they reported on seven recipients of a kidney transplant from a mismatched cadaveric donor 
who had been treated with fixed-dose cyclosporine, initially as the sole immunosuppressive 
agent. Five of these patients were discharged from hospital with functioning grafts. Two of 
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these patients never required glucocorticoids although a cyclophosphamide analogue was 
added to the cyclosporine treatment in all but one. One patient died because of disseminated 
Aspergillosis and Candidiasis; Another patient required a nephrectomy because of 
pyelonephritis in the graft. Importantly, rejection episodes were of mild to moderate degree 
and “none of the patients had typical rejection crises with swollen allografts, pyrexia, and 
severe histological changes”.35 In the same issue of The Lancet, Powles and co-workers36 
showed that cyclosporine was effective in treating acute cutaneous graft-versus-host disease 
after bone marrow transplantation. However, four of the five patients died because of liver 
failure.36
One year later, Calne et al.37 reported on their continuing experience with cyclosporine 
in thirty-four organ transplant recipients who received a total of thirty-two kidneys, two 
pancreases and two livers. At the time of publication, twenty-six kidney allografts were 
still supporting life, among which three after more than one year. Fifteen patients had not 
required the use of any other immunosuppressive drug and the authors concluded that 
“ … in man cyclosporine A is the most powerful immunosuppressive agent so far used in the 
management of patients with cadaveric renal allografts ”.37
Despite these unprecedented results, there was, however, reason for concern. In the first 
patients receiving cyclosporine, the incidence of infectious complications and lymphomas 
was high. Second, cyclosporine proved to be nephrotoxic, a side effect which had not been 
observed in animal studies. As experience with the use of cyclosporine grew, it became 
clear that the initial dose of 25 mg/kg bodyweight per day -which was based on Calne’s 
experience in dogs and pigs- was too high, resulting in overimmunosuppression and 
inhibition of kidney function. Since the nephrotoxic effects of cyclosporine were unknown 
at the time, impaired renal function was interpreted initially as acute rejection and 
additional immunosuppressive treatment was started, aggravating the already impaired 
renal function and further increasing the risk of infectious complications and lymphoma. 
By reducing the dose of cyclosporine (with or without the addition of low-dose prednisone), 
implementing several supportive measures (such as perioperative hydration and inducing 
forced diuresis), and early conversion to azathioprine-glucocorticoid combination therapy 
in case of cyclosporine-resistant rejection, much better results were obtained.38-40
Encouraged by these results, two multicentre trials were launched, one in Europe and one 
in Canada.41,42 Both studies compared the efficacy of cyclosporine (with starting doses 
of 17 and 10 mg/kg per day, respectively), either as monotherapy or in combination with 
prednisone, with conventional treatment, consisting of azathioprine plus glucocorticoids 
with or without the addition of antilymphocyte globulin or cyclophosphamide according 
to local protocol. These trials demonstrated that treatment with cyclosporine resulted in 
a marked improvement of transplantation outcomes. In cyclosporine-treated patients, 
the severity of acute rejection episodes was markedly decreased and graft survival at one 
year after transplantation ranged between 70% and 80% as compared with a graft survival 
of between 50% and 60% in the control group.41,42 The superiority of cyclosporine over 
conventional treatment was maintained with longer follow-up, with graft survival at 
three and five years after transplantation being roughly 15% higher in patients originally 
allocated to receive cyclosporine therapy.43-46 Importantly, the incidence of infections and 
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malignancies was not higher in cyclosporine-treated patients.43-46 Several other randomized 
trials that differed somewhat in their design compared with the European and Canadian 
studies, also demonstrated that cyclosporine-based immunosuppression had advantages 
over conventional immunosuppression as it resulted in a lower incidence of acute rejection 
and infections, and a reduced need to use glucocorticoids.47-49
In the fields of heart,50 liver,51 lung,52 and heart-lung transplantation,53 cyclosporine led to 
even more dramatic improvements in allograft- and patient survival and it was cyclosporine 
that first made these types of transplantation truly therapeutic interventions. After bone 
marrow transplantation, the use of cyclosporine resulted in faster engraftment and a lower 
incidence of severe graft-versus-host disease in comparison with methotrexate prophylaxis.54 
In addition, cyclosporine has been effective in the treatment of a number of autoimmune 
diseases including psoriasis,55,56 rheumatoid arthritis,57 colitis ulcerosa,58-60 membranous 
glomerulonephritis,61 asthma,62,63 and uveitis.64
Although cyclosporine revolutionized transplantation medicine and offered new 
possibilities for treating autoimmune disease, there were several disadvantages to its use. 
First, in addition to being nephrotoxic, the drug turned out to have several other side effects 
including the induction of glucose intolerance, hypertension, and hyperlipidemia. Second, 
the pharmacokinetics of cyclosporine proved to be highly variable and its therapeutic window 
narrow, complicating its clinical use. As a result, other pharmaceutical companies developed 
an interest in transplantation medicine and sought to develop new immunosuppressive 
agents. In 1984, in a manner very much similar to the discovery of cyclosporine, a new 
strain of the bacterium Streptomyces was isolated from a soil sample obtained from Mount 
Tsukuba, Japan by workers of the Fujisawa Pharmaceutical Company. This strain, designated 
Streptomyces tsukubaensis, produced a metabolite, FK-506 or tacrolimus, that possessed 
powerful immunosuppressive activity both in vitro and in vivo.65-68
Thomas E. Starzl and his group in Pittsburgh were the first to test tacrolimus clinically. The 
new agent was remarkably effective as salvage therapy for hepatic allografts that rejected 
under conventional, cyclosporine-based immunosuppression. Encouraged by these results, 
tacrolimus was then used as the primary immunosuppressant in a pilot study in patients 
undergoing liver- or kidney transplantation. Compared with historical, cyclosporine-treated 
controls, tacrolimus reduced the incidence of acute rejection and lowered the requirement 
for glucocorticoids.69,70 These findings caused a sensation and increasing numbers of patients 
in need of tacrolimus “rescue therapy” were referred to Pittsburgh from other transplant 
centres. Articles in the press, hailing tacrolimus as a wonder drug, contributed further to 
the hype.3
Yet, reports indicating toxicity of tacrolimus were reason for concern.71 In addition, Starzl’s 
group was the only one to have access to the drug leading to scepsis among other transplant 
physicians and even allegations of observer bias.3,72 The US Food and Drug Administration 
placed tacrolimus on the fast-track for evaluation but also mandated randomized controlled 
trials comparing the new agent with conventional immunosuppression as a prerequisite for 
approval. This decision, as well as the (design of the) two subsequent trials themselves, led to 
heated debates.72,73 At the start of the multicentre trials in 1990, the Pittsburgh randomized 
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trial comparing tacrolimus plus prednisone to cyclosporine plus prednisone therapy, was 
half-finished (Starzl and co-workers were forced to perform this trial by the institutional 
review board of the Pittsburgh University).74,75 The preliminary results demonstrated that 
tacrolimus halved the incidence of acute rejection compared to cyclosporine-treated liver 
transplant recipients. Considering the superiority of tacrolimus over cyclosporine to be 
settled, the Pittsburgh group condemned the two phase III multicentre trials as “cruel” and 
“unethical”.73-75
The European and American multicentre, randomized, controlled trials demonstrated 
that compared to a cyclosporine-based immunosuppressive regimen, tacrolimus was 
associated with significantly less acute and refractory acute rejection episodes after liver 
transplantation. Patient and graft survival were comparable in both groups but the incidence 
of neurological complications and disturbances of glucose metabolism were more common 
in the tacrolimus group.76,77 These studies were followed by several trials comparing 
the efficacy and safety of tacrolimus to that of the oil-based cyclosporine formulation 
(Sandimmune®) in kidney transplant recipients.78-80 Taken together, these trials showed 
that immunosuppression with tacrolimus resulted in comparable patient and graft survival 
at one year after renal transplantation compared with cyclosporine. However, tacrolimus 
significantly reduced the incidence of acute rejection and the need for antilymphocyte 
antibodies to treat rejection. The risk to develop post-transplant diabetes mellitus (PTDM) 
was about five times higher in patients receiving tacrolimus.81 More recently, tacrolimus has 
been compared head-to-head with the microemulsified cyclosporin formulation (Neoral®), 
either in the context of conventional immunosuppressive regimens or together with newly-
developed immunosuppressive agents such as mycophenolate mofetil (MMF). A meta-
analysis comparing the positive and negative effects of tacrolimus and cyclosporin, and 
incorporating 30 trials, concluded that tacrolimus is superior to cyclosporine in preventing 
acute rejection after kidney transplantation. Importantly, tacrolimus treated patients had an 
improved short-term graft survival (censored for death) but this is at the expense of a higher 
incidence of PTDM.82
Over the past decade, cyclosporine and tacrolimus have remained the cornerstone of 
immunosuppressive therapy after solid organ transplantation. In the United States there 
has, however, been a shift towards a more frequent use of tacrolimus after kidney and liver 
transplantation.83 At present, it is unclear if the reduction in the number of acute rejection 
episodes associated with the use of tacrolimus translates into improved long-term graft 
survival or whether its beneficial immunologic effects are outweighed by its potential to 
cause an excess of PTDM. From recent data it appears that in the current dosing strategies, 
the efficacy of both drugs is similar.84-86 The choice for either cyclosporine or tacrolimus 
should therefore depend on the risks of an individual patient.
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1.2  
PHARMACODYNAMICS OF CALCINEURIN INHIBITORS
Cyclosporine and tacrolimus exert their immunosuppressive effect mainly by inhibiting the 
activation and clonal expansion of T lymphocytes, although these agents also have inhibitory 
effects on B lymphocytes, natural killer cells and dendritic cells.87-89 At the molecular level, 
these effects are mediated through the inhibition of the enzyme calcineurin (CN) and hence 
cyclosporine and tacrolimus are collectively referred to as calcineurin inhibitors (CNIs).
1.2.1 T LYMPHOCYTE ACTIVATION
Binding of a T cell receptor (TCR) complex to its major histocompatibility complex (MHC)-
peptide ligand is followed by the aggregation of several other pairs of TCR-peptide-MHC 
complexes and clustering of TCRs with their co-receptors CD4 or CD8. In addition, 
adhesion and co-stimulatory molecules on the T lymphocyte and antigen-presenting cell 
bind to their respective ligands to form an immunological synapse.88,90 The co-aggregation 
of TCRs leads to the activation of a series of tyrosine kinases (first the Src-family kinases Lck 
and Fyn and then ζ chain-associated protein 70) which in turn activate several major signal 
transduction pathways, including the phospholipase C (PLC)-γ pathway. PLC-γ activation 
results in the release of inositol triphosphate from the cell membrane which increases the 
intracytosolic calcium concentration by releasing calcium from the endoplasmic reticulum 
and by triggering the opening of calcium channels in the plasma membrane.87,88
A sustained rise in the intracellular calcium concentration leads to the activation of calmodulin 
and the serine/threonine phosphatase CN. Calcineurin is a heterodimer consisting of a 
catalytic subunit, calcineurin A (CNA), and a “regulatory” subunit, calcineurin B (CNB). The 
latter contains four calcium binding motifs, whereas CNA contains a calmodulin-binding 
domain and the so-called autoinhibitory domain. Upon binding of calmodulin and calcium 
to the A and B subunits of CN, respectively, a conformational change takes place which 
exposes the active site on CNA by releasing the autoinhibitory domain from the active site 
cleft.91,92 Activation of CN allows the enzyme to dephosphorylate its substrate, the nuclear 
factor of activated T cell (NFAT) family. These proteins are located in the cytosol and inactive 
when phosphorylated at serine/threonine residues. Upon CN-mediated dephosphorylation, 
they localize to the nucleus where they complex with other transcriptional regulatory 
proteins such as activator protein-1 and induce the transcription of several genes required for 
T lymphocyte activation and proliferation, including interleukin (IL)-2, IL-4, IL-2 receptor, 
CD40 ligand, and interferon gamma (IFN-γ).93,94 Recent data suggest that CN co-localizes 
with NFAT to the nucleus where it protects NFAT from kinases which would otherwise re-
phosphorylate NFAT and cause it to be exported from the nucleus.87,88,91,92
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1.2.2 MECHANISMS OF CALCINEURIN  
INHIBITOR-MEDIATED  IMMUNOSUPPRESSION
Cyclosporine and tacrolimus inhibit CN after binding to their cytoplasmic receptors named 
immunophilins.96-98 Each agent binds a different group of immunophilins: cyclosporin 
to the cyclophilins, tacrolimus to the FK-binding proteins (FKBP).99-101 Cyclophilin and 
FKBP are peptidyl-prolyl cis-trans isomerases which are thought to be involved in protein 
folding.100-103 Inhibition of immunophilin rotamase activity is, however, not responsible 
for the immunosuppressive effect of CNIs.104,105 Rather, the cyclosporin-cyclophilin and 
tacrolimus-FKBP complexes bind to CNA, thereby blocking its phosphatase activity.96-98 As 
a result, CN is unable to dephosphorylate NFAT, which remains in the cytoplasm and is 
unable to activate genes required for T lymphocyte activation.93,96-98
In addition to inhibiting the CN-NFAT pathway, cyclosporine and tacrolimus appear to 
exert their immunosuppressive effects by several other mechanisms, as well. Recently, it was 
demonstrated that these agents interfere with the activation of the JNK and p38 signaling 
pathways.106 Moreover, one of the tacrolimus-binding immunophilins, FKBP-52, is associated 
with the cytoplasmic glucocorticoid receptor complex. By binding of tacrolimus to FKBP-52, 
glucocorticoid receptors may be released from the complex and migrate to the nucleus where 
they bind to glucocorticoid response elements in the regulatory regions of certain genes 
(resulting in a steroid-sparing or -mimetic effect).107 Ultimately, the result of interfering by 
CNIs with these “alternative” pathways is, again, suppression of the transcription of genes 
involved in T lymphocyte activation and proliferation.
1.2.3 TOXICITY
In addition to T lymphocytes (which have a rather low CN content), CN is widely distributed 
throughout the human body. The protein is expressed, among others, in the brain, B 
lymphocytes, spleen, thymus, platelets, heart, liver, testes, pancreas, and the kidney.91,92 Apart 
from T lymphocyte activation, numerous functions have been identified for CN, including 
among others, a role in the programmed cell death of neuronal cells, cardiac morphogenesis 
and the induction of cardiac hypertrophy, neutrophil migration, and regulation of the Na+, 
K+-ATPase in kidney and brain.91,92 Not surprisingly, cyclosporine and tacrolimus display 
considerable toxicity (Table 1.1). The clinically most important side effects will now be 
shortly discussed.
The nephrotoxic effects of CNIs were already recognized in the first clinical trials 
exploring their immunosuppressive potential.38,70 Almost three decades later, the intrinsic 
nephrotoxicity of cyclosporine and tacrolimus remains the Achilles heel of CNI-based 
immunosuppression. Clinically, an acute and a chronic form of CNI-induced nephrotoxicity 
can be distinguished.108 Acute nephrotoxicity usually occurs within several days after starting 
CNI treatment. In patients who have received early malfunctioning grafts (for example as a 
result of prolonged ischemia time or when a kidney from an older donor is transplanted) it 
may present as an acute oligoanuric syndrome (delayed graft function). Acute CNI-induced 
nephrotoxicity can also present as a rise in serum creatinine that may resemble other causes 
of early graft dysfunction. In general, acute CNI-induced nephrotoxicity is rapidly and 
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completely reversible upon dose reduction or CNI withdrawal.108 Pathophysiologically, it 
is characterized by constriction of the afferent glomerular arteriole leading to a decreased 
renal plasma flow and a reduction of the glomerular filtration rate.109 This change in vascular 
tone appears to result from an imbalance in the secretion and metabolism of the vasodilatory 
prostaglandins and nitric oxide, and the vasoconstrictive thromboxane and endothelin, as 
well as an increased activity of the sympathic nerve system. Second, CNIs have been reported 
to cause mesangial cell contraction thereby altering glomerular permeability. Finally, CNIs 
may interfere with normal tubular function causing sodium retention and edema, reduced 
excretion of potassium and uric acid (sometimes leading to hyperkalemia or gout), increased 
urinary magnesium excretion, and hyperchloremic metabolic acidosis.108,110,111
Table 1.1 Side of effects of the calcineurin inhibitors cyclosporine and tacrolimus
Alopecia §
Gastrointestinal disturbances
Gingival hyperplasia †
Hemolytic uremic syndrome
Hepatotoxicity
Hyperkalemia
Hyperlipidemia
Hypertension
Hypertrichosis / hirsutism †
Hyperuricemia
Hypomagnesemia
Impaired glucose tolerance ‡
Nephrotoxicity
Neurotoxicity
Pancreatitis
§ Alopecia has been reported to occur more often during the use of tacrolimus
† These side effects occur more often during cyclosporine treatment
‡ The risk of developing diabetes mellitus is higher with tacrolimus than with cyclosporine 
Chronic CNI-induced nephrotoxicity is associated with prolonged use of these agents 
and has been observed after all types of transplantation, as well as during treatment of 
autoimmune disease.108,112-114 The clinical course is characterized by a slow decline in renal 
function that may become stable at a certain level of renal insufficiency or progress to end-
stage renal failure. In addition, most patients have proteinuria and hypertension.108,112-115 In 
contrast to the acute form, chronic CNI-induced renal insufficiency improves little, if at 
all, after dose reduction or cessation of CNIs. Moreover, although the risk of developing 
chronic renal insufficiency has been associated with longer use and higher doses of CNIs, 
this has not been a universal finding.116 Some authors have speculated that the risk of CNI-
induced nephrotoxicity results from individual susceptibility rather than pharmacokinetic 
determinants.116-118 Histologically, chronic CNI-induced nephrotoxicity is characterized by 
extensive alterations in renal architecture that may include arteriolar hyalinosis, glomerular 
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sclerosis and thickening of Bowman’s capsule, tubular atrophy, and interstitial (striped) 
fibrosis. Its pathogenesis is far from being understood but an increased expression of the 
pro-fibrotic transforming growth factor (TGF)-β has been considered an important etiologic 
factor.107,108,112-115,117
A second CNI-related side effect which has raised concern over the long-term safety of 
these agents is their ability to induce arterial hypertension. Between 40% and 70% of renal 
transplant recipients were reported to have hypertension as a result of CNI use.111 The 
pathophysiology  of CNI-induced hypertension is unclear but appears to be closely linked to 
their nephrotoxic effects. Postulated mechanisms include sodium retention and expansion of 
the extracellular volume, direct vasoconstrictive effects (mediated through altered calcium 
responses, upregulation of angiotensin II receptors, changes in nitric oxide metabolism, 
etc.), as well as renal magnesium wasting.111,119 The treatment of CNI-induced hypertension 
should include general measures such as body weight reduction, salt restriction and (if 
possible) dose reduction of CNIs or glucocorticoids, and treatment with antihypertensive 
drugs. Although calcium channel blockers have gained considerable popularity in the 
treatment of CNI-induced hypertension,120 angiotensin-converting enzyme inhibitors and 
angiotensin II receptor blockers appear to be equally effective. The choice for a particular 
agent should therefore depend on the specific conditions in an individual patient. 
Cyclosporine and tacrolimus can both induce glucose intolerance, although the risk 
of developing PTDM appears to be higher in patients using tacrolimus.82 An incidence 
of PTDM as high as 30% has been reported and has even further increased in recent 
years.121,122 PTDM has been associated with a decreased quality of life and substantial 
morbidity resulting from an increased susceptibility to infections and most importantly, 
cardiovascular complications. CNIs may exert their diabetogenic effects by impairing the 
expression and secretion of insulin, whereas peripheral insulin resistance likely results 
from the concomitant use of glucocorticoids.123 Hypercholesterolemia and to a lesser extent 
hypertriglyceridemia, are other metabolic complications resulting from the use of CNIs. 
The mechanism may be related to decreased bile acid synthesis and down-regulation of 
low density lipoprotein receptor levels leading to decreased cholesterol clearance from the 
peripheral circulation.124 In view of the high incidence of cardiovascular morbidity and 
mortality after transplantation (among renal transplant recipients, cardiovascular disease 
accounts for one third of all deaths), aggressive management of hyperlipidemia and PTDM 
appears to be justified.
Neurotoxicity is another side effect of CNIs. The clinical features are diverse and CNI-related 
neurotoxicity may present as tremor of the hands, cortical blindness, a confusional state, 
speech abnormalities, and generalized tonic-clonic seizures. Neurotoxicity results from 
vasogenic edema which may progress to cytotoxic edema if exposure to CNIs is prolonged. 
Risk factors include hypocholesterolemia and hypomagnesemia.125
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1.3 
PHARMACOKINETICS OF CALCINEURIN INHIBITORS
1.3.1 MOLECULAR STRUCTURE, PHYSICO-CHEMICAL  
PROPERTIES AND DOSAGE FORMS
Cyclosporine A (cyclo[[(E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-
L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-
D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl]; C
62
H
111
N
11
O
12
) is a 
neutral, cyclic peptide consisting of 11 amino acids and has a molecular weight of 1203 
g/mol.28,29 Tacrolimus ((3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-8-allyl-5,6,8,11,1
2,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[(E)-2-[(1R,3R,4R)-
4-hydroxy-3-methylcyclohexyl]-1-methylvinyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetron; 
C
44
H
69
NO
12
 · H
2
O) is a macrolide lactone with a molecular weight of 804 g/mol.65 Both 
compounds are poorly soluble in water but dissolve rapidly in organic solvents such as 
ethanol and acetone.
Cyclosporine was originally formulated as an oily solution, available in a liquid form or 
in soft gelatin capsules (Sandimmune®, Novartis, Basle, Switzerland). On contact with 
gastrointestinal fluids, cyclosporine Sandimmune is formed into a crude oil-in-water droplet 
mixture which needs emulsification by bile salts before cyclosporine can be absorbed. As 
this emulsification step is dependent on food intake, bile flow and gastrointestinal motility, 
the oral bioavailability of cyclosporin Sandimmune is poor and highly variable among 
individuals. The new cyclosporine formulation (Neoral®, Novartis, Basle, Switzerland) 
which was designed to overcome these problems, consists of cyclosporine in a lipophilic 
solvent (corn oil mono-, di- and triglycerides) and a hydrophilic solvent [propylene glycol 
(E490)], together with a surfactant [polyoxyl-40 hydrogenated castor oil (Cremophor)], an 
antioxidant [DL-alpha-tocopherol (E307)] and alcohol.126 On contact with gastrointestinal 
fluids this formulation readily forms a homogeneous, monophasic microemulsion 
simulating a mixed micellar phase. This process is not dependent on the presence of bile and 
as a result, the absorption of microemulsified cyclosporin is more extensive and less variable 
compared with the oil-based solution.127-129 Recently, several generic forms of cyclosporine 
were introduced.130 In addition, inhaled cyclosporine was shown to be beneficial after lung 
transplantation.131
Tacrolimus [Prograf(t)®, Astellas Pharmaceuticals, München, Germany] is currently 
available as capsules for oral administration containing a solid dispersion of tacrolimus 
in hydroxypropylmethylcellulose.132 Recently, a slow-release tacrolimus formulation was 
developed. In addition, tacrolimus is available as a solution for intravenous administration 
which contains tacrolimus, alcohol and a surfactant (HCO-16).132 A tacrolimus ointment 
(Protopic®, Astellas Pharmaceuticals, München, Germany) has been approved for the 
treatment of atopic eczema.133
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1.3.2 ABSORPTION
In general, the absorption of cyclosporine and tacrolimus is poor and variable between 
individuals. Oral bioavailability (F) averages around 30% but may be as high as 90% or 
as low as 5%.127-129,134-136 The use of microemulsified cyclosporine is associated with a faster 
and higher absorption leading to an exposure that is around 40% higher when compared 
to the older oil-based formulation.137-139 Peak concentrations (C
max
) of (microemulsified) 
cyclosporine and tacrolimus are usually reached within 2 h although time-to-peak 
concentration (t
max
) varies considerably between patients and may be as long as 6 h.
The absorption of CNIs occurs predominantly in the small intestine and is affected by 
several factors.140 Concomitant ingestion of food may delay the absorption of CNIs and 
reduce exposure.141,142 Biliary diversion (as may occur after liver transplantation) does not 
appear to influence the absorption of tacrolimus. In contrast, an open T-tube leads to a lower 
cyclosporine absorption although this effect is smaller for the microemulsion as compared 
with the oil-based formulation.127-129,134-136 An important limiting factor for the absorption of 
CNIs is the expression on the intestinal surface of the multidrug-efflux pump Permeability-
glycoprotein (P-glycoprotein). P-glycoprotein belongs to the family of adenosine triphosphate 
(ATP)-binding cassette (ABC) proteins which are able to pump many xenobiotics, including 
CNIs, from the cytoplasm or cell membrane to the extracellular space.143,144 In the intestine, 
P-glycoprotein acts as a barrier to CNI absorption by actively extruding these drugs back 
into the gut lumen.145
1.3.3 DISTRIBUTION
Cyclosporine and tacrolimus distribute extensively into tissues and the cellular fraction 
of blood. The highest accumulation of cyclosporine has been observed in liver, pancreas, 
adrenal glands and fat tissue with lower concentrations in kidney, brain and heart.108,127-129 
Tacrolimus distributes in lung, spleen, heart, kidney, pancreas, brain, muscle and liver.134-136 
In human blood, cyclosporine and tacrolimus are mainly distributed into erythrocytes and 
leukocytes. Of the cyclosporine amount present in whole blood, 50% to 60% is located in 
erythrocytes, 10% to 20% is in leukocytes, and between 30% to 40% is located in the plasma. 
Compared with cyclosporine, tacrolimus appears to be more extensively located in the 
erythrocyte compartment with tacrolimus whole blood concentrations being about 15 to 35 
times those measured in plasma. Erythrocytes have a high content of FK-binding proteins 
and since tacrolimus does not bind to hemoglobin, this appears to be the driving force 
behind its distribution in blood. More than 90% of cyclosporine and tacrolimus present in 
plasma is bound to plasma proteins. Cyclosporine binds to lipoproteins, whereas tacrolimus 
associates mainly with albumin and α
1
-acid glycoprotein. Both agents cross the placenta and 
reach the fetal circulation and are detectable in breast milk. The volume of distribution (Vd) 
at steady state (based on whole blood measurements) is around 3 to 5 L/kg bodyweight and 
between 0.5 and 1.4 L/kg for cyclosporine and tacrolimus, respectively.108,127-129,134-136,146,147
22
Chapter 1
1.3.4 METABOLISM
Prior to elimination, cyclosporine and tacrolimus are almost completely metabolized 
(>99%). Biotransformation occurs mainly through the cytochrome P450 (CYP) isozymes 
CYP3A4 and CYP3A5 with hydroxylation and demethylation being the most important 
metabolic pathways.148-154 For cyclosporine, around 30 metabolites have been identified, the 
most important being AM1, AM4N and AM9, which have an immunosuppressive activity 
which is generally less than that of the parent compound. Tacrolimus is metabolized to 
at least 15 metabolites, the predominant being 13-O-demethyl-tacrolimus. 13-O-demethyl-
tacrolimus has an immunosuppressive activity that is one-tenth of that of the parent 
compound. The minor metabolite 31-O-demethyl-tacrolimus may have immunosuppressive 
activity comparable to that of tacrolimus.108,127-129,134-136,148,155,156
Biotransformation of cyclosporine and tacrolimus occurs primarily in the liver but also in 
the wall of the intestine and both agents are subject to a considerable first-pass effect.157-161 
The (whole blood) clearance of both agents varies considerably between patients but averages 
around 0.35 L/h/kg and 0.06 (range 0.03 - 0.09) L/h/kg for cyclosporine and tacrolimus, 
respectively. The corresponding terminal elimination half-lives are between 8 and 27 (range 
4 - 50) h for cyclosporine and 12 (range 4 - 41) h for tacrolimus.108,127-129,134-136,146,147
1.3.5 ELIMINATION
Cyclosporine and tacrolimus metabolites are mainly (>90%) biliary eliminated with around 
5% being excreted in the urine. Less than 1% of the absorbed amount of cyclosporine 
or tacrolimus is eliminated as unchanged drug in the urine.108,127-129,134-136,162 Hepatic 
impairment leads to a reduced clearance of CNIs. This is consistent with the fact that both 
agents are extensively metabolized before elimination. However, increased concentrations 
of tacrolimus metabolites have also been reported in patients with liver failure, indicating 
an impaired biliary excretion. In contrast, renal failure does not have an important effect on 
the clearance of both compounds. Given their large volumes of distribution, dialysis is not 
effective in clearing cyclosporine or tacrolimus.108,127-129,134-136
1.4  
THE NEED FOR CALCINEURIN INHIBITOR  
DOSE INDIVIDUALIZATION
When Roy Y. Calne and co-workers first treated patients with cyclosporine, the drug was 
dosed according to bodyweight and administered once daily (intramuscularly for the first 
few days after transplantation and then orally). This cyclosporine dosing strategy was 
extrapolated from the results of their experiments with the drug in several animal species. 
Formal dose-finding studies in humans were not performed. Although this bodyweight-
based cyclosporine dosing regimen was effective in preventing acute rejection after kidney 
transplantation, many patients developed severe infections or suffered from nephro- or 
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hepatotoxicity. Other patients, using the same (bodyweight-based) dose, did not experience 
cyclosporine-related side effects. A lowering of the cyclosporine dose proved to be effective 
in reducing the incidence of toxicity while efficacy was largely maintained.37
These observations suggested the existence of a cyclosporine concentration-effect 
relationship, as well as interindivual differences in the response to cyclosporine treatment. 
As experience with the use of cyclosporine increased, the practice of prescribing a fixed, 
bodyweight-based dose of cyclosporine was abandoned in favor of the more individualized 
strategy of therapeutic drug monitoring (TDM). TDM is the practice to adjust the dose 
of a drug according to blood concentration measurements, in order to reach a certain 
pre-defined (blood) concentration of that particular agent, the so-called target range. The 
rationale for performing TDM of CNIs will now be discussed, namely (1) the existence of a 
concentration-effect relationship (which is closer than the correlation between CNI dose and 
clinical events); (2) a narrow therapeutic window; and (3) large inter- and intra-individual 
variability in pharmacokinetics and pharmacodynamics. 
1.4.1 CONCENTRATION-EFFECT RELATIONSHIP (PHARMACOKINETICS-
PHARMACODYNAMICS INTERACTION)
In 1981, Keown and co-workers163 described 6 kidney transplant recipients in whom 
immunological reactivity and serum cyclosporine concentrations were measured in the early 
postoperative phase. They observed that the cyclosporine concentration in serum samples 
correlated positively with the ability of those particular samples to suppress the response to 
third-party cells in a mixed lymphocyte culture. Maintenance of patients at a cyclosporine 
serum predose concentration between 100 and 400 ng/mL resulted in almost complete 
suppression of immunological activity (as measured by various cytotoxicity assays) against 
their donors. One of the 6 patients experienced acute graft rejection. Serum cyclosporine 
concentrations during acute rejection were consistently below 100 ng/mL. When therapeutic 
cyclosporine concentrations were achieved (and methylprednisolone therapy was given), 
clinical and immunological resolution rapidly ensued.163
Since the publication of this landmark paper, other investigators have reported on 
the cyclosporine concentration-effect relationship and the poor correlation between 
cyclosporine dose and clinical outcomes. Halloran and others found that CN activity in 
whole blood or in peripheral blood leukocytes correlated inversely with the rise and fall of 
cyclosporine concentrations.164-166 In addition, the ex vivo expression of the IL-2 gene was 
inhibited by cyclosporine in a concentration-dependent manner.167 These experimental 
findings have been corroborated by clinical observations. Yee et al.,168 studying 179 recipients 
of bone marrow grafts, demonstrated that low cyclosporine predose concentrations were 
significantly associated with an increased risk of developing acute graft-versus-host disease. 
In an analysis of 1868 whole-blood cyclosporine pharmacokinetic profiles obtained from 
160 renal transplant recipients, Lindholm and Kahan169 found that a cyclosporine clearance 
>325 mL/min and the resulting lower cyclosporine concentrations, were associated with an 
increased incidence of acute rejection and poorer graft survival. Cyclosporine doses were 
not different between rejecting and non-rejecting patients.169
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A cyclosporine concentration-effect relationship has also been identified with regard to its 
side effects. Several investigators have reported that a high cyclosporine exposure increases 
the risk of developing acute nephrotoxicity.163,170-173 Other cyclosporine-related adverse events 
have been less intensely studied. An association between high plasma cyclosporine trough 
levels and hepatoxicity has been reported.170,174 In pediatric renal transplant recipients, a high 
cyclosporine exposure was found to correlate positively with the incidence of hypertrichosis 
and tremor but not gingival hyperplasia.175
For tacrolimus, comparable correlations between tacrolimus exposure and the incidence of 
side effects and acute rejection have been described. In a dose-ranging trial performed among 
120 de novo kidney transplant recipients, patients were randomized to a cyclosporine-based 
regimen or to one of three tacrolimus-based regimens designed to achieve low (5-14 ng/
mL), medium (15-25 ng/mL) or high (26-40 ng/mL) predose whole blood concentrations. 
Corresponding starting doses were 0.2, 0.3, and 0.4 mg/kg per day, respectively. In the group 
that was maintained at the highest predose concentration range, a 62% incidence of toxicity 
was observed whereas only 10% of the patients experienced an acute rejection episode. In 
the lowest target range group, the reverse was observed with 33% of patients experiencing 
tacrolimus toxicity and an acute rejection incidence of 21%. Based on these results, a 
tacrolimus concentration range between 5 and 15 ng/mL was considered to provide optimal 
efficacy with minimal toxicity.176 Other investigators have reported that higher tacrolimus 
exposure is associated with an increased risk of nephrotoxicity, severe neurotoxicity or the 
development of infections.177,178
1.4.2 THERAPEUTIC WINDOW
The therapeutic index, or the ratio between toxic and effective concentrations, of CNIs 
is small, equaling 1 or less. This notion is based on the fact that the CNI concentration-
effect relationship as discussed under 1.4.1, has not been a universal finding and appears 
not to be simply linear. For example, in the study by Lindholm and Kahan,169 which 
is one of the largest and most detailed studies investigating the concentration-effect 
relationship of cyclosporine performed to date, no significant relationship between 
either nephrotoxicity nor hepatotoxicity and cyclosporine pharmacokinetics could be 
identified. Some of these “inconsistencies” between studies may be related to, for example, 
differences in the analytical methods or sampling strategies used, patient characteristics 
or immunosuppressive regimens. However, even investigators who did find a relationship 
between CNI concentrations and the occurrence of acute rejection or a particular side 
effect, noticed that some patients in the “toxic” concentration range did not suffer from 
any side effects and had excellent renal function. Vice versa, low CNI exposure does not 
necessarily result in rejection in all patients. In other words, the optimal CNI concentration 
range is individually determined and toxic and effective concentrations show considerable 
overlap between patients. Nevertheless, target ranges for both cyclosporine and tacrolimus 
(for the “average” patient) have been determined. For tacrolimus, in the early postoperative 
phase, many centers aim for tacrolimus predose concentrations between 10 and 15 ng/mL, 
a 50% difference between minimally effective and toxic concentrations.179 For cyclosporine, 
Mahalati et al.,172,173 recommended a target area-under the concentration versus time-curve 
(AUC) between 0 and 4 h of 4400 to 5500 ng/h per mL for kidney transplant patients in the 
first months after kidney transplantation, corresponding to a 25% difference.
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1.4.3 VARIABILITY IN CALCINEURIN INHIBITOR  
PHARMACOKINETICS AND PHARMACODYNAMICS
A third reason for performing TDM for CNIs is their considerable interpatient variability 
in pharmacokinetics and pharmacodynamics. Studies investigating the pharmacokinetics 
of the oil-based cyclosporine formulation found bioavailability to average around 30% 
with a range between 10% and 90%, thus displaying a more than 9-fold variability. Time-
to-peak concentration was generally between 3 h and 4 h but was sometimes as long as 
22 h.137-139,146,169,180 In addition, Lindholm169 reported a 7-fold interindividual variability in 
cyclosporine clearance in renal transplant recipients, whereas Ptachcinski146 reported a 
mean clearance of 0.34 L/h/kg with a range between 0.036 and 1.43 L/h/kg, representing a 
40-fold difference. The findings of the latter study, however, may be somewhat limited by the 
fact that two renal transplant recipients used concomitant medication known to induce the 
CYP3A system.146,169
There also exists considerable within-patient variability for cyclosporine pharmacokinetics. 
Several investigators have observed a decrease in cyclosporine bioavailability and clearance, 
as well as a reduced cyclosporine dose-requirement with time after renal transplantation. 
These time-dependent changes occur mostly during the first 3 months after transplantation 
and have been attributed to changes in co-medication, alterations of gastrointestinal motility 
and changes in biochemical parameters such as hematocrit and serum albumin, which may 
alter cyclosporine distribution.138,169,171,181-184 However, even in stable patients there is marked 
intraindividual variability in cyclosporine Sandimmune pharmacokinetics. Kovarik et 
al.,137 studying 55 renal transplant patients who had used cyclosporine for a minimum of 
6 months, found intraindividual coefficients of variation (CV) in t
max
, (dose-adjusted) C
0
, 
C
max
, and AUC
0-12
 of 74%, 20%, 33%, and 18%, respectively.
Because of the large intra- and interindividual differences in the pharmacokinetics of 
cyclosporine Sandimmune, which are most pronounced during the absorption phase of the 
drug, the cyclosporine microemulsion formulation was developed. As outlined in paragraphs 
1.3.1 and 1.3.2, this formulation has self-emulsifying properties making its absorption less 
dependent on gastrointestinal motility or on the presence of bile or food. Consistent with 
its physico-chemical properties, absorption of microemulsified cyclosporine is generally 
higher, faster and shows less intraindividual variability (reviewed in references 127-129). 
In renal transplant recipients who were converted from the oil-based to the microemulsion 
formulation on a milligram-to-milligram basis, the use of microemulsified cyclosporine 
resulted in a t
max
 which was approximately 1 h shorter, and C
max
 and AUC
0-12
 increased 
by 59% and 30%, respectively.137 In studies in which patients were randomized to receive 
either the conventional or the microemulsion formulation, use of the latter resulted in a 
cyclosporine exposure that was on average between 40% and 60% higher and a shortening 
of t
max
 to between 1 and 2 h.138,139 Importantly, intraindividual variation in cyclosporine 
pharmacokinetics of patients using the microemulsion formulation was reduced compared 
with the oil-base formulation with a reduction of the intraindividual CV for t
max
 (-45%), 
C
max
 (-20%), and AUC
0-12
 (-10%).127-129,137-139 However, the interindividual variability in 
cyclosporine pharmacokinetics appears to be comparable between the two formulations or 
at most only modestly decreased in favor of microemulsified cyclosporine.138,139
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Tacrolimus also displays considerable interindividual variability in its pharmacokinetics 
and, comparable to cyclosporine, this variability is most marked during the absorption 
phase. Bioavailability is around 25% with a range of 4% to 93%. Interindividual differences 
in tacrolimus clearance appear to be less pronounced and have been reported to differ 3-
fold, whereas terminal elimination half-life may vary up to 10-fold between individuals.134,147 
These interindividual differences in tacrolimus pharmacokinetics are reflected by the wide 
range of oral tacrolimus dosages (1 to 44 mg/day) that were needed to maintain tacrolimus 
whole blood trough concentrations between 5 and 20 ng/mL as reported by Venkataramanan 
et al.134
Intraindividual variability of tacrolimus pharmacokinetics has been less well studied. 
The apparent oral clearance of tacrolimus decreases after transplantation resulting in 
a reduction of the tacrolimus dose requirement.147,185 These changes over time have been 
attributed to changes in hematocrit, serum albumin and tapering of glucocorticoids.186 Not 
surprisingly, intraindividual variability in tacrolimus pharmacokinetics is largest during 
the first few months after transplantation and stabilizes thereafter. Nonetheless, changes 
in tacrolimus dose requirement may occur up to one year posttransplant. Over this period, 
mean intraindividual CV of tacrolimus AUC
0-12
 is around 20%.178,185
Only limited data are available with regard to variability in CNI pharmacodynamics. No 
studies have been conducted at a population level to investigate the natural variability 
in CN activity or interindividual differences in the pharmacodynamic response to CNI 
administration. From several studies performed in a small number of individuals, it 
appears that the pharmacodynamic effects of CNIs display considerable variability between 
individuals. However, repeated administration of CNIs resulted in an inhibition of CN that 
was stable over time which argues against a significant adaptation to the pharmacodynamic 
effects of these agents.164-167
The consequence of the large variability in CNI pharmacokinetics is that, especially in the 
critical early phase after transplantation, large proportions of patients will have an exposure 
to CNIs that is well outside the therapeutic window.187 Because of the poor correlation between 
CNI dose and exposure, most transplant centers have long since adopted the strategy to 
start patients on a certain dose of CNIs (based on their bodyweight) followed by rapid dose 
adjustments based on whole blood concentration measurements. Yet, even with intensive 
TDM in the early postoperative period, many patients (percentages of up to 50% have been 
reported) will have CNI exposure that is outside of the target range.182,184,185,188,189 Obviously, 
this puts patients at risk for either acute rejection or toxicity. Pre-operative assessment of 
CNI pharmacokinetics has not solved these difficulties as the correlation between pre- and 
posttransplant values is poor.169 In addition, for reasons outlined in section 1.5, some patients 
may experience changes in CNI exposure longer after transplantation.
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1.5 
CAUSES OF VARIABILITY IN CALCINEURIN INHIBITOR 
PHARMACOKINETICS
1.5.1 P-GLYCOPROTEIN
P-glycoprotein, or ABCB1, belongs to subfamily B of the ABC membrane transporter family. 
The protein serves as an efflux pump capable of pumping a wide variety of endogenous 
and exogenous substances, including cyclosporine and tacrolimus, to the cell exterior.143 
P-glycoprotein is widely expressed throughout the human body and has, among others, 
been identified on the apical surface of mature enterocytes in the small intestine, at the 
canalicular surface of hepatocytes, the brush border of proximal tubular cells in the kidney, 
and on the luminal surface of endothelial cells in the brain. The specific tissue expression 
of P-glycoprotein suggests that its physiological role is to limit the exposure to potentially 
toxic substances and xenobiotics by reducing their absorption from the gut, facilitating their 
biliary or renal elimination, and by maintaining barriers between different compartments 
of the body (for example, the blood-brain barrier).144,145,190
The expression of P-glycoprotein is highly variable between individuals. In addition, the 
expression of P-glycoprotein has been shown to correlate with CNI pharmacokinetics. 
Several authors have reported cases histories of small bowel transplant recipients in whom 
CNI dose requirement was positively correlated with intestinal P-glycoprotein expression.191-
193 Similarly, in liver transplant recipients with a high intestinal P-glycoprotein expression, 
an approximately 2-fold higher tacrolimus dose was needed to reach target concentrations 
compared with patients expressing P-glycoprotein at a low level. Importantly, high P-
glycoprotein expression was associated with a significantly worse survival after liver 
transplantation (relative risk 1.63; 95% confidence interval 1.08-2.46).194 In stable kidney 
transplant recipients, 17% of the variability in apparent oral cyclosporine clearance 
was accounted for by intestinal P-glycoprotein content. In addition, the P-glycoprotein 
concentration in the gut explained 30% of the variability in cyclosporine C
max
.195
1.5.2 CYTOCHROME P450 3A
The activity of the isoenzymes CYP3A4 and CYP3A5, which are responsible for the metabolism 
of CNIs, displays considerable inter- and intraindivual variability.196,197 Analogous to P-
glycoprotein, variability in CYP3A activity explains part of the interindividual differences in 
CNI disposition. In kidney transplant recipients, more than half of the variability in apparent 
oral cyclosporine clearance was accounted for by variation in hepatic CYP3A activity as 
measured by the erythromycin breath test.195 There is also evidence that heterogeneity in 
intestinal CYP3A activity translates into considerable differences in CNI pharmacokinetics 
between individuals. Combined administration of tacrolimus or cyclosporine with either 
ketoconazole (a potent CYP3A inhibitor) or rifampin (a CYP3A inducer) to volunteers or 
renal transplant recipients resulted in marked changes in CNI bioavailability (increased and 
decreased with ketoconazole and rifampin coadministration, respectively). 
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The observed changes could not be explained by alterations in hepatic bioavailability or 
hepatic metabolism alone and were thus attributed to changes in intestinal CNI metabolism. 
However, as ketoconazole and rifampin may also affect intestinal P-glycoprotein activity, 
the exact contributions of CYP3A and P-glycoprotein to the observed alterations in CNI 
pharmacokinetics could not be dissected.158-160,198-200 Nonetheless, these data do indicate that 
variability in intestinal and hepatic P-glycoprotein and CYP3A activity explains much of 
the variation in the pharmacokinetics of CNIs.
1.5.3  DRUG INTERACTIONS
Drug interactions may also affect the outcome of CNI treatment. Interactions with other drugs 
may occur at any time during CNI therapy and can be divided into two types: pharmacodynamic 
and pharmacokinetic drug interactions.201,202 A pharmacodynamic interaction occurs when 
coadministration of a particular drug  enhances the immunosuppressive activity of CNIs or 
potentiates their toxicity. An example of the latter is the enhanced nephrotoxicity that may 
occur when CNIs are used in combination with other nephrotoxins such as aminoglycosides, 
amphotericin B or non-steroidal anti-inflammatory drugs.201,202 Pharmacokinetic drug 
interactions may theoretically occur during the absorption, distribution, metabolism or 
elimination of a drug. For CNIs several drug interactions during the absorption phase have 
been described. The prokinetic agents cisapride and metoclopramide, for example, have been 
shown to increase CNI absorption.201,202 However, inhibition or induction of both intestinal 
and hepatic CYP3A-mediated CNI metabolism is generally regarded as the most important 
drug interaction mechanism.201-203 A large number of antimicrobial, anticonvulsant, and 
antiarrhythmic drugs has been shown to have clinically relevant interactions with CNIs 
via this mechanism (Table 1.2). Most of these agents also have inhibitory or inducing effects 
on P-glycoprotein which further contributes to changes in CNI bioavailability. In addition, 
it has been suggested that coadministration of P-glycoprotein inhibitors may increase the 
incidence of CNI-mediated neurotoxicity, not only by increasing blood concentrations but 
also by facilitating distribution into the central nervous system.202,204
1.5.4 DEMOGRAPHIC FACTORS AND OTHER PATIENT CHARACTERISTICS
Children require higher CNI doses to reach target concentrations compared with adults. This 
has been related to a decreasing clearance with advancing age -possibly due to changes in 
CYP3A isozyme expression- rather than changes in bioavailability.129,134,169,180,181,202 The effect 
of gender on CNI pharmacokinetics appears to be less marked and dosage recommendations 
for male and female patients are the same.169,180,181,202,205 Serum albumin and triglyceride 
concentration, as well as hematocrit have all been correlated with CNI disposition. Changes 
in these variables explain part of the alterations in CNI pharmacokinetics that occur shortly 
after transplantation.129,134,169,169,180,181,185,186,202 As discussed in paragraph 1.3.5, decreased liver 
function leads to a reduced clearance of CNIs and to impaired biliary excretion of their 
metabolites, whereas impaired kidney function does not significantly affect CNI pharmaco
kinetics.129,134,169
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Table 1.2 Drugs having clinically relevant pharmacokinetic interactions  
with the calcineurin inhibitors cyclosporine and tacrolimus
Drug Clinical effect
Antibiotics
     Clarithromycin
     Doxycyclin
     Erythromycin
     Rifampicin
Antiepileptics
     Carbamazepine
     Phenobarbital
     Phenytoin
Antihypertensive and antiarrhythmic  agents
     Amiodarone
     Diltiazem
     Nicardipine
     Nifedipine
     Verapamil
Antimycotic drugs
     Fluconazole
     Itraconazole
     Ketoconazole
Other
     HIV protease inhibitors
     Theophyllin
Increased exposure
Increased exposure
Increased exposure
Reduced exposure
Reduced exposure
Reduced exposure
Reduced exposure
Increased exposure
Increased exposure
Increased exposure
Increased exposure
Increased exposure
Increased exposure
Increased exposure
Increased exposure
Increased exposure
Increased exposure
There has been much controversy with regard to the influence of ethnicity on CNI 
pharmacokinetics. The outcomes of transplantation in African Americans in general is 
worse compared to white transplant recipients.206 Heightened immune reactivity and 
socioeconomic disparities have been suggested to account for these differences. However, 
several authors have reported that the oral bioavailability of both cyclosporine and tacrolimus 
is lower in black compared to white subjects.169,180,205-208 It has been speculated that these 
inter-ethnic differences may have resulted from differences in CYP3A and P-glycoprotein 
expression or activity. An alternative explanation may be differences in meal habits. The 
latter hypothesis has been supported by the fact that cyclosporine exposure was comparable 
between black and white individuals under controlled dietary conditions.209,210
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1.6  
STRATEGIES TO OPTIMIZE TREATMENT WITH 
CALCINEURIN INHIBITORS
Over the past 50 years, solid organ transplantation has evolved from an experimental therapy 
for a limited number of selected patients to the treatment of choice for patients with end-
stage organ failure.211 This remarkable success is in part attributable to the development of 
immunosuppressive drug therapy. The introduction of CNIs and other immunosuppressive 
agents has led to a dramatic reduction in the incidence and severity of acute rejection and 
consequently, much improved short- and medium-term graft and patient survival. The 
long-term outcomes of solid organ transplantation have, however, not improved to a similar 
degree.86,212 Today, the main obstacles to successful (long-term) engraftment are the high 
incidence of cancer, infection, and cardiovascular disease among transplant recipients, as 
well as late allograft loss due to chronic rejection. 
Although there is some evidence that certain immunosuppressive agents are more 
carcinogenic than others, the high risk of transplant recipients to develop cancer is first 
and foremost related to the overall level of immunosuppression.213,214 Likewise, the high 
frequency of infectious complications after transplantation is related to the net state of 
immunosuppression rather than to the use of a particular immunosuppressive agent.215,216 
In contrast, the use of CNIs probably contributes to the high incidence of cardiovascular 
disease among transplant recipients. These agents often cause hypertension, hyperlipidemia, 
and diabetes mellitus which are all established cardiovascular risk factors in the general 
population.217
Chronic rejection is characterized clinically by a gradual decrease in transplant function 
together with (transplanted) organ-specific histopathologic changes. It is now recognized 
that various nonimmunologic factors are involved in the pathogenesis of chronic rejection 
and therefore the more inclusive term “chronic allograft nephropathy” (CAN) has been 
introduced for kidney transplant recipients (in analogy, chronic rejection in heart, lung, 
and liver transplant recipients is also known as “transplant coronary artery disease”, 
“bronchiolitis obliterans” and “vanishing bile duct syndrome”, respectively). Among the 
factors that have been shown to contribute to the risk of chronic rejection, hyperlipidemia 
and hypertension can be induced by CNIs. In addition, cyclosporine appears to contribute 
directly to the development of chronic rejection by means of its pro-fibrotic properties.218,219
At present, the main challenge to transplant physicians is to improve the long-term outcomes 
of solid organ transplantation while maintaining the excellent short- and medium-term 
results that are currently being achieved. As an episode of (severe) acute rejection is one of 
the major risk factors for chronic rejection, any strategy to achieve this goal must not do so 
at the expense of an increased risk of acute rejection.218,220
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1.6.1 CALCINEURIN INHIBITOR AVOIDANCE AND MINIMIZATION
Given the association between the use of CNIs and the risk of cardiovascular disease and CAN, 
complete avoidance of these agents is a logical strategy. In several randomized clinical trials 
in de novo primary kidney transplant recipients, the efficacy of a CNI-free, sirolimus-based 
immunosuppressive regimen has been explored. Treatment with sirolimus in combination 
with either MMF or azathioprine plus corticosteroids with or without basiliximab induction 
therapy, resulted in a patient and graft survival, as well as an incidence of biopsy-proven 
acute rejection that was comparable to cyclosporine-based therapy. In addition, these initial 
studies demonstrated a significantly better renal function in the absence of cyclosporine.221-223
However, data from more recent studies have not been able to confirm these benefits of 
CNI avoidance.224,225 In SYMPHONY, a prospective, randomized study with four parallel 
arms, 1645 kidney transplant recipients were randomized to standard immunosuppression 
consisting of normal-dose cyclosporine, MMF and corticosteroids, or to one of three 
regimens consisting of daclizumab induction, MMF, and corticosteroids plus either 
low-dose cyclosporine, tacrolimus or sirolimus. At six and twelve months follow-up, the 
incidence of biopsy-proven acute rejection was highest in patients randomized to receive 
sirolimus-based immunosuppression (33% and 35%, respectively).224 Another, smaller study 
has also demonstrated an unacceptably high risk of acute rejection in association with a 
sirolimus-based, CNI-free immunosuppressive protocol.225 In addition, in the most recent 
studies, the main promise of CNI-free immunosuppression, namely an improvement of 
renal function and a lower incidence of CAN, was not achieved by completely avoiding the 
use of CNIs.224,226 
An alternative approach to reduce the long-term toxicity of CNIs while capturing the 
benefit of low acute rejection rates associated with their use, is to treat patients for only a 
limited period of time with CNIs followed by CNI dose reduction or complete elimination. 
In the first studies that explored the safety of cyclosporine withdrawal, cyclosporine was 
either converted to azathioprine, or completely eliminated from azathioprine-containing 
immunosuppressive regimens. A meta-analysis of these trials demonstrated that cyclosporine 
withdrawal resulted in an overall 11% higher incidence of acute rejection compared with 
patients who continued cyclosporine treatment.227 However, this increased risk of acute 
rejection was not associated with increased graft loss.227 Similarly, the safety of cyclosporine 
withdrawal from MMF-based immunosuppressive regimens has been investigated. This 
strategy also resulted in a significantly higher incidence of acute rejection (ranging between 
10% and 22%) but again not at the expense of increased graft loss at short-term follow-up. In 
addition, blood pressure and lipid profile improved after cyclosporine withdrawal.228-230 
Finally, several investigators have studied the safety of early cyclosporine elimination 
from sirolimus-containing immunosuppressive regimens. In the Rapamune Maintenance 
Regimen Study, 430 kidney transplant recipients were randomized at month three 
posttransplantation to remain on sirolimus, cyclosporine and corticosteroid therapy or to 
have cyclosporine withdrawn and continue treatment with (increased dose) sirolimus and 
corticosteroids.231,232 At one and two years follow-up, renal function was significantly better 
in the cyclosporine-withdrawal group but at the expense of a somewhat higher incidence 
of biopsy-proven acute rejection (9.8% versus 5.1% in the cyclosporine-withdrawal and 
32
Chapter 1
sirolimus-cyclosporine groups, respectively).231,232 Following a somewhat similar approach, 
Gonwa et al.233 also observed an improvement in renal function after early cyclosporine 
cessation but without an increased risk of acute rejection.
Although (early) cyclosporine withdrawal does not appear to result in increased graft 
loss at short-term follow-up, there has remained considerable concern that cessation of 
cyclosporine may not be the safest strategy to follow. Pascual and colleagues234 therefore 
randomized stable kidney transplant recipients at one year after transplantation to either 
have their cyclosporine dose reduced by 50% or continue their maintenance dose. At six 
months follow-up, no acute rejection episodes were observed in either group. Importantly, 
cyclosporine dose reduction did result in a significantly improved renal function, whereas 
serum creatinine worsened in the control group.234
In summary, it appears that the lowest incidence of acute rejection is currently achieved 
by treating patients with immunosuppressive regimens that contain a CNI. At present it 
is unclear whether the benefits of early CNI withdrawal are outweighed by the increased 
risk of acute rejection associated with such an approach. Moreover, the side effects of newer 
immunosuppressive agents such as sirolimus (e.g. hyperlipidemia) are reason for concern as 
they may also negatively influence patient and graft survival. The question as to which is the 
optimal immunosuppressive strategy to follow can only be answered by longer follow-up of 
appropriately designed clinical trials.
1.6.2 DRUG FORMULATION
As discussed previously, the cyclosporine microemulsion formulation was developed to 
improve the unfavorable pharmacokinetic characteristics of the older oil-based formulation. 
This attempt has been partially successful. Compared with cyclosporine Sandimmune, 
microemulsified cyclosporine is more rapidly and completely absorbed and displays less 
intraindividual pharmacokinetic variability. However, the interindivual pharmacokinetic 
variability appears to be comparable between the two formulations and therefore the 
introduction of microemulsified cyclosporine has not abrogated the need to perform 
TDM.138,139 Nonetheless, most transplant centers have abandoned cyclosporine Sandimmune 
in favor of the microemulsion formulation.83
1.6.3 THERAPEUTIC DRUG MONITORING
Given their narrow therapeutic window, variable pharmacokinetics, and the existence of a 
concentration-effect relationship, both cyclosporine and tacrolimus meet the requirements 
for a successful clinical application of TDM (see section 1.4). In addition, monitoring blood 
levels can be helpful to check for patient compliance. Over the years, the practice to adjust 
the CNI dose according to blood concentrations has gained widespread acceptance in the 
field of transplantation, although no trials comparing fixed-dose versus a TDM-based CNI 
dosing strategy (i.e. concentration-controlled) were ever conducted.
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Which parameter to use for TDM is still a matter for debate. Traditionally, the CNI dose 
has been adjusted according to the predose concentration. However, for cyclosporine, the 
C
0
 correlates poorly with total drug exposure within a dosing interval and with clinical 
outcomes after transplantation.182-184,187 As determination of full pharmacokinetic profiles 
is impractical for routine clinical use, there has been a search for simple alternatives 
to C
0
 for profiling cyclosporine pharmacokinetics. Because of the large variability in 
cyclosporine pharmacokinetics during its absorption phase, limited sampling strategies 
focusing on the first few hours after oral administration have become a popular method 
for monitoring cyclosporine therapy. In several studies it was demonstrated that the AUC
0-4
 
correlated very well with AUC
0-12
 and accurately predicted clinical outcomes after kidney 
transplantation.172,173,182-184,187 This strategy does, however, require the drawing of several 
blood samples and measurement of multiple cyclosporine concentrations (thereby increasing 
workload and costs), in addition to the application of a (simple) mathematical calculation step. 
The cyclosporine whole blood concentration two hours after Neoral® administration (C2) 
has been shown to be the single-sampling point that correlates best with total drug exposure 
and the probability of developing acute rejection after transplantation.182-184,187 Based on 
these studies, target levels for C
2
 were defined and patient management by C
2
 monitoring 
was subsequently shown to result in excellent short-term efficacy and safety among de novo 
renal transplant recipients.189,235,236 However, to date only few studies have directly compared 
cyclosporine C
2
 (or other limited-sampling strategies) to traditional C
0
 monitoring. Levy 
et al.237 studied 307 de novo liver transplant recipients who were randomized to receive 
cyclosporine either titrated to reach predefined C
2
 or C
0
 target level ranges. At 3 months 
follow-up, graft loss and the overall incidence of acute rejection were comparable between 
the two groups, although the incidence of moderate to severe histological grades of acute 
rejection was significantly higher among patients monitored by C
0
 (47% versus 73% for the 
C
2
 and C
0
 groups, respectively).237 In the International Neoral Renal Transplant Study, there 
were no statistically significant differences between de novo renal transplant recipients (n 
= 204) managed by either C
0
 or AUC monitoring with regard to rejection rate, rejection 
severity, graft survival or nephrotoxicity.184 Although the absence of any statistically 
significant differences in major clinical endpoints in these studies may be explained by 
insufficient statistical power, these results do suggest that any benefits of limited sampling 
strategies are relatively small. Moreover, only few data exist on the benefits and safety of 
limited sampling strategies in stable patients longer after transplantation.238,239
With regard to tacrolimus, both poor and strong correlations between the C
0
 and total drug 
exposure have been reported. This correlation appears to be stronger than that reported 
for cyclosporine and most centers still rely on the tacrolimus C
0
.179,240 However, Kuypers 
and colleagues178 demonstrated that tacrolimus exposure as determined by AUC
0-12
 is a 
more reliable pharmacokinetic parameter than C
0
 for predicting infectious complications 
in the early phase after renal transplantation. Recently, a more sophisticated method to 
guide tacrolimus dosing was reported.185 However, although this limited sampling strategy 
adequately predicted tacrolimus exposure, it is unlikely to rapidly gain widespread clinical 
acceptance because of its rather complicated mathematics, the unfamiliarity of clinicians 
with Bayesian forecasting, the lasting need to sample at multiple time points and the lack of 
any data demonstrating improved clinical outcomes over C
0
 monitoring.185
34
Chapter 1
1.6.4 PHARMACOGENETICS AND PATIENT CHARACTERISTICS
Another strategy to attain CNI dose individualization is to consider patient characteristics 
that explain an important part of the interindividual variability in CNI pharmacokinetics 
and pharmacodynamics. As discussed in section 1.5, a large part of the variability in CNI 
disposition has been attributed to interindividual differences in the activity and expression 
of the metabolizing enzymes CYP3A4 and CYP3A5 and the drug transporter P-glycoprotein. 
In addition, an association between P-glycoprotein expression in the kidney allograft and the 
risk of CNI toxicity has been reported.241 The possibility that differences in CYP3A and P-
glycoprotein activity are in part explained by genetic variation was considered for a long time, 
but it was not until the recent identification of a number of single-nucleotide polymorphisms 
(SNPs) in the CYP3A4, CYP3A5, and ABCB1 (or MDR1, the gene encoding P-glycoprotein) 
genes that further evidence for this hypothesis was provided.144,242 At present, the impact of 
these SNPs on CNI pharmacokinetics or transplantation outcome is unknown. If the efficacy 
or toxicity of CNI treatment is (partially) genetically determined, then such information 
would theoretically be of great value in order to achieve a further individualization of CNI-
based immunosuppressive therapy. A pharmacogenetics-based approach to CNI treatment 
could assist in determining the (starting) dose of these agents or identify patients at high 
risk for toxic effects. Importantly and unlike TDM, (pharmaco)genetic screening of a patient 
can be performed before transplantation. Moreover, genetic information is constant over an 
individual’s lifetime, and steady-state conditions are not required for the interpretation of 
results. Pharmacogenetics may also provide a mechanistic explanation of drug behavior for 
single, as well as for multiple drugs.243-245
Finally, several other patient characteristics may assist in choosing a particular 
immunosuppressive regimen. For example, black patients may need higher CNI doses 
to reach target concentrations. Obese patients or other individuals at risk for developing 
post-transplant diabetes mellitus may benefit from treatment with cyclosporine rather 
than tacrolimus. In addition, an understanding of drug interactions may avoid under- or 
overexposure to CNIs when other drugs are added to or withdrawn from CNI-containing 
immunosuppressive regimens.
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1.7  
AIMS OF THE THESIS
Despite the ongoing development of new immunosuppressive drugs, at present, the best 
transplantation results are arguably being achieved by using an immunosuppressive 
regimen that incorporates a CNI.246,247 There is however, room for improvement. Therefore, 
the overall aim of this dissertation was to explore ways of optimizing CNI treatment. More 
specifically, we investigated the following:
1.  The relationship between cyclosporine exposure and the occurrence of cyclosporine-
related side effects in stable heart, kidney, and liver transplant recipients on maintenance 
therapy (Chapter 2.1).
2.  The benefits and drawbacks of cyclosporine dosing based on C
2
 levels compared with 
conventional C
0
 level monitoring in stable heart, kidney, and liver transplant recipients 
(Chapters 2.1 and 2.2).
3.  The effect of glucocorticoids on tacrolimus pharmacokinetics (Chapter 3.1).
4.  The evidence for a pharmacokinetic interaction between cyclosporine and mycophenolic 
acid (Chapter 3.2).
5.  The role of the multidrug resistance-associated protein 2 (MRP2) in the cyclosporine-
mycophenolic acid interaction (Chapter 3.3).
6.  The effect of single-nucleotide polymorphisms in the MDR-1, CYP3A4 and CYP3A5 genes 
on the pharmacokinetics of cyclosporine and tacrolimus (Chapters 4.1, 4.2, and 4.3).
36
Chapter 1
REFERENCES
1. Merrill JP, Murray JE, Harrison JH, Guild 
WR. Successful homotransplantation of the 
human kidney between identical twins. JAMA 
1956;160:277-82
2. Morris PJ. Transplantation: a medical miracle of 
the 20th century. N Engl J Med 2004;351:2678-80
3. Tilney NL. Transplant: from myth to reality. 
New Haven, Conn.: Yale University Press, 2003
4. Murray JE, Merrill JP, Harrison, JH. Kidney 
transplantation between seven pairs of identical 
twins. Ann Surg 1958;148:343-59
5. Dammin GJ, Couch NP, Murray JE. Prolonged 
survival of skin homografts in uremic patients. 
Ann N Y Acad Sci 1957;64:967-76
6. Lawler RH, West JW, McNulty PH, Clancy EJ, 
Murphy RP. Homotransplantation of the kidney 
in the human. JAMA 1950;144:844-5
7. Lawler RH, West JW, McNulty PH, Clancy EJ, 
Murphy RP. Homotransplantation of the kidney 
in the human: supplemental report of a case. 
JAMA 1951;147:45-6
8. Küss R, Teinturier J, Milliez P. Quelques essais 
de greffe de rein chez l’homme. Mém Acad Chir 
1951;77:755-64
9. Michon L, Hamburger J, Oeconomos N, et al. 
Une tentative de transplantation rénale chez 
l’homme: aspects médicaux et biologiques. 
Presse Méd 1953;61:1419-23
10. Hume DM, Merrill JP, Miller, BF, Thorn, GW. 
Experiences with renal homotransplantation in 
the human: report of nine cases. J Clin Invest 
1955;34:327-82
11. Merrill JP, Murray JE, Harrison JH, Friedman 
EA, Dealy JB Jr, Dammin GJ. Successful 
homotransplantation of the kidney between 
nonidentical twins. N Engl J Med 1960;262:1251-60
12. Hamburger J, Vaysse J, Crosnier J, Auvert J, 
Lalanne CM, Hopper J Jr. Renal transplantation 
in man after radiation of the recipient: 
experience with six patients since 1959. Am J 
Med 1962;32:854-71
13. Murray JE, Merrill JP, Dammin GJ, Dealy 
JB Jr, Alexandre GW, Harrison JH. Kidney 
transplantation in modified recipients. Ann Surg 
1962;156:337-55
14. Schwartz R, Dameshek W. Drug-induced 
immunological tolerance. Nature 1959;183:1682-3
15. Schwartz R, Eisner A, Dameshek W. The effect 
of 6-mercaptopurine on primary and secondary 
immune responses. J Clin Invest 1959;38:1394-1403
16. Calne RY. The rejection of renal homografts: 
inhibition in dogs by 6-mercaptopurine. Lancet 
1960;1:417-8
17. Zukoski CF, Lee HM, Hume DM. The 
prolongation of functional survival of canine 
renal homografts by 6-mercaptopurine. Surg 
Forum 1960;2:470-2
18. Merrill JP, Murray JE, Takacs FJ, Hager 
EB, Wilson RE, Dammin GJ. Successful 
transplantation of kidney from a human cadaver. 
JAMA 1963;185:347-53
19. Murray JE, Merrill JP, Harrison JH, Wilson RE, 
Dammin GJ. Prolonged survival of human-
kidney homografts by immunosuppressive drug 
therapy. N Engl J Med 1963;268:1315-23
20. Belzer FO, Ashby BS, Gulyassy PF, Powell M. 
Successful seventeen-hour preservation and 
transplantation of human-cadaver kidney. N 
Engl J Med 1968;278:608-10
21. Tilney NL, Strom TB, Vineyard GC, Merrill JP. 
Factors contributing to the declining mortality 
rate in renal transplantation. N Engl J Med 
1978;299:1321-5
22. Salvatierra O Jr, Feduska NJ, Cochrum KC, 
Najarian JS, Kountz SL, Belzer FO. The impact 
of 1000 renal transplants at one center. Ann Surg 
1977;186:424-34
37
General Introduction
23. Opelz G, Mickey MR, Terasaki PI. HLA 
matching and cadaver kidney transplant 
survival in North America: influence of center 
variation and presensitization. Transplantation 
1977;23:490-7
24. Barnard CN. The operation. A human cardiac 
transplant: an interim report of a successful 
operation performed at Groote Schuur Hospital, 
Cape Town. S Afr Med J 1967;41:1271-4
25. McDonald JC, Vaughn W, Filo RS, et al. Cadaver 
donor renal transplantation by centers of the 
Southeastern Organ Procurement Foundation. 
Ann Surg 1981;193:1-8
26. Borel JF, Kis ZL. The discovery and development 
of cyclosporine (Sandimmune). Transplant Proc 
1991;23:1867-74
27. Dreyfuss M, Härri E, Hofmann H, Kobel H, 
Pache W, Tscherter H. Cyclosporin A and C: new 
metabolites from Trichoderma polysporum (Link 
ex Pers.) Rifai. Eur J Appl Microbiol 1976;3:125-33
28. Rüegger A, Kuhn M, Lichti H, et al. Cyclosporin 
A, ein immunosuppressiv wirksamer 
Peptidmetabolit aus Trichoderma polysporum 
(Link ex Pers.) Rifai. Helv Chim Acta 
1976;59:1075-92 
29. Petcher TJ, Weber H-P, Rüegger A. Crystal and 
molecular structure of an iodo-derivative of the 
cyclic undecapeptide cyclosporin A. Helv Chim 
Acta 1976;59:1480-9
30. Wenger R. Synthesis of cyclosporine and 
analogues: structure, activity, relationships of 
new cyclosporin derivatives. Transplant Proc 
1983;15(Suppl 1):2230-41
31. Borel JF, Feurer C, Gubler HU, Stähelin 
H. Biological effects of cyclosporin A: a 
new antilymphocyte agent. Agents Actions 
1976;6:468-75
32. Kostakis AJ, White DJG, Calne RY. Prolongation 
of rat heart allograft survival by cyclosporin A. 
IRCS Med Sci 1977;5:280
33.  Green CJ, Allison AC. Extensive prolongation of 
rabbit kidney allograft survival after short-term 
cyclosporin-A treatment. Lancet 1978;1:1182-3
34. Calne RY, White DJG, Rolles K, Smith DP, 
Herbertson BM. Prolonged survival of pig 
orthotopic heart grafts treated with cyclosporin 
A. Lancet 1978;1:1183-5
35. Calne RY, White DJG, Thiru S, et al. Cyclosporin 
A in patients receiving renal allografts from 
cadaver donors. Lancet 1978;2:1323-7
36. Powles RL, Barrett AJ, Clink H, Kay HEM, 
Sloane J, McElwain TJ. Cyclosporin A for the 
treatment of graft-versus-host disease in man. 
Lancet 1978;2:1327-31
37. Calne RY, Rolles K, White DJG, et al. Cyclosporin 
A initially as the only immunosuppressant in 
34 recipients of cadaveric organs: 32 kidneys, 2 
pancreases, and 2 livers. Lancet 1979;2:1033-6
38. Calne RY, White DJG, Evans DB, et 
al. Cyclosporin A in cadaveric organ 
transplantation. BMJ 1981;282:934-6
39. Starzl TE, Weil R III, Iwatsuki S, et al. The use 
of cyclosporin A and prednisone in cadaver 
kidney transplantation. Surg Gynecol Obstet 
1980;151:17-26
40. Starzl TE, Klintmalm GBG, Weil R III, et al. 
Cyclosporin A and steroid therapy in sixty-six 
cadaver kidney recipients. Surg Gynecol Obstet 
1981;153:486-94
41. European Multicentre Trial Group. Cyclosporin 
A in cadaveric renal transplantation: one-
year follow-up of a multicentre trial. Lancet 
1983;2:986-9
42. Canadian Multicentre Transplant Study 
Group. A randomized trial of cyclosporine in 
cadaveric renal transplantation. N Engl J Med 
1983;309:809-15
43. Calne RY, Wood AJ. Cyclosporin in cadaveric 
renal transplantation: 3-year follow-up of a 
European multicentre trial. Lancet 1985;2:549
38
Chapter 1
44. Johnson RWG. Cyclosporine in cadaveric 
renal transplantation: three-year follow-up of 
a European multicentre trial. Transplant Proc 
1986;18:1229-33
45. Calne RY. Cyclosporin in cadaveric renal 
transplantation: 5-year follow-up of a multicentre 
trial. Lancet 1987;2:506-7
46. Canadian Multicentre Transplant Study Group. 
A randomized clinical trial of cyclosporine in 
cadaveric renal transplantation: analysis at three 
years. N Engl J Med 1986;314:1219-25
47. Sheil AGR, Hall BM, Tiller DJ, et al. Australian 
trial of cyclosporine (CsA) in cadaveric 
donor renal transplantation. Transplant Proc 
1983;15(Suppl 1):2485-9
48. McMaster P, Haynes IG, Michael J, et al. 
Cyclosporine in cadaveric renal transplantation: 
a prospective randomized trial. Transplant Proc 
1983;15(Suppl 1):2523-7
49. Najarian JS, Fryd DS, Strand M, et al. A 
single institution, randomized, prospective 
trial of cyclosporine versus azathioprine-
antilymphocyte globulin for immunosuppression 
in renal allograft recipients. Ann Surg 
1985;201:142-57
50. Oyer PE, Stinson EB, Jamieson SW, et al. 
Cyclosporine in cardiac transplantation: a 2½ 
year follow-up. Transplant Proc 1983;15(Suppl 
1):2546-52
51. Starzl TE, Klintmalm GBG, Porter KA, Iwatsuki 
S, Schröter GPJ. Liver transplantation with use 
of cyclosporin A and prednisone. N Engl J Med 
1981;305:266-9
52. Toronto Lung Transplant Group. Experience 
with single-lung transplantation for pulmonary 
fibrosis. JAMA 1988;259:2258-62
53. Reitz BA, Wallwork JL, Hunt SA, et al. Heart-
lung transplantation: successful therapy for 
patients with pulmonary vascular disease. N 
Engl J Med 1982;306:557-64
54. Deeg HJ, Storb R, Thomas ED, et al. 
Cyclosporine as prophylaxis for graft-versus-
host disease: a randomized study in patients 
undergoing marrow transplantation for acute 
nonlymphoblastic leukemia. Blood  
1985;65:1325-34
55. Ellis CN, Gorsulowsky DC, Hamilton TA, et al. 
Cyclosporine improves psoriasis in a double-
blind-study. JAMA 1986;256:3110-6
56. Ho VCY, Griffiths CEM, Berth-Jones J, et al. 
Intermittent short courses of cyclosporine 
microemulsion for the long-term management 
of psoriasis: a 2-year cohort study. J Am Acad 
Dermatol 2001;44:643-51
57. Tugwell P, Pincus T, Yocum D, et al. 
Combination therapy with cyclosporine and 
methotrexate in severe rheumatoid arthritis. N 
Engl J Med 1995;333:137-41
58. Lichtiger S, Present DH, Kornbluth A, et 
al. Cyclosporine in severe ulcerative colitis 
refractory to steroid therapy. N Engl J Med 
1994;330:1841-5
59. Cohen RD, Stein R, Hanauer SB. Intravenous 
cyclosporin in ulcerative colitis: a five year 
experience. Am J Gastroenterol 1999;94:1587-92
60. Actis GC. Cyclosporin for steroid-refractory 
ulcerative colitis [letter]. Am J Gastroenterol 
2000;95:830   
61. Cattran DC. Idiopathic membranous 
glomerulonephritis. Kidney Int 2001;59:1983-94
62. Khan LN, Kon OM, MacFarlane AJ, et al. 
Attenuation of the allergen-induced late 
asthmatic reaction by cyclosporin A is associated 
with inhibition of bronchial eosinophils, 
interleukin-5, granulocyte macrophage colony 
stimulating factor, and eotaxin. Am J Respir Crit 
Care Med 2000;162:1377-82
63. Frew AJ, Plummeridge MJ. Alternative agents in 
asthma. J Allergy Clin Immunol 2001;108:3-10
39
General Introduction
64. Hesselink DA, Baarsma GS, Kuijpers RWAM, 
van Hagen PM. Experience with cyclosporine in 
endogenous uveitis posterior. Transplant Proc 
2004;36(Suppl 2):S372-7 
65. Kino T, Hatanaka H, Miyata S, et al. FK-506, 
a novel immunosuppressant isolated from a 
Streptomyces. I. Fermentation, isolation, and 
physico-chemical and biological characteristics. J 
Antibiot 1987;40:1249-55
66. Kino T, Hatanaka H, Miyata S, et al. FK-506, 
a novel immunosuppressant isolated from a 
Streptomyces. II. Immunosuppressive effect of 
FK-506 in vitro. J Antibiot 1987;40:1256-65
67. Tanaka H, Kuroda A, Marusawa H, et al. 
Structure of FK506: a novel immunosuppressant 
isolated from Streptomyces. J Am Chem Soc 
1987;109:5031-3
68. Ochiai T, Nakajima K, Nagata M, et al. Effect 
of a new immunosuppressive agent, FK506, on 
heterotopic cardiac allotransplantation in the rat. 
Transplant Proc 1987;19:1284-6
69. Starzl TE, Todo S, Fung J, Demetris AJ, 
Venkataramman R, Jain A. FK 506 for liver, 
kidney, and pancreas transplantation. Lancet 
1989;334:1000-4
70. Starzl TE, Fung J, Jordan M, et al. Kidney 
transplantation under FK 506. JAMA 
1990;264:63-7
71. Thiru S, Collier DSJ, Calne R. Pathological 
studies in canine and baboon renal allograft 
recipients immunosuppressed with FK-506. 
Transplant Proc 1987;19(Suppl 6):98-9
72. Morris RE, Brown BWM Jr. Tacrolimus for 
prevention of liver allograft rejection: clinical 
trials and tribulations. Lancet 1995;346:1310-1
73. Starzl TE, Donner A, Eliasziw M, et al. 
Randomised trialomania? The multicentre 
liver transplant trials of tacrolimus. Lancet 
1995;346:1346-50
74. Fung J, Abu-Elmagd K, Jain A, et al. A 
randomized trial of primary liver transplantation 
under immunosuppression with FK 506 vs 
cyclosporine. Transplant Proc 1991;23:2977-83
75. Fung JJ, Eliasziw M, Todo S, et al. The Pittsburgh 
randomized trial of tacrolimus compared to 
cyclosporine for hepatic transplantation. J Am 
Coll Surg 1996;183:117-25
76. The US Multicenter FK506 Liver Study Group. 
A comparison of tacrolimus (FK506) and 
cyclosporine for immunosuppression in liver 
transplantation. N Engl J Med 1994;331:1110-5
77. European FK506 Multicentre Liver Study Group. 
Randomised trial comparing tacrolimus (FK506) 
and cyclosporin in prevention of liver allograft 
rejection. Lancet 1994;344:423-8
78. Vincenti F, Laskow DA, Neylan JF, Mendez 
R, Matas AJ. One-year follow-up of an open-
label trial of FK506 for primary kidney 
transplantation. Transplantation 1996;61:1576-81
79. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, 
Filo RS. A comparison of tacrolimus (FK506) 
and cyclosporine for immunosuppression after 
cadaveric renal transplantation. Transplantation 
1997;63:977-83
80. Mayer AD, Dmitrewski J, Squifflet J-P, et al. 
Multicenter randomized trial comparing 
tacrolimus (FK506) and cyclosporine in 
the prevention of renal allograft rejection. 
Transplantation 1997;64:436-43
81. Knoll GA, Bell RC. Tacrolimus versus 
cyclosporin for immunosuppression in renal 
transplantation: meta-analysis of randomized 
trials. BMJ 1999;318:1104-7
82. Webster AC, Woodroffe RC, Taylor RS, Chapman 
JR, Craig JC. Tacrolimus versus cyclosporin 
as primary immunosuppression for kidney 
transplant recipients: meta-analysis and meta-
regression of randomised trial data. BMJ 
2005;331:810-20
40
Chapter 1
83. Kaufman DB, Shapiro R. Lucey MR, Cherikh 
WS, Bustami RT, Dyke DB. Immunosuppression: 
practice and trends. Am J Transplant 
2004;4(Suppl 9):38-53
84. Ahsan N, Johnson C, Gonwa T, et al. 
Randomized trial of tacrolimus plus 
mycophenolate mofetil or azathioprine 
versus cyclosporine oral solution (modified) 
plus mycophenolate mofetil after cadaveric 
kidney transplantation: results at 2 years. 
Transplantation 2001;72:245-50
85. Meier-Kriesche H-U, Kaplan B. Cyclosporine 
microemulsion and tacrolimus are associated 
with decreased chronic allograft failure and 
improved long-term graft survival as compared 
with Sandimmune. Am J Transplant 2002;2:100-
4
86. Meier-Kriesche H-U, Schold JD, Srinivas TR, 
Kaplan B. Lack of improvement in renal allograft 
survival despite a marked decrease in acute 
rejection rates over the most recent era. Am J 
Transplant 2004;4:378-83
87. Halloran PF, Kung L, Noujaim J. Calcineurin 
and the biological effect of cyclosporine and 
tacrolimus. Transplant Proc 1997;30:2167-70
88. Janeway CA Jr, Travers P, Walport M, Shlomchik 
MJ. Immunobiology: the immune system in 
health and disease. 6th ed. New York: Garland 
Science Publishing, 2005
89. Hackstein H, Thomson AW. Dendritic 
cells: emerging pharmacological targets of 
immunosuppressive drugs. Nat Rev Immunol 
2004;4:24-34
90. Halloran PF. Immunosuppressive drugs 
for kidney transplantation. N Engl J Med 
2004;351:2715-29
91. Klee CB, Ren H, Wang X. Regulation of the 
calmodulin-stimulated protein phosphatase, 
calcineurin. J Biol Chem 1998;273:13367-70
92. Rusnak F, Mertz P. Calcineurin: form and 
function. Physiol Rev 2000;80:1483-1521
93. Krönke M, Leonard WJ, Depper JM, et al. 
Cyclosporin A inhibits T-cell growth factor gene 
expression at the level of mRNA transcription. 
Proc Natl Acad Sci USA 1984;81:5214-8
94. Shaw J-P,Utz PJ, Durand DB, Toole JJ, Emmel 
EA, Crabtree GR. Identification of a putative 
regulator of early T cell activation genes. Science 
1988;241:202-5 
95. Beals CR, Sheridan CM, Turck CW, Gardner 
P, Crabtree GR. Nuclear export of NF-ATc 
enhanced by glycogen synthase kinase-3. Science 
1997;275:1930-3
96. Liu J, Farmer JD Jr, Lane WS, Friedman J, 
Weissman I, Schreiber SL. Calcineurin is a 
common target of cyclophilin-cyclosporine A 
and FKBP-FK506 complexes. Cell 1991;66:807-15
97. O’Keefe SJ, Tamura J, Kincaid RL, Tocci 
MJ, O’Neill EA. FK-506- and CsA-sensitive 
activation of the interleukin-2 promoter by 
calcineurin. Nature 1992;357:692-4
98. Clipstone NA, Crabtree GR. Identification of 
calcineurin as a key signalling enzyme in T-
lymphocyte activation. Nature 1992;357:695-7
99. Handschumacher RE, Harding MW, Rice J, 
Drugge RJ. Cyclophilin: a specific cytosolic 
binding protein for cyclosporin A. Science 
1984;226:544-7
100. Siekierka JJ, Hung SHY, Poe M, Lin CS, Sigal 
NH. A cytosolic binding protein for the 
immunosuppressant FK506 has peptidyl-
prolyl isomerase activity but is distinct from 
cyclophilin. Nature 1989;341:755-7
101. Harding MW, Galat A, Uehling DE, Schreiber 
SL. A receptor for the immunosuppressant 
FK506 is a cis-trans peptidyl-prolyl isomerase. 
Nature 1989;341:758-60
102. Takahashi N, Hayano T, Suzuki M. Peptidyl-
prolyl cis-trans isomerase is the cyclosporin 
A-binding protein cyclophilin. Nature 
1989;337:473-5
41
General Introduction
103. Fischer G, Wittmann-Liebold B, Lang K, 
Kiefhaber T, Schmid FX. Cyclophilin and 
peptidyl-prolyl cis-trans isomerase are probably 
identical proteins. Nature 1989;337:476-8
104. Bierer BE, Mattila PS, Standaert RF, et al. 
Two distinct signal transmission pathways 
in T lymphocytes are inhibited by complexes 
formed between an immunophilin and either 
FK506 or rapamycin. Proc Natl Acad Sci USA 
1990;87:9231-5
105. Sigal NH, Dumont F, Durette P, et al. Is 
cyclophilin involved in the immunosuppressive 
and nephrotoxic mechanism of action of 
cyclosporin A? J Exp Med 1991;173:619-28
106. Matsuda S, Koyasu S. Mechanisms of action of 
cyclosporine. Immunopharmacol 2000;47:119-25
107. Hutchinson IV, Bagnall W, Bryce P, Pufong B, 
Geraghty P, Brogan I. Differences in the mode of 
action of cyclosporine and FK 506. Transplant 
Proc 1998;30:959-60
108. Kahan BD. Cyclosporine. N Engl J Med 
1989;321:1725-38
109. English J, Evan A, Houghton DC, Bennett WM. 
Cyclosporine-induced acute renal dysfunction in 
the rat: evidence of arteriolar vasoconstriction 
with preservation of tubular function. 
Transplantation 1987;44:135-41
110. McNally PG, Feehally J. Pathophysiology of 
cyclosporin A nephrotoxicity: experimental and 
clinical observations. Nephrol Dial Transplant 
1992;7:791-804
111. Morales JM, Andres A, Rengel M, Rodicio 
JL. Influence of cyclosporin, tacrolimus and 
rapamycin on renal function and arterial 
hypertension after renal transplantation. 
Nephrol Dial Transplant 2001;16(Suppl 1):121-4
112. Myers BD, Ross J, Newton L, Luetscher J, 
Perlroth M. Cyclosporine-associated chronic 
nephropathy. N Engl J Med 1984;311:699-705
113. Palestine AG, Austin HA III, Balow JE, et al. 
Renal histopathologic alterations in patients 
treated with cyclosporine for uveitis. N Engl J 
Med 1986;314:1293-8
114. Isnard Bagnis C, Tezenas du Montcel S, Beaufils 
H, et al. Long-term renal effects of low-dose 
cyclosporine in uveitis-treated patients: follow-
up study. J Am Soc Nephrol 2002;13:2962-8
115. Nankivell BJ, Borrows RJ, Fung CLS, O’Connell 
PJ, Allen RDM, Chapman JR. The natural history 
of chronic allograft nephropathy. N Engl J Med 
2003;349:2326-33
116. van Gelder T, Balk AHMM, Zietse R, Hesse 
C, Mochtar B, Weimar W. Renal insufficiency 
after heart transplantation: a case-control study. 
Nephrol Dial Transplant 1998;13:2322-6
117. Baan CC, Balk AHMM, Holweg CTJ, et al. 
Renal failure after clinical heart transplantation 
is associated with the TGF-β1 codon 10 gene 
polymorphism. J Heart Lung Transplant 
2000;19:866-72
118. Lemos FBC, Mol WM, Roodnat JI, et al. The 
beneficial effects of recipient-derived vascular 
endothelial growth factor on graft survival 
after kidney transplantation. Transplantation 
2005;79:1221-5
119. Avdonin PV, Cottet-Maire F, Afanasjeva GV, 
Loktionova SA, Lhote P, Ruegg UT. Cyclosporine 
A up-regulates angiotensin II receptors and 
calcium responses in human vascular smooth 
muscle cells. Kidney Int 1999;55:2407-2414 
120. van Riemsdijk IC, Mulder PG, de Fijter JW, et al. 
Addition of isradipine (lomir) results in a better 
renal function after kidney transplantation: a 
double-blind, randomized, placebo-controlled, 
multicenter study. Transplantation 2000;70:122-6
121. Cosio FG, Pesavento TE, Osei K, Henry ML, 
Ferguson RM. Post-transplant diabetes mellitus: 
increasing incidence in renal allograft recipients 
in recent years. Kidney Int 2001;59:732-7
42
Chapter 1
122. Maes BD, Kuypers D, Messiaen T, et al. 
Posttransplantation diabetes mellitus in FK-
506-treated renal transplant recipients: analysis 
of incidence and risk factors. Transplantation 
2001;72:1655-61
123. van Duijnhoven EM. Metabolic and 
pharmacokinetic aspects of tacrolimus in 
renal transplantation. [dissertation]. Sittard: 
Universitaire Pers Maastricht, 2002
124. Hricik DE. Hyperlipidemia in renal transplant 
recipients. Graft 2000;3:177-84
125. Wijdicks EFM. Neurotoxicity of 
immunosuppressive drugs. Liver Transplant 
2001;7:937-42
126. Neoral®. Package insert
127. Noble S, Markham A. Cyclosporin: a review of 
the pharmacokinetic properties, clinical efficacy 
and tolerability of a microemulsion-based 
formulation (Neoral®). Drugs 1995;50:924-41
128. Friman S, Bäckman L. A new microemulsion 
formulation of cyclosporin: pharmacokinetic 
and clinical features. Clin Pharmacokinet 
1996;30:181-93
129. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, 
Goa KL. Cyclosporin: an updated review of the 
pharmacokinetic properties, clinical efficacy 
and tolerability of a microemulsion-based 
formulation (Neoral®) in organ transplantation. 
Drugs 2001;61:1957-2016
130. van Hest RM, van Gelder T. Formuleringen 
ciclosporine niet zonder meer uitwisselbaar. 
Pharm Weekblad 2004;139:1643-7 
131. Iacono AT, Johnson BA, Grgurich WF, et al. 
A randomized trial of inhaled cyclosporine 
in lung-transplant recipients. N Engl J Med 
2006;354:141-50 
132. Prograf®. Package insert
133. Reynolds NJ, Al-Daraji WI. Calcineurin 
inhibitors and sirolimus: mechanisms of action 
and applications in dermatology. Clin Exp 
Dermatol 2002;27:555-61
134. Venkataramanan R, Swaminathan A, Prasad T, 
et al. Clinical pharmacokinetics of tacrolimus. 
Clin Pharmacokinet 1995;29:404-30
135. Spencer CM, Goa KL, Gillis JC. Tacrolimus: an 
update of its pharmacology and clinical efficacy 
in the management of organ transplantation. 
Drugs 1997;54:925-75
136. Plosker GL, Foster RH. Tacrolimus: a further 
update of its pharmacology and therapeutic use 
in the management of organ transplantation. 
Drugs 2000;59:323-89
137. Kovarik JM, Mueller EA, van Bree JB, et al. 
Cyclosporine pharmacokinetics and variability 
from a microemulsion formulation: a multicenter 
investigation in kidney transplant patients. 
Transplantation 1994;58:658-63
138. Kovarik JM, Mueller EA, Richard F, et al. 
Evidence for earlier stabilization of cyclosporine 
pharmacokinetics in de novo renal transplant 
patients receiving a microemulsion formulation. 
Transplantation 1996;62:759-63
139. Keown P, Landsberg D, Halloran P, et al. 
A randomized, prospective multicenter 
pharmacoepidemiologic study of cyclosporine 
microemulsion in stable renal graft recipients: 
report of the Canadian Neoral Renal Transplant 
Study Group. Transplantation 1996;62:1744-52
140. Drewe J, Beglinger C, Kissel T. The absorption 
site of cyclosporin in the human gastrointestinal 
tract. Br J Clin Pharmacol 1992;33:39-43
141. Bekersky I, Dressler D, Mekki Q. Effect of low- 
and high-fat meals on tacrolimus absorption 
following 5 mg single oral doses to healthy 
human subjects. J Clin Pharmacol 2001;41:176-82
142. Bekersky I, Dressler D, Mekki Q. Effect of time 
of meal consumption on bioavailability of a 
single 5 mg tacrolimus dose. J Clin Pharmacol 
2001;41:289-97
143. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano 
T. Human P-glycoprotein transports cyclosporin 
A and FK506. J Biol Chem 1993;268:6077-80
43
General Introduction
144. Marzolini C, Paus E, Buclin T, Kim RB. 
Polymorphisms in human MDR1 (P-
glycoprotein): recent advances and clinical 
relevance. Clin Pharmacol Ther 2004;75:13-33
145. Zhang Y, Benet LZ. The gut as a barrier to drug 
absorption: combined role of cytochrome P450 
3A and P-glycoprotein. Clin Pharmacokinet 
2001;40:159-68
146. Ptachcinski RJ, Venkataramanan R, Rosenthal 
JT, Burckart GJ, Taylor RJ, Hakala TR. 
Cyclosporine kinetics in renal transplantation. 
Clin Pharmacol Ther 1985;38:296-300
147. Jusko WJ, Piekoszewski W, Klintmalm GB, 
et al. Pharmacokinetics of tacrolimus in liver 
transplant patients. Clin Pharmacol Ther 
1995;57:281-90
148. Maurer G, Loosli HR, Schreier E, Keller B. 
Disposition of cyclosporine in several animal 
species and man: I. structural elucidation of its 
metabolites. Drug Metab Dispos 1984;12:120-6
149. Kronbach T, Fischer V, Meyer UA. Cyclosporine 
metabolism in human liver: identification of a 
cytochrome P-450III gene family as the major 
cyclosporine-metabolizing enzyme explains 
interactions of cyclosporine with other drugs. 
Clin Pharmacol Ther 1988;43:630-5
150. Aoyama T, Yamano S, Waxman DJ, et al. 
Cytochrome P-450 hPCN3, a novel cytochrome 
P-450 IIIA gene product that is differentially 
expressed in adult human liver: cDNA and 
deduced amino acid sequence and distinct 
specificities of cDNA-expressed hPCN1 and 
hPCN3 for the metabolism of steroid hormones 
and cyclosporine. J Biol Chem 1989;264:10388-95
151. Karanam BV, Vincent SH, Lee Chiu SH. FK 
506 metabolism in human liver microsomes: 
investigation of the involvement of cytochrome 
P450 isoenzymes other than CYP3A4. Drug 
Metab Dispos 1994;22:811-4
152. Dai Y, Iwanaga K, Lin YS, et al. In vitro 
metabolism of cyclosporine A by human kidney 
CYP3A5. Biochem Pharmacol 2004;68:1889-1902
153. Kamdem LK, Streit F, Zanger UM, et al. 
Contribution of CYP3A5 to the in vitro 
hepatic clearance of tacrolimus. Clin Chem 
2005;51:1374-81
154. Dai Y, Hebert MF, Isoherranen N, et al. Effect 
of CYP3A5 polymorphism on tacrolimus 
metabolic clearance in vitro. Drug Metab Dispos 
2006;34:836-47
155. Rosano TG, Freed BM, Cerilli J, Lempert N. 
Immunosuppressive metabolites of cyclosporine 
in the blood of renal allograft recipients. 
Transplantation 1986;42:262-7
156. Freed BM, Rosano TG, Lempert N. In vitro 
immunosuppressive properties of cyclosporine 
metabolites. Transplantation 1987;43:123-7 
157. Kolars JC, Awni WM, Merion RM, Watkins PB. 
First-pass metabolism of cyclosporin by the gut. 
Lancet 1991;338:1488-90
158. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert 
MF, Benet LZ. The effects of ketoconazole on 
the intestinal metabolism and bioavailability of 
cyclosporine. Clin Pharmacol Ther 1995;58:15-9
159. Lampen A, Christians U, Guengerich FP, et 
al. Metabolism of the immunosuppressant 
tacrolimus in the small intestine: cytochrome 
P450, drug interactions, and interindividual 
variability. Drug Metab Dispos 1995;23:1315-24
160. Tuteja S, Alloway RR, Johnson JA, Gaber AO. 
The effect of gut metabolism on tacrolimus 
bioavailability in renal transplant recipients. 
Transplantation 2001;71:1303-7
161. Shimada T, Terada A, Yokogawa K, et al. Lowered 
blood concentrations of tacrolimus and its 
recovery with changes in expression of CYP3A 
and P-glycoprotein after high-dose steroid 
therapy. Transplantation 2002;74:1419-24
162. Möller A, Iwasaki K, Kawamura A, et al. 
The disposition of 14C-labeled tacrolimus 
after intravenous and oral administration in 
healthy human subjects. Drug Metab Dispos 
1999;27:633-6
44
Chapter 1
163. Keown PA, Stiller CR, Ulan RA, et al. 
Immunological and pharmacological monitoring 
in the clinical use of cyclosporin A. Lancet 
1981;1:686-9
164. Batiuk TD, Pazderka F, Halloran PF. Calcineurin 
activity is only partially inhibited in leukocytes 
of cyclosporine-treated patients. Transplantation 
1995;59:1400-4
165. Halloran PF, Helms LMH, Kung L, Noujaim J. 
The temporal profile of calcineurin inhibition 
by cyclosporine in vivo. Transplantation 
1999;68:1356-61
166. Caruso R, Perico N, Cattaneo D, et al. Whole-
blood calcineurin activity is not predicted 
by cyclosporine blood concentration in renal 
transplant recipients. Clin Chem 2001;47:1679-87
167. Stein CM, Murray JJ, Wood AJJ. Inhibition of 
stimulated interleukin-2 production in whole 
blood: a practical measure of cyclosporine effect. 
Clin Chem 1999;45:1477-84
168. Yee GC, Self SG, McGuire TR, Carlin J, Sanders 
JE, Deeg HJ. Serum cyclosporine concentration 
and risk of acute graft-versus-host disease after 
allogeneic marrow transplantation. N Engl J Med 
1988;319:65-70
169. Lindholm A, Kahan BD. Influence of 
cyclosporine pharmacokinetics, trough 
concentrations, and AUC monitoring on 
outcome after kidney transplantation. Clin 
Pharmacol Ther 1993;54:205-18
170. Klintmalm G, Säwe J, Ringdén O, von Bahr C, 
Magnusson A. Cyclosporine plasma levels in 
renal transplant patients: association with renal 
toxicity and allograft rejection. Transplantation 
1985;39:132-7
171. Henny FC, Kleinbloesem CH, Moolenaar 
AJ, Paul LC, Breimer DD, van Es LA. 
Pharmacokinetics and nephrotoxicity of 
cyclosporine in renal transplant recipients. 
Transplantation 1985;40:261-5
172. Mahalati K, Belitsky P, Sketris I, West K, Panek 
R. Neoral monitoring by simplified sparse 
sampling area under the concentration-time 
curve: its relationship to acute rejection and 
cyclosporine nephrotoxicity early after kidney 
transplantation. Transplantation 1999;68:55-62 
173. Mahalati K, Belitsky P, West K, et al. 
Approaching the therapeutic window for 
cyclosporine in kidney transplantation: 
a prospective study. J Am Soc Nephrol 
2001;12:828-33
174. Keown PA, Stiller CR, Laupacis AL, et al. 
The effects and side effects of cyclosporine: 
relationship to drug pharmacokinetics. 
Transplant Proc 1982;14:659-61
175. David-Neto E, Lemos FB, Furusawa EA, et al. 
Impact of cyclosporin A pharmacokinetics on 
the presence of side effects in pediatric renal 
transplantation. J Am Soc Nephrol 2000;11:343-9
176. Laskow DA, Vincenti F, Neylan JF, Mendez R, 
Matas AJ. An open-label, concentration-ranging 
trial of FK506 in primary kidney transplantation: 
a report of the United States Multicenter FK506 
Kidney Transplant Group. Transplantation 
1996;62:900-5
177. Bäckman L, Nicar M, Levy M, et al. FK506 
trough levels in whole blood and plasma in 
liver transplant recipients: correlation with 
clinical events and side effects. Transplantation 
1994;57:519-25
178. Kuypers DRJ, Claes K, Evenepoel P, Maes 
B, Vanrenterghem Y. Clinical efficacy and 
toxicity profile of tacrolimus and mycophenolic 
acid in relation to combined long-term 
pharmacokinetics in de novo renal allograft 
recipients. Clin Pharmacol Ther 2004;75:434-47
179. Oellerich M, Armstrong VW, Schütz E, 
Shaw LM. Therapeutic drug monitoring of 
cyclosporine and tacrolimus. Clin Biochem 
1998;31:309-16
45
General Introduction
180. Lindholm A, Welsh M, Alton C, Kahan BD. 
Demographic factors influencing cyclosporine 
pharmacokinetic parameters in patients with 
uremia: racial differences in bioavailability. Clin 
Pharmacol Ther 1992;52:359-71
181. Wu K-H, Cui Y-M, Guo J-F, et al. Population 
pharmacokinetics of cyclosporine in clinical 
renal transplant patients. Drug Metab Dispos 
2005;33:1268-75
182. Canadian Neoral Renal Transplantation Study 
Group. Absorption profiling of cyclosporine 
microemulsion (Neoral) during the first 2 weeks 
after renal transplantation. Transplantation 
2001;72:1024-32
183. International Neoral Renal Transplantation 
Study Group. Cyclosporine microemulsion 
(Neoral®) absorption profiling and sparse-
sample predictors during the first 3 months 
after renal transplantation. Am J Transplant 
2002;2:148-56 
184. International Neoral Renal Transplantation 
Study Group. Randomized, international study of 
cyclosporine microemulsion absorption profiling 
in renal transplantation with basiliximab 
immunoprophylaxis. Am J Transplant 
2002;2:157-66 
185. Scholten EM, Cremers SCLM, Schoemaker RC, 
et al. AUC-guided dosing of tacrolimus prevents 
progressive systemic overexposure in renal 
transplant recipients. Kidney Int 2005;67:2440-7
186. Undre NA, Schäfer A. Factors affecting the 
pharmacokinetics of tacrolimus in the first year 
after renal transplantation. European Tacrolimus 
Multicentre Renal Study Group. Transplant Proc 
1998;30:1261-3
187. Clase CM, Mahalati K, Kiberd BA, et al. 
Adequate early cyclosporin exposure is critical 
to prevent renal allograft rejection: patients 
monitored by absorption profiling. Am J 
Transplant 2002;2:789-95
188. MacPhee IAM, Fredericks S, Tai T, et al. The 
influence of pharmacogenetics on the time 
to achieve target tacrolimus concentrations 
after kidney transplantation. Am J Transplant 
2004;4:914-9
189. Vincenti F, Mendez R, Curtis J, et al. A 
multicenter, prospective study of C2-monitored 
cyclosporine microemulsion in a U.S. population 
of de novo renal transplant recipients. 
Transplantation 2005;80:910-6
190. Gottesman MM, Pastan I. Biochemistry of 
multidrug resistance mediated by the multidrug 
transporter. Annu Rev Biochem 1993;62:385-427
191. Kaplan B, Lown K, Craig R, et al. Low 
bioavailability of cyclosporine microemulsion 
and tacrolimus in a small bowel transplant 
recipient: possible relationship to intestinal 
P-glycoprotein activity. Transplantation 
1999;67:333-8
192. Masuda S, Uemoto S, Hashida T, Inomata 
Y, Tanaka K, Inui K. Effect of intestinal P-
glycoprotein on daily tacrolimus trough level 
in a living-donor small bowel recipient. Clin 
Pharmacol Ther 2000;68:98-103
193. Masuda S, Uemoto S, Goto M, Fujimoto Y, 
Tanaka K, Inui K. Tacrolimus therapy according 
to mucosal MDR1 levels in small-bowel 
transplant recipients. Clin Pharmacol Ther 
2004;75:352-61
194. Hashida T, Masuda S, Uemoto S, Saito H, Tanaka 
K, Inui K. Pharmacokinetic and prognostic 
significance of intestinal MDR1 expression in 
recipients of living-donor liver transplantation. 
Clin Pharmacol Ther 2001;69:308-16
195. Lown KS, Mayo RR, Leichtman AB, et al. Role of 
intestinal P-glycoprotein (mdr1) in interpatient 
variation in the oral bioavailability of  
cyclosporine. Clin Pharmacol Ther 1997;62:248-60
196. Lown KS, Kolars JC, Thummel KE, et al. 
Interpatient heterogeneity in expression of 
CYP3A4 and CYP3A5 in small bowel: lack of 
prediction by the erythromycin breath test. Drug 
Metab Dispos 1994;22:947-55
197. Goto M, Masuda S, Saito H, et al. C3435T 
polymorphism in the MDR1 gene affects the 
enterocyte expression level of CYP3A4 rather 
than Pgp in recipients of living-donor liver 
transplantation. Pharmacogenetics 2002;12:451-7
46
Chapter 1
198. Hebert MF, Roberts JP, Prueksaritanont T, 
Benet LZ. Bioavailability of cyclosporine 
with concomitant rifampin administration is 
markedly less than predicted by hepatic enzyme 
induction. Clin Pharmacol Ther 1992;52:453-7
199. Floren LC, Bekersky I, Benet LZ, et al. 
Tacrolimus oral bioavailability doubles with 
coadministration of ketoconazole. Clin 
Pharmacol Ther 1997;62:41-9
200. Turgeon DK, Leichtman AB, Lown KS, et al. 
P450 3A activity and cyclosporine dosing in 
kidney and heart transplant recipients. Clin 
Pharmacol Ther 1994;56:253-60
201. Campana C, Regazzi MB, Buggia I, Molinaro 
M. Clinically significant drug interactions with 
cyclosporin: an update. Clin Pharmacokinet 
1996;30:141-79
202. Christians U, Jacobsen W, Benet LZ, Lampen 
A. Mechanisms of clinically relevant drug 
interactions associated with tacrolimus. Clin 
Pharmacokinet 2002;41:813-51
203. Dresser GK, Spence JD, Bailey DG. 
Pharmacokinetic-pharmacodynamic 
consequences and clinical relevance of 
cytochrome P450 3A4 inhibition. Clin 
Pharmacokinet 2000;38:41-57
204. Yamauchi A, Ieiri I, Kataoka Y, et al. 
Neurotoxicity induced by tacrolimus after 
liver transplantation: relation to genetic 
polymorphisms of the ABCB1 (MDR1) gene. 
Transplantation 2002;74:571-8
205. Min DI, Lee M, Ku Y-M, Flanigan M. Gender-
dependent racial difference in disposition of 
cyclosporine among healthy African American 
and white volunteers. Clin Pharmacol Ther 
2000;68:478-86
206. Schroeder TJ, Shah M, Hariharan S, First MR. 
Increased resources are required in patients with 
low cyclosporine bioavailability. Transplant Proc 
1996;28:2151-5
207. Andrews PA, Sen M, Chang RWS. Racial 
variation in dosage requirements of tacrolimus. 
Lancet 1996;348:1446
208. Mancinelli LM, Frassetto L, Floren LC, et al. The 
pharmacokinetics and metabolic disposition of 
tacrolimus: a comparison across ethnic groups. 
Clin Pharmacol Ther 2001;69:24-31 
209. Pollak R, Wong RL, Chang CT. Cyclosporine 
bioavailability of Neoral and Sandimmune 
in white and black de novo renal transplant 
recipients. Neoral Study Group. Ther Drug Monit 
1999;21:661-3
210. Stein CM, Sadeque AJ, Murray JJ, Wandel C, Kim 
RB, Wood AJJ. Cyclosporine pharmacokinetics 
and pharmacodynamics in African American 
and white subjects. Clin Pharmacol Ther 
2001;69:317-23
211. Wolfe RA, Ashby VB, Milford EL, et al. 
Comparison of mortality in all patients 
on dialysis, patients on dialysis awaiting 
transplantation, and recipients of a first cadaveric 
transplant. N Engl J Med 1999;341:1725-30
212. Hariharan S, Johnson CP, Bresnahan BA, 
Taranto SE, McIntosh MJ, Stablein D. Improved 
graft survival after renal transplantation in 
the United States, 1988 to 1996. N Engl J Med 
2000;342:605-12
213. Dantal J, Hourmant M, Cantarovich D, et al. 
Effect of long-term immunosuppression in 
kidney-graft recipients on cancer incidence: 
randomised comparison of two cyclosporin 
regimens. Lancet 1998;351:623-8
214. Dantal J, Soulillou J-P. Immunosuppressive 
drugs and the risk of cancer after organ 
transplantation. N Engl J Med 2005;352:1371-3
215. Fishman JA, Rubin RH. Infection in 
organ-transplant recipients. N Engl J Med 
1998;338:1741-51
216. Fishman JA. BK virus nephropathy: 
polyomavirus adding insult to injury. N Engl J 
Med 2002;347:527-30
217. Raine AEG. Hypertension and ischaemic heart 
disease in renal transplant recipients. Nephrol 
Dial Transplant 1995;10(Suppl 1):95-100
47
General Introduction
218. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin 
N, Cosimi AB. Strategies to improve long-term 
outcomes after renal transplantation. N Engl J 
Med 2002;346:580-90
219. Shihab FS, Andoh TF, Tanner AM, et al. Role of 
transforming growth factor-β1 in experimental 
chronic cyclosporine nephropathy. Kidney Int 
1996;49:1141-51
220. Hariharan S, McBride MA, Cherikh WS, Tolleris 
CB, Bresnahan BA, Johnson CP. Post-transplant 
renal function in the first year predicts long-
term kidney transplant survival. Kidney Int 
2002;62:311-8
221. Groth CG, Bäckman L, Morales J-M, et al. 
Sirolimus (rapamycin)-based therapy in human 
renal transplantation: similar efficacy and 
different toxicity compared with cyclosporine. 
Sirolimus European Renal Transplant Study 
Group. Transplantation 1999;67:1036-42
222. Kreis H, Cisterne J-M, Land W, et al. Sirolimus 
in association with mycophenolate mofetil 
induction for the prevention of acute graft 
rejection in renal allograft recipients. Sirolimus 
European Renal Transplant Study Group. 
Transplantation 2000;69:1252-60
223. Flechner SM, Goldfarb D, Modlin C, et al. 
Kidney transplantation without calcineurin 
inhibitor drugs: a prospective, randomized trial 
of sirolimus versus cyclosporine. Transplantation 
2002;74:1070-6
224. Ekberg H, Tedesco-Silva H, Demirbas A, 
et al. SYMPHONY: comparing standard 
immunosuppression to low-dose cyclosporine, 
tacrolimus or sirolimus in combination with 
MMF, daclizumab and corticosteroids in renal 
transplantation [Abstract 49]. Am J Transplant 
2006;6(Suppl 2):83
225. Gelens M, Christiaans M, van Heurn E, van 
Hooff J. Calcineurin-free immunosuppression 
and limited steroid exposure in renal 
transplantation [Abstract 865]. Am J Transplant 
2005;5(Suppl 11):376
226. Larson TS, Dean PG, Stegall MD, et al. Complete 
avoidance of calcineurin inhibitors in renal 
transplantation: a randomized trial comparing 
sirolimus and tacrolimus. Am J Transplant 
2006;6:514-22
227. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A 
meta-analysis of immunosuppression withdrawal 
trials in renal transplantation. J Am Soc Nephrol 
2000;11:1910-7
228. Schnuelle P, Homan van der Heide J, Tegzess 
A, et al. Open randomized trial comparing 
early withdrawal of either cyclosporine or 
mycophenolate mofetil in stable renal transplant 
recipients initially treated with a triple drug 
regimen. J Am Soc Nephrol 2002;13:536-43
229. Smak Gregoor PJH, de Sévaux RGL, Ligtenberg 
G, et al. Withdrawal of cyclosporine 
or prednisone six months after kidney 
transplantation in patients on triple drug 
therapy: a randomized, prospective, multicenter 
study. J Am Soc Nephrol 2002;13:1365-73
230. Abramowicz D, Manas D, Lao M, et al. 
Cyclosporine withdrawal from a mycophenolate 
mofetil-containing immunosuppressive 
regimen in stable kidney transplant recipients: a 
randomized, controlled study. The Cyclosporine 
Withdrawal Study Group. Transplantation 
2002;74:1725-34
231. Johnson RWG, Kreis H, Oberbauer R, Brattström 
C, Claesson K, Eris J. Sirolimus allows early 
cyclosporine withdrawal in renal transplantation 
resulting in improved renal function and lower 
blood pressure. Transplantation 2001;72:777-86
232. Oberbauer R, Kreis H, Johnson RWG, et al. 
Long-term improvement in renal function with 
sirolimus after early cyclosporine withdrawal 
in renal transplant recipients: 2-year results 
of the rapamune maintenance regimen study. 
Rapamune Maintenance Regimen Study Group. 
Transplantation 2003;76:364-70 
48
Chapter 1
233. Gonwa TA, Hricik DE, Brinker K, Grinyo 
JM, Schena FP. Improved renal function in 
sirolimus-treated renal transplant patients 
after early cyclosporine elimination. Sirolimus 
Renal Function Study Group. Transplantation 
2002;74:1560-7
234. Pascual M, Curtis J, Delmonico FL, et al. 
A prospective, randomized clinical trial of 
cyclosporine reduction in stable patients greater 
than 12 months after renal transplantation. 
Transplantation 2003;75:1501-5
235. Levy GA. C
2
 monitoring strategy for optimising 
cyclosporin immunosuppression from the 
Neoral® formulation. Biodrugs 2001;15:279-90
236. Thervet E, Pfeffer P, Scolari MP, et al. Clinical 
outcomes during the first three months 
posttransplant in renal allograft recipients 
managed by C
2
 monitoring of cyclosporine 
microemulsion. Transplantation 2003;76:903-8
237. Levy G, Burra P, Cavallari A, et al. Improved 
clinical outcomes for liver transplant recipients 
using cyclosporine monitoring based on 
2-hr post-dose levels (C
2
). Transplantation 
2002;73:953-9
238. Cantarovich M, Elstein E, de Varennes B, Barkun 
JS. Clinical benefit of Neoral dose monitoring 
with cyclosporine 2-hr post-dose levels compared 
with trough levels in stable heart transplant 
patients. Transplantation 1999;68:1839-42
239. Cole E, Maham N, Cardella C, et al. Clinical 
benefits of Neoral C
2
 monitoring in the long-
term management of renal transplant recipients. 
Transplantation 2003;75:2086-90
240. Wong KM, Shek CC, Chau KF, Li CS. 
Abbreviated tacrolimus area-under-the-curve 
monitoring for renal transplant recipients. Am J 
Kidney Dis 2000;35:660-6
241. Koziolek MJ, Riess R, Geiger H, Thévenod F, 
Hauser IA. Expression of multidrug resistance 
P-glycoprotein in kidney allografts from 
cyclosporine A-treated patients. Kidney Int 
2001;60:156-66
242. Wojnowski L. Genetics of the variable expression 
of CYP3A in humans. Ther Drug Monit 
2004;26:192-9
243. Ensom MHH, Chang TKH, Patel P. 
Pharmacogenetics: the therapeutic drug 
monitoring of the future? Clin Pharmacokinet 
2001;40:783-802
244. Evans WE, McLeod HL. Pharmacogenomics: 
drug disposition, drug targets, and side effects. N 
Engl J Med 2003;348:538-49
245. Weinshilboum R. Inheritance and drug response. 
N Engl J Med 2003;348:529-37
246. Vincenti F, Larsen C, Durrbach A, et al. 
Costimulation blockade with belatacept in renal 
transplantation. Belatacept Study Group. N Engl 
J Med 2005;353:770-81
247. Kappos L, Antel J, Comi G, et al. Oral fingolimod 
(FTY720) for relapsing multiple sclerosis. 
FTY720 D2201 Study Group. N Engl J Med 
2006;355:1124-40
49
General Introduction

PART 2
THERAPEUTIC DRUG 
MONITORING

CHAPTER 2.1
THE RELATIVE 
IMPORTANCE OF 
CYCLOSPORINE 
EXPOSURE IN HEART, 
KIDNEY OR LIVER 
TRANSPLANT RECIPIENTS 
ON MAINTENANCE 
THERAPY
Dennis A Hesselink, Thea van Dam, Herold J Metselaar, Aggie HMM Balk,  
Ron AA Mathôt, Peter JH Smak Gregoor, Willem Weimar, Teun van Gelder
Transplant Int 2004;17:495-504
54
Chapter 2.1
ABSTRACT
We investigated the relationship between cyclosporine exposure and the presence of 
cyclosporine-related side effects and assessed the advantage of the cyclosporine concentration 
2 h postdose (C
2
) over predose concentration (C
0
) monitoring. Cyclosporine area-under the 
concentration versus time-curves were measured during the absorption phase (AUC
0-4 h
) in 
49 liver, 28 heart and 26 kidney transplant recipients (time since transplantation >6 years) 
with or without cyclosporine-related side effects on maintenance therapy. The cyclosporine 
C
0
 correlated well with AUC
0-4 
(r = 0.77), whereas C
2
 levels correlated strongly with AUC
0-
4
 (r = 0.92). Although we observed a trend towards higher cyclosporine concentrations 
in transplant recipients with side effects as compared with patients without cyclosporine 
toxicity, the large majority of those differences were not statistically significant. Thus, as 
cyclosporine exposure was not clearly related to the presence of side effects, and C
0 
correlated 
fairly with AUC
0-4
, the advantage of monitoring cyclosporine treatment using C
2 
rather than 
C
0
, may be limited for patients on cyclosporine maintenance therapy.
55
The relative importance of cyclosporine exposure in heart, kidney or liver transplant recipients on maintenance therapy
INTRODUCTION
The introduction of cyclosporine in the early 1980s resulted in a significant improvement 
in the results of solid organ transplantation.1 However, the clinical use of cyclosporine is 
complex, due to its narrow therapeutic index, many drug interactions and highly variable 
pharmacokinetics.2 Moreover, cyclosporine has numerous side effects, such as nephrotoxicity, 
hypertension, hypercholesterolemia and the induction of glucose intolerance.1 Most 
transplantation centers have adopted the strategy of monitoring cyclosporine using whole 
blood, predose or trough concentration (C
0
) measurements and adjusting the cyclosporine 
dose to reach a certain predefined C
0 
target range, the limits of which may differ, depending 
on the organ transplanted and the time since transplantation.3
The clinical utility of this approach suffers from the fact that, in de novo transplant recipients, 
the cyclosporine C
0
 does not predict total drug exposure over a 12 h or 24 h time period [as 
measured by the area-under the cyclosporine concentration versus time-curve (AUC)] at the 
individual level and does not correlate well with clinical outcome.4-8 This is explained by the 
highly variable first-pass metabolism of cyclosporine that occurs mostly during the first 4 h 
following oral administration of the drug.9 Therefore, a potential risk of the monitoring of 
cyclosporine using C
0
 is that low drug exposure may not be detected, possibly resulting in 
under-immunosuppression and the risk of acute rejection.
Likewise, high cyclosporine exposure may go unnoticed, resulting in (long-term) toxicity. 
Some have, therefore, advocated the use of an abbreviated AUC instead of the C
0
 to monitor 
cyclosporine therapy. The cyclosporine AUC in the first 4 h after oral administration (AUC
0-
4
) has been shown to correlate well with the AUC
0-12
 and to predict clinical outcome after 
kidney transplantation.5,6,10 Because the determination of an AUC
0-4
 is time consuming, 
expensive and not practicable for use in an outpatient clinic, there has been continuing 
interest in simpler parameters for therapeutic drug monitoring (TDM) of cyclosporine. The 
whole-blood cyclosporine concentration 2 h after administration of the drug (C
2
) was shown 
to be the single time point with the best correlation with total drug exposure.6,9,11
Subsequently, C
2
 monitoring
 
has been used for TDM in several clinical trials and has, 
generally, resulted in a low or decreased incidence of acute rejection and excellent (renal) 
tolerability when compared with C
0
 monitoring.12-16 Following the outcomes of these trials, 
target values for C
2
 have been identified. Currently, the recommended C
2
 values for liver 
and kidney transplant recipients more than 6 months after transplantation are 600 ng/mL 
± 20% and 800 ng/mL ± 20%, respectively.9,11,16 C
2
 target levels have not yet been established 
for heart transplant recipients. The measuring of C
2
 concentrations, however, does require 
a considerable effort to reliably draw blood at exactly the correct time point. Because of the 
practical limitations of this approach, many transplantation centers have not changed their 
policy of performing TDM on the basis of cyclosporine trough levels.
Although the correlation between acute rejection and nephrotoxicity and cyclosporine 
exposure as measured by an AUC
0-4
 or C
2
 has been established in de novo transplant recipients, 
the relation between drug exposure and other cyclosporine-related side effects is less clearly 
defined, especially in patients on long-term cyclosporine treatment. We feel that this is very 
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important because these other cyclosporine-related side effects negatively influence patient 
survival, quality of life and the long-term outcome after transplantation. Moreover, the 
occurrence of cyclosporine-related side effects may lead to patient non-compliance, with the 
risk of acute rejection. In our center we routinely measure cyclosporine C
0
 after kidney, liver 
and heart transplantation. We do acknowledge that individual patients may suffer from side 
effects that seem to be cyclosporine related, although predose concentrations are within, or 
even at the lower end of, the defined target range. Possibly, the use of another method for 
TDM, i.e. an AUC
0-4
 or C
2
, would recognize the increased exposure to cyclosporine in these 
patients.
The aim of this study was twofold. First we investigated whether solid organ allograft 
recipients with cyclosporine-related side effects on maintenance therapy with cyclosporine 
and with cyclosporine C
0
 within the therapeutic range, had a higher exposure to cyclosporine 
than did a control group of transplant recipients, at similar cyclosporine C
0
 but without 
cyclosporine-related side effects. We therefore measured the cyclosporine AUC
0-4
 in 103 
liver, kidney and heart allograft recipients more than 6 months after transplantation. Second 
we determined how many of those patients had C
2
 levels above the currently recommended 
target ranges.
MATERIALS AND METHODS
PATIENTS
During routine outpatient clinical visits, all patients who had received a heart, kidney or 
liver transplant at the Erasmus Medical Center in the Netherlands were asked to participate 
in the study. Patients had to have been on cyclosporine treatment, for at least 3 months 
without changes in cyclosporine dosage, during the 3 months before entry into the study. All 
patients used the cyclosporine microemulsion formulation (Neoral®, Novartis) twice daily in 
two equally divided doses. Patients taking medication known to interact with cyclosporine, 
such as the calcium-channel blockers diltiazem, nicardipine or verapamil, anti-epileptics 
(phenytoin and carbamazepine), antimycotics (fluconazole and ketoconazole) and macrolide 
antibiotics (erythromycin and clarithromycin), were not included in the study.
On the day of the pharmacokinetic study, patients were (physically) examined for the 
presence of renal insufficiency (serum creatinine ≥125 μmol/L in liver and heart transplant 
recipients; not determined in kidney transplant recipients), hypertension (blood pressure 
≥150/100 mmHg or the use of antihypertensive medication), hypercholesterolemia (total 
serum cholesterol >7.5 mmol/L or the need for lipid-lowering drugs that was not present 
prior to transplantation), gum hyperplasia, hirsutism and hypertrichosis, polyneuropathy 
or tremor of the hands (not caused by diabetes mellitus or otherwise explained by co-
medication such as theophyllin or sympathicomimetics), diabetes mellitus (defined by the 
need for glucose-lowering drugs that was not present before transplantation) and (post-
transplantation) gout. If any of these symptoms was present, on the day of the study as well 
as during the 3-month period before entry into the study (determined by history taking 
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and patient chart review), patients were classified as having cyclosporine-related side effects. 
As a control group we selected solid organ allograft recipients who exhibited none of the 
above-mentioned cyclosporine-related side effects. The study was carried out in accordance 
with the declaration of Helsinki and was approved by the ethics committee of the Erasmus 
Medical Center. All patients gave written informed consent.
CYCLOSPORINE AUC0-4 MEASUREMENT
On the day of the AUC
0-4
 measurement an intravenous cannula was inserted and maintained 
with 0.9% NaCl solution. After the C
0
 whole-blood sample had been drawn, patients were 
asked to take their cyclosporine. Following cyclosporine administration, blood was drawn 
at 1, 2, 3 and 4 h. All patients had been instructed to take their regular cyclosporine dose 
12 h before, on the previous day. The blood samples were frozen and stored at -30°C 
until the cyclosporine concentration was determined. Cyclosporine concentrations were 
determined by Emit 2000 assay (Syva, Dade Behring, Cupertino, CA, USA) on a Cobas 
Mira Plus analyzer (Roche). We used the trapezoidal rule to calculate the AUC
0-4
. The peak 
cyclosporine concentration (C
max
) and the time to peak cyclosporine concentration (t
max
) 
were obtained directly from the data.
STATISTICAL ANALYSIS
We used Student’s unpaired t-test, Fisher’s exact test with Yates’ continuity correction or one-
way ANOVA followed by Tukey’s post-hoc test, as appropriate, to compare pharmacokinetic 
parameters. For correlation analysis, we calculated Pearson’s correlation coefficient, followed 
by linear regression and used Fisher’s Z-transformation to compare correlation coefficients. 
Unless stated otherwise, data are presented as means ± SD. A P value of less than 0.05 was 
considered statistically significant.
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RESULTS
GENERAL DATA
A total number of 103 patients was included, of whom 49 had received a liver transplant, 28 a heart 
transplant and 26 patients a kidney transplant. The mean age at the time of transplantation was 
45.7 ± 11.4 years for liver transplant recipients, 45.7 ± 14.3 years for heart transplant recipients 
and 46.2 ± 14.4 years for kidney transplant recipients and was not different between the three 
groups (P = 0.99, one-way ANOVA). Time after transplantation was comparable between the 
three groups, with a mean follow-up time of 6.3 ± 3.1 years for liver transplant recipients, 6.7 
± 3.7 years for heart transplant recipients and 7.2 ± 5.9 years for kidney transplant recipients 
(P = 0.63). The other patient characteristics are summarized in Table 2.1.1.
Table 2.1.1 Characteristics of 103 solid organ transplant recipients.  
All values are expressed as means ± SD
Characteristic Liver Heart Kidney
Number of patients 49 28 26
Male / female sex (n) 20/29 22/6 17/9
Age at time of transplantation 
(years) 45.7 ± 11.4 45.7 ± 14.3 46.2 ± 14.4
Range (years) 19 - 64 14 - 66 13 - 71
Time since transplantation (years) 6.3 ± 3.1 6.7 ± 3.7 7.2 ± 5.9
Range (years) 1.4 - 12.6 0.9 - 15.3 1.6 - 26
Underlying disease
     Primary sclerosing cholangitis 8
     Primary biliary cirrhosis 10
     Hepatitis B 8
     Hepatitis C 2
     Alcohol-induced liver cirrhosis 5
     Acute or toxic liver failure 7
     Unknown cause 5
     Other 4
     Ischemic heart disease 13
     Cardiomyopathy 14
     Congenital heart disease 1
     Hypertensive nephropathy 6
     Polycystic kidney disease 4
     Diabetic nephropathy 1
     Glomerulonephritis 2
     Unknown cause 8
     Other 5
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CYCLOSPORINE PHARMACOKINETICS
Daily cyclosporine dose was comparable between all three groups: 216 ± 80 versus 229 ± 76 
versus 238 ± 61 mg/day for liver, heart and kidney allograft recipients, respectively (P = 0.44; 
Table 2.1.2). Cyclosporine dose, calculated on a mg per kg bodyweight basis, was equal in 
all three groups as well: 2.9 ± 1.2 versus 2.9 ± 1.0 versus 3.1 ± 0.9 mg/kg/day for liver, heart 
and kidney allograft recipients, respectively (P = 0.79; Table 2.1.2). However, liver transplant 
recipients were maintained at significantly lower cyclosporine predose concentrations than 
were kidney transplant recipients: 115 ± 46 versus 144 ± 50 ng/mL (P < 0.05). The mean 
cyclosporine C
0
 of heart transplant recipients was not significantly different from those 
observed in either liver or kidney allograft recipients. In addition, cyclosporine C
1
, C
2
, C
3
, 
AUC
0-4
 and C
max
 were all significantly lower in liver transplant recipients compared with 
kidney allograft recipients, but not heart transplant recipients (Table 2.1.2). As illustrated 
in Figure 2.1.1, C
0
 correlated fairly with AUC
0-4
 and numerically less well with C
2
: Pearson’s 
r (r2) 0.77 and 0.72 (0.59 and 0.51), respectively (P < 0.0005). However, this difference was 
not statistically significant (P = 0.42, comparison of Pearson’s correlation coefficients using 
Fisher’s Z-transformation). The correlation between C
2
 and AUC
0-4
 was strong, with an 
r (r2) of 0.92 (0.85; P < 0.0005). The difference in correlation of C
0
 and C
2 
with AUC
0-4
 was 
statistically significant (P < 0.0005).
Table 2.1.2 Cyclosporine (CsA) dosage and pharmacokinetics in three groups of solid organ 
transplant recipients. All values are expressed as means ± SD. NS not significant
Transplantation type Liver Heart Kidney P §
Number of patients 49 28 26
CsA dose (mg/day) 216 ± 80 229 ± 76 238 ± 61 NS
CsA dose (mg/kg per day) 2.9 ± 1.2 2.9 ± 1.0 3.1 ± 0.9 NS
CsA C
0
 (ng/mL) 115 ± 46 122 ± 50 144 ± 50 < 0.05
CsA C
1
 (ng/mL) 754 ± 350 926 ± 352 1014 ± 452 < 0.05
CsA C
2
 (ng/mL) 641 ± 248 729 ± 290 884 ± 191 < 0.001
CsA C
3
 (ng/mL) 434 ± 202 449 ± 194 556 ± 160 < 0.05
CsA C
4
 (ng/mL) 305 ± 143 312 ± 140 382 ± 112 NS
CsA AUC
0-4
 (ng/mL per h) 2039 ± 727 2321 ± 827 2718 ± 671 < 0.01
C
max 
(ng/mL) 833 ± 319 975 ± 303 1116 ± 365 < 0.01
t
max
 (h) 1.4 ± 0.6 1.3 ± 0.4 1.4 ± 0.5 NS
§ P values indicate differences in pharmacokinetic parameters between liver transplant recipients and kidney 
transplant recipients (one-way ANOVA with Tukey’s post-hoc test).
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CYCLOSPORINE PHARMACOKINETICS  
AND CYCLOSPORINE-RELATED SIDE EFFECTS
Of the 49 liver transplant recipients included in the study, 30 patients (61.2%) had cyclosporine-
related side effects, whereas 19 patients (38.8%) had none. Hypertension was present in 25 of the 
30 patients with side effects (51.0%), renal insufficiency in 22 patients (44.9%) and hypertrichosis/
hirsutism in 21 patients (42.9%). Gingival hyperplasia was found in 11 patients (22.4 %) and 
tremor of the hands and hypercholesterolemia were each found in seven patients (14.3%). No liver 
transplant recipients with gout were identified. Although there was an overall trend towards lower 
cyclosporine concentrations in patients without side effects as compared with the group of patients 
with cyclosporine toxicity, none of these differences reached statistical significance (Table 2.1.3).
Figure 2.1.1 A-C  Correlation between 
cyclosporine C0 and AUC0-4 (A); cyclosporine 
C0 and C2 (B); cyclosporine C2 and AUC0-4 
(C) in 103 liver, heart and kidney transplant 
recipients on maintenance cyclosporine 
therapy
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Table 2.1.3 Cyclosporine (CsA)-related side 
effects and cyclosporine pharmacokinetics. 
No statistically significant differences in 
any of the cyclosporine pharmacokinetic 
parameters were observed between patients 
with and patients without side effects in the 
three groups. All values are expressed as 
means ± SD
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Table 2.1.4 
Cyclosporine 
(CsA)-related side 
effects and CsA 
pharmacokinetics 
in liver, heart and 
kidney transplant 
recipients. All values 
are expressed as 
means ± SD
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Next, we compared cyclosporine exposure in liver transplant patients suffering from an 
individual side effect with that in patients who did not have that particular side effect (Table 
2.1.4). Patients with gingival hyperplasia used significantly more cyclosporine than did with 
patients who did not have gingival hyperplasia: 3.6 ± 1.5 versus 2.7 ± 1.0 mg/kg per day, 
respectively (P = 0.025). As a result, cyclosporine exposure (C
2
, C
max
 and AUC
0-4
) was also 
significantly higher in patients with gingival hyperplasia (Table 2.1.4). Likewise, patients 
with hypertrichosis or hirsutism used significantly more cyclosporine than those patients 
with no excessive hair growth: 3.3 ± 1.5 versus 2.6 ± 0.8 mg/kg per day, respectively (P = 
0.045). This difference was reflected by a higher cyclosporine C
max
 in the former patient 
group: 936 ± 325 versus 755 ± 298 ng/mL (P = 0.049). For all other side effects studied 
(including nephrotoxicity and hypertension, data not shown), cyclosporine exposure in liver 
transplant recipients with a specific side effect was not statistically, significantly different 
from patients who did not have that side effect (Table 2.1.4).
Of the 28 heart transplant recipients included in the study, 20 were identified as having side 
effects. Hypertension and hypertrichosis/hirsutism were the most common, each present in 
18 (64.3%) patients, followed by hypercholesterolemia (12 patients; 42.9%), renal insufficiency 
(11 patients; 39.3%), tremor/polyneuropathy (10 patients; 35.7%) and gingival hyperplasia 
(nine patients; 32.1%). When cyclosporine pharmacokinetics were compared between heart 
transplant recipients with, and those without, any side effects, no significant differences 
were observed in any pharmacokinetic parameter (Table 2.1.3). The pharmacokinetics of the 
patients suffering from individual side effects (including nephrotoxicity, hypertension and 
gout) were not different from those of patients without those individual side effects (Table 
2.1.4).
Finally, cyclosporine-related side effects were identified in 14 of the 26 renal transplant 
recipients included in the study. Hypertrichosis/hirsutism and gingival hyperplasia were 
the most frequently observed side effects and were each present in 11 patients (42.3%). 
Tremor or polyneuropathy was identified in seven patients (26.9%) and hypertension and 
hypercholesterolemia were present in four patients (15.4%); one patient (3.8%) suffered 
from gout. Because renal insufficiency in kidney transplant recipients is often determined 
by many factors and difficult to distinguish from cyclosporine nephrotoxicity (especially 
in the absence of a kidney biopsy), this side effect was not studied in this patient group. 
However, all patients that were classified as having no side effects did not show any clinical 
evidence for the presence of cyclosporine nephrotoxicity. As in liver and heart transplant 
recipients, no significant differences in any of the cyclosporine pharmacokinetic parameters 
were observed between the groups of patients with and without cyclosporine side effects 
(Table 2.1.3). When individual side effects were analyzed, we observed a higher cyclosporine 
dose and cyclosporine C
max
 in patients with neurotoxicity than in patients who did not have 
tremor or polyneuropathy: 3.6 ± 1.0 versus 2.8 ± 0.7 mg/kg per day (P = 0.036), and 1017 
± 201 versus 835 ± 167 ng/mL (P = 0.028), respectively. In addition, the four patients with 
hypercholesterolemia had a higher cyclosporine exposure than those patients with normal 
serum cholesterol levels (Table 2.1.4). Cyclosporine exposure in patients with gingival 
hyperplasia, hypertrichosis/hirsutism, hypertension or gout was comparable to that in 
patients without those specific side effects (Table 2.1.4).
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CYCLOSPORINE-RELATED SIDE EFFECTS AND C2
Of the 49 liver transplant recipients, 19 patients (38.8%), had a C
2
 value above the recommended 
target range of 600 ng/mL ± 20%. C
2
 was below this target range in 16 (32.7%) liver 
transplant recipients (Figure 2.1.2A). The percentage patients with C
2
 levels above target was 
not different between the group of liver transplant recipients with or without cyclosporine-
related side effects (P = 0.55, Fisher’s exact test with Yates’ continuity correction). Of the 26 
kidney transplant recipients, eight patients (30.8%) had a C
2
 value above the recommended 
target value of 800 ng/mL ± 20%. The C
2
 value was below this target range in two (7.7%) 
kidney transplant recipients (Figure 2.1.2B). Again, the number of patients with C
2
 levels 
above target was not different between the group of kidney transplant recipients with or 
without cyclosporine-related side effects (P = 1.00). Of the 28 heart transplant recipients, 
ten (35.7%) had a C
2
 value above 600 ng/mL ± 20%. In four of those patients (14.3%) the C
2
 
value exceeded 800 ng/mL ± 20%.
Figure 2.1.2 A-B Cyclosporine (CsA) C2 levels and CsA-related side effects in 49 liver (A) and 26 
kidney (B) transplant recipients. The target level ± 20% range is indicated by dotted lines.
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DISCUSSION
The introduction of microemulsified cyclosporine and the publication of several clinical 
trials that compared the effectiveness of cyclosporine to tacrolimus, have led to a renewed 
interest in TDM and the pharmacokinetics of cyclosporine.17,18 In recent years, both C
2
 and 
AUC
0-4
 have been demonstrated to be useful cyclosporine-monitoring tools that correlate 
well with the incidence of acute rejection and nephrotoxicity.5,6,10,12-15 However, most of those 
studies were performed in de novo transplant recipients and did not relate cyclosporine 
pharmacokinetics to cyclosporine-related side effects other than renal insufficiency or 
hypertension.
The kidney transplantation program of the Erasmus Medical Center started in 1971 and 
was followed by the heart transplant program in 1984 and the liver transplant program 
in 1986. Since then, more than 1500 kidney, 400 heart and 350 liver transplantations have 
been carried out. For many years, cyclosporine was the calcineurin inhibitor of choice, but, 
in recent years we have switched to tacrolimus-based immunosuppressive regimens for our 
kidney and liver transplant recipients. However, many of our patients still use cyclosporine 
and often suffer from cyclosporine-related side effects. In the present study we therefore 
investigated the relationship between cyclosporine pharmacokinetics and cyclosporine-
related side effects.
In our cohort of patients on cyclosporine maintenance therapy, cyclosporine pharmacokinetics 
did not correlate well with the presence of cyclosporine-related side effects. Although we did 
find an overall trend towards higher cyclosporine exposure in patients with (a specific) side 
effect(s), the majority of those differences did not reach statistical significance. In addition, 
the same cyclosporine exposure that was associated with the presence of a particular side 
effect in one type of transplant recipient was not related to the occurrence of that same side 
effect in patients who had had a different organ transplanted. In our opinion, this argues 
against a clear relationship between cyclosporine whole-blood concentrations and the 
presence of cyclosporine toxicity.
David-Neto et al. studied a pediatric kidney transplant cohort and found statistically 
significant correlations between cyclosporine pharmacokinetics and the occurrence 
of side effects.19 An AUC greater than or equal to 4158 ng/mL predicted the presence of 
hypertrichosis, whereas a C
max
 greater than or equal to 878 ng/mL was the best predictor 
for the appearance of tremors. Gingival hyperplasia was not associated with any of the 
pharmacokinetic parameters studied.19 Those results are not necessarily contradictory to 
our findings. The mean cyclosporine dose and AUC
0-4
 of our adult patients were much lower 
than those reported in the Brazilian pediatric study cohort. This could be explained by the 
fact that most of our patients were on long-term cyclosporine therapy and many of them had 
already undergone several cyclosporine dose reductions before the start of the study.
In many cases, the presence of side effects had been an important reason for cyclosporine dose 
reduction. Those previous dose reductions could have reduced a difference in cyclosporine 
exposure that might have existed between patients with or without side effects. As this was a 
cross-sectional study we do not have data on cyclosporine exposure at the time of emergence 
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of cyclosporine-related side-effects. Furthermore, a positive selection of the investigated 
patients might have occurred, as patients with severe side effects might have been switched 
to cyclosporine-free immunosuppressive regimens prior to the start of our study.
Our observations raise the question as to whether a further cyclosporine dose reduction 
in our population will result in a decrease in the incidence and severity of side effects. 
Cyclosporine exerts its immunosuppressive effect through inhibition of calcineurin (CN), 
an enzyme that is important for the activation of T cells. Several studies investigating the 
relationship between cyclosporine pharmacokinetics and CN inhibition demonstrated that, 
in vivo, CN is only partially inhibited. At C
0
 (ranging between 148 and 180 ng/mL), CN 
was inhibited by 50%, while cyclosporine peak concentrations (about 400 to 1800 ng/mL) 
resulted in around 70-80% CN inhibition.20-22 Moreover, CN inhibition rarely reached 100% 
and was greater in some tissues due to drug accumulation.22
From these data it can be concluded that, at commonly used cyclosporine target levels, the 
maximal pharmacodynamic effect of the drug is obtained and that further increasing drug 
blood levels will probably result only in a high incidence of side effects and considerable drug 
toxicity. Therefore, many transplant patients probably receive too much cyclosporine and 
can undergo dose reduction, while the desired immunosuppressive effect of the drug is still 
maintained. More than one-third of our patients had C
2
 levels above currently recommended 
target ranges, and adaptation of C
2
 monitoring could result in (early) identification of 
cyclosporine “overexposure” and, subsequently, in (further) dose reductions. Levy et al. 
recently reported the results of conversion of liver transplant patients in the maintenance 
phase from C
0
 to C
2
 monitoring.23 Of the 351 patients that were converted, 36% had C
2
 levels 
above the recommended target range. In those patients, a mean cyclosporine dose reduction 
of 16% was required to achieve target range, resulting in a significant improvement of renal 
function, blood pressure and serum cholesterol.23
Similar results have recently been reported for renal transplant recipients.24 To study whether 
this approach will also lead to fewer (or less severe) side effects in our patient cohort, we 
are currently converting all liver transplant patients reported here to C
2
 level monitoring 
followed by dose reduction, if indicated. However, C
0 
correlated much better with AUC
0-4
 
than has been reported previously.5,24 Possibly, the difference in time after transplantation 
explains the difference between the results of Mahalati et al. and our own. Nonetheless, 
our results may indicate that the reported beneficial effects of C
2
 level monitoring might be 
limited for patients on cyclosporine maintenance therapy. Lowering currently used C
0
 target 
levels could result in a substantial cyclosporine dose reduction as well, without the logistic 
problems associated with (the implementation of) C
2
 level monitoring.
Alternatively, conversion of patients to tacrolimus is another possibility to decrease the 
incidence and severity of cyclosporine-related side effects. In 55 heart transplant recipients 
that were converted from cyclosporine to tacrolimus-based immunosuppressive therapy 
at our center, a significant improvement in blood pressure, serum cholesterol and gum 
hyperplasia, without signs of acute rejection, was observed, even in patients who were as 
long as 14 years after transplantation.25
67
The relative importance of cyclosporine exposure in heart, kidney or liver transplant recipients on maintenance therapy
In kidney transplant recipients, conversion to tacrolimus has been shown to be safe and 
to result in lower serum cholesterol levels with an improvement in gingival hyperplasia 
and hypertrichosis26,27 and with an improved creatinine clearance in one study.27 In a 
retrospective analysis of 94 liver transplant recipients, converted to tacrolimus for a variety 
of reasons, conversion resulted in a reduction of serum creatinine from 167 ± 36 to 119 ± 
28 mmol/L (1 year after conversion).28 Besides conversion to tacrolimus, complete cessation 
of cyclosporine is another possibility that has been studied. The results of the meta-analysis 
by Kasiske et al. demonstrate that discontinuation of cyclosporine results in an 11% higher 
risk for the development of acute rejection than in controls, in kidney transplantation.29 
However, the relative risk of graft failure was not significantly different from that of the 
control group.
In conclusion, we demonstrate no clear differences in cyclosporine exposure in solid organ 
transplant recipients with or without cyclosporine-related side effects. Cyclosporine C
2
 levels 
were above currently recommended target ranges in 38.8% of liver and 30.8% of kidney 
transplant recipients, but C
2
 levels above target were not more frequent in patients with side 
effects than in those with none. Cyclosporine dose reduction could be effective and safe 
in those patients. However, as the correlation between C
0
 and AUC
0-4 
was better than that 
previously reported, the advantage of C
2
 over conventional C
0
 level monitoring might be 
limited in patients on low or moderate dose cyclosporine maintenance therapy.
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ABSTRACT
Background Recent studies suggest that cyclosporine dose adjustment based on C
2
 levels 
results in improvement of renal function. This study investigated the effect on renal function 
of dose reduction based on C
2
 levels in long-term liver transplant patients. Methods In 60 
patients (>1 year after transplantation), C
2
 levels were assessed (target 600 ng/mL ± 20%). 
Dose reduction was performed if C
2
 exceeded 720 ng/mL. Serum creatinine concentrations 
were measured and creatinine clearance was calculated. Results Twenty-three patients (38%) 
had C
2
 values >720 ng/mL. After dose reduction, the mean cyclosporine dose decreased 
by 25% (P < 0.01). The mean C
2
 value decreased by 42% (P < 0.01). Serum creatinine 
concentrations remained stable. After dose reduction two patients experienced recurrence 
of primary biliary cirrhosis, in one patient autoimmune hepatitis recurred and rejection 
was diagnosed in one patient. Conclusion Cyclosporine C
2 
concentrations
 
above 720 ng/mL 
are common in long-term liver transplant patients. Dose reduction of 25% did not improve 
kidney function and was accompanied by immune activation.
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INTRODUCTION
Renal dysfunction after transplantation is considered a problem for transplant recipients as 
it may progress towards end-stage renal failure requiring dialysis or renal transplantation.1,2 
The incidence of chronic renal failure is reported to be as high as 7% to 21% five years after 
transplantation of a non-renal organ. Forty-six percent of the patients in whom end-stage 
renal failure developed were placed on the waiting list for kidney transplantation.3
The incidence of chronic renal failure in liver transplant patients is 18% and seems to be 
higher compared with heart, lung and heart-lung transplant patients. Diabetes mellitus, 
hypertension and hepatitis C infection were independent risk factors for renal failure.3
Monitoring cyclosporine blood levels to avoid underdosing or toxicity is one of the essential 
issues in the follow-up of long-term liver transplant patients. Traditionally, cyclosporine 
dose is adjusted based on predose levels (C
0
). However, there is accumulating evidence that 
the cyclosporine concentration 2 h after administration (C
2
) is a more sensitive tool for 
optimizing cyclosporine dosing.4,5 The C
2
 level may be the most accurate predictor of the 
area-under the concentration versus time-curve (AUC) as a measure of total cyclosporine 
exposure.4 Recent studies report a decreased incidence of acute rejection, as well as a 
decrease in cyclosporine-related side effects, in organ transplant patients by using C
2 
monitoring instead of the conventional C
0
 monitoring.6,7 Dose reduction in overexposed 
patients according to C
2
 levels is reported to result in improvements in renal function and 
blood pressure.8-10
So far, one study has examined the effects of dose adjustment based on C
2
 levels in liver 
transplant patients more than 1 year post-transplantation.9 At our center, the incidence of 
renal dysfunction shows an increase after onset of treatment with calcineurin inhibitors. In 
177 patients we observed that 50.1% of the patients had a glomerular filtration rate below 60 
mL/min 2 years after liver transplantation (unpublished results). This is then followed by a 
slow but continuing loss of renal function.
Therefore, we analyzed the effects of dose individualization by C
2
 monitoring in liver 
transplant patients more than 1 year after transplantation. The aim of this study was twofold. 
First, we wanted to investigate the effects on renal function after dose reduction based on the 
C
2
 levels in long-term liver transplant patients and secondly, to evaluate the possible risks of 
this dose reduction.
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PATIENTS AND METHODS
PATIENTS
In February 2002, 60 stable liver transplant patients who received their first liver transplant 
between April 1988 and January 2001, were included in the study. The characteristics of the 
patients are presented in Table 2.2.1.
Table 2.2.1 Patient characteristics
All patients Group 1
(C2 ≥ 720 ng/mL)
Group 2
(C2 < 720 ng/mL)
P
Gender (male/female) 25/35 9/14 16/21 NS
Mean age at transplantation (year) 47.1 ± 11.6 46.7 ± 7.9 47.4 ± 13.6 NS
Mean time post-transplant (year) 6.0 ± 3.2 5.1 ± 2.8 6.5 ± 3.3 NS
Liver disease
(HBV/HCV/ALD/PBC/other) (n) 10/3/5/25/17 3/0/2/11/7 7/3/3/14/10 NS
Conversion from Sandimmune to 
Neoral (n) 20 8 12 NS
HBV, hepatitis B; HCV, hepatitis C; ALD, alcohol-induced liver disease; PBC, primary biliary cirrhosis.
INCLUSION CRITERIA
Patients with stable allograft function, who had received their transplant at least 1 year 
earlier and who used microemulsified cyclosporine as maintenance immunosuppressive 
drug, were eligible to participate in this study. Written informed consent was given by all 
participants.
IMMUNOSUPPRESSION
Standardized immunosuppression protocols were used. All patients had previously been 
monitored by C
0
. Cyclosporine was initiated within 24 h post-reperfusion and adopted to 
reach a C
0
 of between 200 and 400 ng/mL during the first 3 months after transplantation 
and between 100 and 200 ng/mL thereafter. The cyclosporine dose was adjusted in case of 
rejection or cyclosporine-related toxicity.
In September 1995, conversion from the oil-based cyclosporine formulation (Sandimmune; 
Novartis, Basle, Switzerland) to the microemulsion cyclosporine formulation (Neoral; Novartis) 
took place at our center. Before replacement of Sandimmune by Neoral, 20 patients were 
initially treated with Sandimmune. At the time of inclusion in this study, 38 patients (63.3%) 
were on Neoral monotherapy, 13 patients (21.7%) were treated with Neoral and prednisone, 
five patients (8.3%) were treated with Neoral, prednisone and azathioprine, two patients were 
treated with Neoral and azathioprine, one patient was treated with Neoral and mycophenolate 
mofetil (MMF) and one patient was treated with Neoral, prednisone and MMF.
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STUDY DESIGN
At the beginning of the study all 60 patients had their C
0
 and C
2
 levels assessed. For the 
purpose of this study, the target C
0
 level was defined as 125 ng/mL (± 20%). The target 
C
2
 level was defined as 600 ng/mL (± 20%).11 Cyclosporine dose reduction was performed 
when the C
2
 value exceeded 720 ng/mL using the formula: New dose = (old dose x 600) / 
actual C
2
 level.12 Cyclosporine dosage was left unaltered in patients whose C
2
 levels were 
more than 20% below target (<480 ng/mL) in order to avoid cyclosporine overexposure in 
stable patients. Patients were divided into two subgroups based on whether or not they had 
cyclosporine dose reduction. Patients in group 1 had C
2
 values above 720 ng/mL and the 
dose of cyclosporine was reduced. Patients in group 2 had C
2
 values below 720 ng/mL and 
their dose of cyclosporine was not changed.
In order to assess changes in renal function, serum creatinine concentrations were collected 
6 months before inclusion and measured at 2 weeks, 4 weeks, 8 weeks, 3 months and 6 months 
after cyclosporine dose reduction. Additionally, the creatinine clearance was calculated 
using the Modification of Diet in Renal Disease Study (MDRD) formula.13 Clinical outcome 
was monitored by routine biochemical measurements at similar visits. Graft rejection and 
recurrence of liver disease were diagnosed by increased levels of aspartate aminotransferase, 
alanine aminotransferase, alkaline phosphatase and bilirubin and were confirmed by 
histological examination of a liver biopsy.
CYCLOSPORINE CONCENTRATION MEASUREMENT
After drawing the predose whole-blood sample, patients were asked to take their cyclosporine. 
Then, blood was drawn 2 h ± 15 minutes after cyclosporine intake. After collection of the 
blood samples, cyclosporine concentrations were determined using the Emit 2000 assay 
(Syva company, Dade Behring inc., Cupertino, CA) on a Cobas Mira Plus analyzer (Roche 
diagnostic systems).
STATISTICAL ANALYSIS
Statistical analysis was conducted using the SPSS statistics software SPSS/PC 11.1. The paired 
t-test was used to test the difference between 6 months follow-up and start (t = 0) of the 
cyclosporine dose, C
2
, serum creatinine concentration and creatinine clearance separately 
for group 1 and in group 2. The Pearson’s correlation coefficient between C
0
 and C
2
 was 
calculated. Differences in the distribution of gender, age at transplantation, time since 
transplantation, liver disease and conversion from Sandimmune to Neoral between group 
1 and group 2 were assessed with the chi-square test for categorical variables and Student’s 
t-test for continuous variables. P values smaller than 0.05 were considered statistically 
significant. All data are represented as means ± standard deviation (SD).
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RESULTS
The mean cyclosporine C
0
 was 122.1 ± 54.9 ng/mL and the mean C
2
 level was 652.1 ± 274.3 
ng/mL. There was a wide range of C
2
 values (188.0 - 1510.0 ng/mL). The correlation between 
C
0
 and C
2
 was weak (r = 0.59). Twenty-three patients had C
2
 values above 720 ng/mL, 16 
patients had C
2
 values within the target range of 480-720 ng/mL and 21 patients had C
2
 
values below 480 ng/mL. Eleven of the 23 patients (48%) with high C
2
 had C
0
 values below 
or within the 100-150 ng/mL range (Table 2.2.2).
Table 2.2.2 C0 and C2
C0 / C2 Low C2
(≤ 480 ng/mL)
Normal C2
(480-720 ng/mL)
High C2
(≥ 720 ng/mL)
Total
Low C
0
 15 5 1 21
Normal C
0
 5 8 10 23
High C
0
1 3 12 16
Total 21 16 23 60
C
0
, cyclosporine predose concentration; C
2
, cyclosporine concentration 2 h after administration.
Figure 2.2.1 Cyclosporine dose and C2 level (group 1)
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Accordingly, 23 patients with C
2
 levels >720 ng/mL were selected for cyclosporine dose 
reduction. However, three of 23 patients did not agree with dose reduction and were 
not included in prospective part of the study. Dose reduction was performed in twenty 
patients (group 1). In 37 patients with the C
2
 level within or below the desired target range, 
cyclosporine dosage was not reduced (group 2).
At 6 months follow-up, the mean cyclosporine dose was decreased from 3.58 ± 0.95 mg/kg 
per day to 2.69 ± 0.91 mg/k per day in group 1, representing a 25% reduction in cyclosporine 
dosage (P < 0.01). The corresponding mean C
2
 decreased from 933.9 ± 209.0 ng/ml to 545.3 ± 
228.3 ng/mL (P < 0.01), representing a 42% decrease, 6 months after dose reduction (Figure 
2.2.1). Seventy-five percent of the patients were on target after 2 weeks.
Table 2.2.3 Renal function, blood pressure and lipid levels before and after dose reduction
t = 0 t = 6 months P
Group 1 (C
2
 ≥ 720 ng/mL; n = 20)
     Serum creatinine (mg/dL) 1.3 ± 0.4 1.4 ± 0.4 NS
     Creatinine clearance (ml/min per 1.73m2) 55.2 ± 18.1 53.0 ± 19.1 NS
     Systolic blood pressure (mmHg) 148 ± 20 144 ± 21 NS
     Diastolic blood pressure (mmHg) 92 ± 8 83 ± 11 0.01
     Total cholesterol (mmol/L) 5.3 ± 0.7 5.6 ± 1.6 NS
     Triglycerides(mmol/L) 2.0 ± 1.1 1.9 ± 1.4 NS
Group 2 (C
2
 < 720 ng/mL; n = 37)
     Serum creatinine (mg/dL) 1.4 ± 0.4 1.4 ± 0.4 NS
     Creatinine clearance (ml/min per 1.73m2) 53.2 ± 20.2 53.1 ± 21.1 NS
     Systolic blood pressure (mmHg) 143 ± 19 139 ± 16 NS
     Diastolic blood pressure (mmHg) 85 ± 14 85 ± 9 NS
     Total cholesterol (mmol/L) 5.4 ± 1.1 5.5 ± 1.5 NS
     Triglycerides(mmol/L) 1.9 ± 0.6 1.9 ± 1.4 NS
Figure 2.2.2 Mean creatinine clearance (group 1)
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The mean creatinine concentration, creatinine clearance, systolic blood pressure and lipid 
level of group 1 remained stable during follow-up. None of the patients developed end-stage 
renal failure. Mean creatinine concentration 6 months before inclusion was measured and 
did not differ from the mean creatinine concentration at time of inclusion [6 months before 
inclusion: 1.4 ± 0.4 mg/dL versus at time of inclusion: 1.3 ± 0.4 mg/dL (NS)]. Mean diastolic 
blood pressure decreased significantly after cyclosporine dose reduction (P = 0.01). In group 
2, the renal function, blood pressure and lipid level did not change. Results of group 1 and 2 
before and after follow-up are presented in Table 2.2.3. Mean creatinine clearance of group 
1 during the 6 months follow-up is depicted in Figure 2.2.2.
In group 1, 1 patient (patient 1) experienced cellular rejection after 3 months follow-up, which 
was histologically classified as RAI 6. Corticosteroid pulse therapy was given as treatment 
and the cyclosporine dose was left unchanged. The C
2
 level at the time of diagnosis was 800 
ng/mL. In 2 patients (patients 2 and 3) recurrence of primary biliary cirrhosis was diagnosed 
clinically at the week 8 and month 6 visit, respectively. The diagnosis was confirmed 
histologically. Both patients were treated with ursodeoxycholic acid and the cyclosporine 
dosage of patient 3 was increased. The C
2
 levels at the time of diagnosis were 555 ng/mL and 
680 ng/mL, respectively. In a fourth patient (patient 4) autoimmune hepatitis recurred in 
week 8. Subsequently, the cyclosporine dosage was increased and allopurinol was given as 
additional treatment. In this patient, the C
2
 level at the time of diagnosis was 640 ng/mL.
Patients 1, 2 and 3 were on cyclosporine monotherapy and patient 4 was treated with 
cyclosporine and prednisolone at the time of diagnosis. Patients 1, 2, and 3 had a C
2
 value 
below the C
2
 target range at 1 visit. These events occurred before the diagnosis of rejection 
or recurrence. Patient 1 had a C
2
 level of 180 ng/mL at week 4, patient 2 had a C
2
 level of 470 
ng/mL at week 4, and patient 3 had a C
2
 level of 395 ng/mL 8 weeks after dose reduction. In 
group 2, no rejection or recurrence of autoimmune liver disease was observed.
DISCUSSION
This study of C
2
 monitoring in 60 stable liver transplant patients more than 1 year after 
transplantation shows that cyclosporine C
2 
concentrations
 
above 720 ng/mL in this group 
of patients is common. Overexposure was observed in 23 of the 60 patients (38%). Eleven of 
the 23 patients (48%) had C
0
 values below or within target range, indicating the limitation of 
C
0
 monitoring. These findings confirm the role of C
2
 monitoring in detecting cyclosporine 
overexposure in long-term liver transplant patients.
In an earlier publication, Cole et al. reported a cyclosporine overexposure of 49% in renal 
transplant patients more than 3 months after transplantation.8 In liver transplant patients, an 
overexposure of 68% was documented in patients more than 6 months after transplantation.14 
In 2 studies in stable renal transplant patients more than 1 year after transplantation, one 
described a C
2
 level exceeding 800 ng/mL in 29% of the patients, and the other observed a 
C
2
 above 850 ng/mL in 18% of the patients.15,16 Our study showing an overexposure of 38% 
is in line with these findings.
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Despite the linear relation in the used formula, a discrepancy was observed in our study 
between the cyclosporine dose and the measured C
2
 level. In renal transplant patients, after 
a dose reduction of 27.5%, Cole et al. observed a 37.3% decrease in the mean C
2
 value.8 
In liver transplant patients, Langers et al. reported that a 26.9 % dose reduction resulted 
in a 25.8% decrease in the mean C
2
 value measured on day 2 after dose reduction.14 We 
noticed that the discrepancy between the cyclosporine dose and the measured C
2
 level in 
our study is considerable compared with the studies mentioned above. This may be because 
of high within-patient variability. Also differences in studied patient populations with the 
time post-transplantation and the use of co-medication differing between groups should be 
taken into consideration.
After dose reduction we observed a decline in mean diastolic blood pressure in group 1. This 
was in line with findings of previous studies in long-term renal, heart and liver transplant 
patients.8-10 The mean serum creatinine concentration and mean creatinine clearance 
remained unchanged in our study. As the mean creatinine concentration 6 months before 
enrolment was comparable to that at the time of inclusion, we consider that there was no 
decline in slope of renal function in group 1 post-transplantation. Thus, the stabilized renal 
function during follow-up was not because of cyclosporine dose reduction. In contrast to 
other studies in non-renal transplant patients, we did not observe improvement in kidney 
function 6 months after cyclosporine dose reduction based on C
2 
levels. In liver transplant 
patients, Langers et al. reported a significant improvement of 11.6% (P = 0.016) in creatinine 
clearance at more than 6 months after transplantation (target C
2
 was 600 ± 15%).14 In a 
study by Cantarovich et al., a 5.1% (P = 0.006) decrease of the mean serum creatinine 
level was observed after cyclosporine dose reduction based on C
2
 levels in liver transplant 
patients more than 1 year after transplantation. The target C
2
 was between 300 and 600 
ng/mL.9 In a second study by Cantarovich et al. in heart transplant patients more than 1 
year after transplantation, a 2.3% decrease of serum creatinine was reported after dose 
reduction based on C
2
 levels, aiming at a range between 300 and 600 ng/mL.10 The lack 
of improvement in renal function in our study can be related to the C
2
 target range we 
used, which was higher than in the above-mentioned studies. Consistent with this idea, 
Cantarovich et al. reported an increase of the mean serum creatinine by 16% when a C
2
 
target level between 700 and 1000 ng/mL was used.9  Therefore, the selected C
2
 range is 
crucial in order to observe effects of dose adjustment based on C
2
 levels performed in long-
term liver transplant patients. Furthermore, our population had received a liver transplant 
at least 1 year before the enrolment. Consequently, irreversible damage to the kidney and 
its management by the reduction of cyclosporine dose already took place at the discretion 
of the attending hepatologist. The reversibility of cyclosporine nephrotoxicity is most likely 
to be more prominent early after transplantation. Cole et al. reported a significant decrease 
of serum creatinine levels in 54% of renal transplant patients at more than 3 months after 
transplantation by performing cyclosporine dose reduction based on C
2
 levels.8 Therefore, 
early introduction of dose adjustment based on C
2
 is probably more effective.
However, during follow-up we observed a brief period of increase in mean creatinine 
clearance in the first 4 weeks after cyclosporine dose reduction. These improvements in renal 
function were temporary. We hypothesize that this event is an acute reaction of the kidney 
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to a lower cyclosporine dose, which cannot be maintained because of irreversible damage to 
the kidney. Therefore, we doubt the necessity of a longer follow-up.
It is noteworthy that cyclosporine dose reduction in long-term liver transplant patients 
may lead to allograft rejection and recurrence of autoimmune hepatitis or primary biliary 
cirrhosis. This might be attributable to a period of cyclosporine underexposure, which 
could not be confirmed, as the C
2
 levels at the time of diagnosis were within the target 
range. However, a short period of low immune suppression cannot be ruled out. In addition, 
patients using no or a small amount of co-medication are probably susceptible to experience 
complications of low immune suppression. Fluctuation of C
2
 levels during follow-up may 
easily cause immune activation as the patients are using only cyclosporine or cyclosporine 
plus prednisone as immunosuppressive drugs. Therefore, the use of co-medication should be 
taken into consideration when cyclosporine dose adjustment is performed. When a patient is 
on cyclosporine monotherapy, dose reduction should be done with caution and it is probable 
that the target C
2
 level for this group of patients is higher than 600 ng/mL (± 20%).
So far, none of the related studies in stable renal transplant patients reported such side 
effects.8,16 After late conversion from C
0
 to C
2
 monitoring of cyclosporine in pediatric living-
donor liver transplant recipients, rejection was reported in one patient (1,7%).17 In adult 
stable liver transplant patients, rejection was reported in two patients after dose reduction. 
The AUC in these patients was below target.14 The authors performed cyclosporine dose 
reduction in liver transplant patients at more than 6 months after transplantation with 
19.4% of the patients on cyclosporine monotherapy.14 In our study 63.3% (38 of 60) of the 
patients (more than 1 year after transplantation) were on cyclosporine monotherapy and 
6.7% (4 of 60) of the patients had complications of immune activation. The problem of 
under-immunosuppression after cyclosporine dose reduction based on C
2
 levels is expected 
to be more prominent in long-term transplant patients because the number of patients who 
are using no immunosuppressive co-medication increases with time after transplantation.
In conclusion, cyclosporine dose reduction based on C
2
 levels in liver transplant patients more 
than 1 year post-transplantation is less profitable than in earlier stages and renal function may 
not be influenced. We realize that the risks of rejection and recurrence of autoimmune liver 
disease are not to be underestimated, especially in patients on cyclosporine monotherapy. 
By aiming for a C
2
 target range of 600 ng/mL (± 20%) no benefit in renal function was 
observed after cyclosporine dose reduction in long-term liver transplant patients.
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ABSTRACT
Aims To evaluate the effect of corticosteroids on tacrolimus pharmacokinetics. Methods 
In a randomized trial, kidney transplant recipients were treated with tacrolimus and 
mycophenolate mofetil with either daclizumab (n = 31) or 3 months of prednisone (n = 34). 
Tacrolimus dose-adjusted predose concentrations (C
0
) at month 1-6 were compared between 
both groups and within the corticosteroid group before and after prednisone withdrawal. 
Results At month 1 the tacrolimus dose-adjusted C
0
 in the corticosteroid group was 83 ± 8 
versus 119 ± 17 ng/mL per mg/kg in the daclizumab group. The tacrolimus dose-adjusted 
C
0
 within the corticosteroid group at month 1 and 2 was 42% and 29% lower compared 
with month 4 (P < 0.001). Conclusion A higher tacrolimus dose is required to reach target 
concentrations when used in combination with corticosteroids.
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INTRODUCTION
Tacrolimus is a standard immunosuppressive drug in many transplant centers.1 However, 
tacrolimus has a narrow therapeutic index and its pharmacokinetics show considerable 
interindividual variation. Therapeutic drug monitoring of tacrolimus whole-blood, predose 
concentrations (C
0
) is recommended and target ranges have been defined.2 Nevertheless, 
in everyday clinical practice new and sometimes life-threatening interactions with 
tacrolimus are encountered.3 These interactions may result in increased or decreased drug 
concentrations or in altered pharmacodynamic effects of tacrolimus, and deserve further 
and continued attention.4,5
Tacrolimus is metabolized by cytochrome P450 (CYP) 3A in liver and intestinal mucosa.6 
Intestinal phase I metabolism by CYP3A and active efflux of absorbed drug by P-glycoprotein 
are major determinants of oral bioavailability, which can be influenced by concomitant 
administration of inhibitors/inducers of these enzymes.7 Corticosteroids induce the CYP 
system, but it is unclear whether commonly used doses of these drugs have a clinically relevant 
effect on tacrolimus concentrations. Therefore we investigated whether corticosteroid use 
causes important changes in the pharmacokinetics of tacrolimus.
METHODS
PATIENTS
Sixty-five kidney transplant recipients, participating in a multicenter randomized clinical 
trial, were treated with tacrolimus and mycophenolate mofetil in combination with either 
daclizumab or corticosteroids. Tacrolimus was dosed twice daily to achieve C
0
 concentrations 
of 15-20 ng/mL during the first 14 days, 10-15 ng/mL between weeks 3 and 6, and 5-10 
ng/mL thereafter. Mycophenolate mofetil (1000 mg twice daily) was started 2 days after 
transplantation. All patients received 100 mg prednisolone i.v. on the first 3 postoperative 
days. Thereafter only patients in the corticosteroid group were given prednisone orally 
(dosed to bodyweight), which was tapered and stopped at month 3 post-transplantation. 
Patients in the daclizumab group received 1 mg/kg of the drug on day 0 and day 10.
In all patients tacrolimus dose, tacrolimus C
0
, bodyweight and serum creatinine were 
recorded at months 1, 2, 3, 4, 5 and 6. Dose-adjusted tacrolimus concentrations were 
calculated by dividing C
0
 by the corresponding tacrolimus dose (mg/kg). Patients did not 
take drugs known to interact with CYP3A or P-gp. Patients using the calcium-channel 
blockers nifedipine or amlodipine were included in the study, but patients using verapamil, 
nicardipine or diltiazem were not.
ETHICS
The study was performed in accordance with the Declaration of Helsinki and its amendments. 
The protocol was approved by the Ethics Committee of the Erasmus Medical Center. Written 
informed consent was obtained from all subjects. 
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DRUG CONCENTRATION MEASUREMENTS
Tacrolimus C
0
 were determined using the Emit 2000 assay (Syva Company, Dade Behring 
Inc., Cupertino, CA) on a Cobas Mira Plus analyzer (Roche Diagnostic Systems Inc.). In our 
laboratory, the coefficients of variation of Bio-Rad control samples with mean concentrations 
of 4.5, 11.8 and 24.1 ng/mL, were 10.7%, 5.2% and 5.4%, respectively. More details on the 
sensitivity, reproducibility and specificity of the tacrolimus assay in our laboratory have 
been published previously.8 Proficiency samples were obtained from the United Kingdom 
Quality Assessment Scheme (Dr Holt, St George’s Hospital Medical School, London, UK). 
The performance of the tacrolimus assay in our laboratory meets proficiency standards. 
Corticosteroid concentrations were not determined.
STATISTICAL ANALYSIS
We used linear mixed effect (LME) models to compare tacrolimus dose and concentration 
between the two groups over 6 months, with patients as the random effect. Residuals 
were checked for normality. A Student’s unpaired t-test was used for comparisons at each 
individual time point when overall comparisons based on the LME were significant. We 
used paired t-tests to test within group differences. Results are presented as means ± SEM 
(95% CI). P values ≤ 0.05 were considered statistically significant.
RESULTS
Of the 65 patients included, 31 were treated with daclizumab and 34 patients received 
prednisone for 3 months. All patients received mycophenolate mofetil and tacrolimus. Renal 
function, bodyweight and tacrolimus C
0
 were not significantly different between the two 
groups at any time point between months 1 and 6. The incidence of acute rejection was 
comparable: five versus three patients in the corticosteroid and daclizumab group, respectively 
(P = 0.71, Fisher’s exact test). These patients received 1000 mg methylprednisolone on 3 
consecutive days. 
Tacrolimus dose-adjusted C
0
 was lower at month 1 in the corticosteroid group compared 
with the daclizumab group: 83 ± 8 versus 119 ± 17 ng/mL per mg/kg, respectively. Although 
this difference was also observed at months 2 and 3 (Figure 3.1.1A), the overall differences 
were not statistically significant (LME P = 0.06). Within the corticosteroid group, significant 
differences in tacrolimus dose-adjusted C
0
 were observed before and after prednisone 
withdrawal. Thus, tacrolimus dose-adjusted C
0
 at months 1 and 2 was lower compared with 
months 4-6 (P = 0.001 and P < 0.05, respectively; Figure 3.1.1A, Table 3.1.1).
When patients using nifedipine or amlodipine (nine patients in each treatment group) 
were excluded from the analysis, tacrolimus dose-adjusted C
0
 was again lower in the 
corticosteroid group compared with the daclizumab group [LME, 95% CI 15.6, 58.5, P < 
0.001; at month 1: 83 ± 9 versus 138 ± 22 ng/mL per mg/kg (95% CI -102, -7, P = 0.03; Figure 
3.1.1B)]. This difference in tacrolimus dose-adjusted C
0
 resulted from a significantly higher 
overall mean tacrolimus dose required for patients treated with corticosteroids compared 
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with patients treated with daclizumab [LME, 95% CI -3.4, -1.0, P < 0.001). At month 1 the 
mean tacrolimus dose was: 13.4 ± 1.2 versus 9.5 ± 1.0 mg/day (95% CI 0.8, 7.1, P = 0.015). 
This difference was still present at month 2 (11.3 ± 1.1 versus 7.6 ± 1.0 mg (95% CI 0.6, 
6.6, P = 0.021], and diminished thereafter. The same between-group difference existed for 
tacrolimus dose corrected for bodyweight (LME, 95% CI -0.01, -0.04, P < 0.001). At month 
1 the mean tacrolimus dose per kg bodyweight was: 0.18 ± 0.013 versus 0.13 ± 0.014 mg/kg 
(95% CI 0.01, 0.09, P = 0.013) and at month 2 it was 0.15 ± 0.012 versus 0.10 ± 0.013 mg/kg 
(95% CI 0.01, 0.08, P = 0.021). However, at month 2 the tacrolimus C
0
 was also higher in the 
corticosteroid group: 11.6 ± 0.9 versus 9.2 ± 0.7 ng/mL (95% CI 0.06, 4.6, P = 0.04).
Table 3.1.1 Mean % differences in tacrolimus dose-adjusted predose concentrations (ng/mL per 
mg/kg) for patients in the corticosteroid group (n = 34), before (month 1-3) and after (month 
4-6) prednisone withdrawal. Differences are expressed as absolute values and as percentage of 
the corresponding values before corticosteroid withdrawal.
Month 1 2 3
4 33.5 § (42%) 25.4 § (29%) -2.6 (-2%)
5 44.3 § (54%) 33.4 † (37%) 7.3 (6%)
6 44.0 § (58%) 22.5 (25%) 1.8 (3%)
§ P ≤ 0.001, † P ≤ 0.01
Figure 3.1.1  Mean tacrolimus dose-adjusted predose concentrations [C0;  ng/mL per mg/
kg (± SEM)] in all patients (A). At months 1-3 the tacrolimus dose-adjusted C0 is higher for 
patients treated with daclizumab [n = 31 (closed triangles)] compared with patients treated 
with corticosteroids [n = 34 (open squares)], but the overall difference between the two groups 
was not significantly different (LME P = 0.06). Within the corticosteroid group, the tacrolimus 
dose-adjusted C0 is significantly lower before prednisone withdrawal (months 1 and 2) compared 
with after prednisone withdrawal (months 4-6). When patients using calcium-channel blockers 
were excluded (B), a lower tacrolimus dose-adjusted C0 was observed in patients treated with 
corticosteroids [n = 25 (open squares)] compared with patients treated with daclizumab [n = 22 
(closed triangles)].
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DISCUSSION
We have demonstrated that for the same tacrolimus C
0
 value, a higher tacrolimus dose was 
required for renal transplant recipients who were concomitantly treated with corticosteroids, 
compared with patients treated with daclizumab. The difference in tacrolimus dose-
adjusted C
0
 between the corticosteroid and daclizumab groups was maximal at month 1 
(around 30%). It is questionable whether this statistical difference is clinically relevant. 
Interindividual variability in tacrolimus dose-adjusted C
0
 is large and could exceed the 
effect of corticosteroids. Moreover, renal function was the same in both groups and did not 
deteriorate after corticosteroid discontinuation. However, in individual patients the latter 
may occur.9
Another finding was the influence of nifedipine and amlodipine on tacrolimus concentrations. 
Verapamil, diltiazem and nicardipine are known to interact with cyclosporine, but nifedipine 
and amlodipine have no or only minor effects on cyclosporine pharmacokinetics.10-12 
Inhibition of tacrolimus metabolism has been demonstrated in vitro and in a retrospective 
analysis for nifedipine, but not amlodipine.13,14 Interactions between calcineurin inhibitors 
and calcium-channel blockers are believed to result from competitive inhibition of CYP3A 
by the latter.6 Because prednisone induces CYP3A, its effects on calcineurin inhibitor 
metabolism are opposite to those of calcium-channel blockers.7 Our observation that 
the differences in tacrolimus dose and dose-adjusted C
0
 between the corticosteroid and 
daclizumab groups were larger when patients using calcium-channel blockers were excluded, 
could be explained by this phenomenon.
In conclusion, tacrolimus dose requirement was higher when used in combination with 
corticosteroids. The effects of corticosteroids on tacrolimus pharmacokinetics appeared 
smaller when patients were treated with calcium-channel blockers. Changes in prednisone 
dosage can result in altered tacrolimus C
0
. Therefore monitoring of tacrolimus concentrations 
is necessary in corticosteroid weaning protocols. 
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ABSTRACT
If mycophenolate mofetil (MMF) treatment is combined with cyclosporine, mycophenolic 
acid (MPA) plasma concentrations decrease, mycophenolic acid glucuronide (MPAG) 
increases, and the second peak in the MPA pharmacokinetic profile disappears. This is 
presumed to be caused by a cyclosporine-induced inhibition of the biliary excretion of MPAG, 
probably at the level of one of the drug transporters in the apical (canalicular) membrane 
of the hepatocyte. The most likely candidate for this inhibitory effect is canalicular multiple 
organic anion transporter. In patients switched from cyclosporine therapy to tacrolimus, as 
a result of this switch with unchanged MMF dose, the MPA concentrations will increase. It 
is not impossible that, after patients are switched from cyclosporine to tacrolimus, suddenly 
patients will have MMF-related side effects, although they may have been fine with that 
same dose before discontinuation of cyclosporine. Clinically, the difference in MPA 
concentrations between cyclosporine- and non-cyclosporine-containing regimens is also 
important in view of the accumulating evidence relating drug concentrations to efficacy. 
A potential strategy of increasing the MMF dose early after transplantation to reach the 
target concentration and tapering the dose at later points could reduce the incidence of acute 
rejection and avoid toxicity. In March 2003, the so-called Fixed Dose versus Concentration 
Controlled trial was started. In the FDCC trial, 900 patients will be randomized for either 
standard-dose therapy or concentration-controlled MMF therapy. The final results of this 
trial are expected in early 2006. 
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INTRODUCTION
The prodrug mycophenolate mofetil (MMF) is now a standard immunosuppressive drug in 
patients after organ transplantation and is mostly used in combination with the calcineurin 
inhibitors cyclosporine or tacrolimus.1 After oral administration, MMF is rapidly absorbed 
from the gut and then converted to mycophenolic acid (MPA), the active immunosuppressant.1 
After an initial peak (C
max
) at 1 h, a second increase in MPA plasma concentration occurs 8 
to 12 h after administration, which is caused by enterohepatic recirculation of MPA.2 Thus 
the total area-under the MPA plasma concentration versus time-curve (AUC) results from 
the following 2 processes: (1) intestinal absorption and de-esterification of MMF, and (2) 
enterohepatic recirculation of MPA.3
Most pharmacokinetic drug interactions with cyclosporine and tacrolimus are caused by 
these immunosuppressants being substrates for both the adenosine triphosphate-binding 
cassette (ABC) transporter P-glycoprotein and for cytochrome P450 3A enzymes. In contrast, 
MPA is not a P-glycoprotein or P450 substrate and is mainly eliminated by conjugation 
reactions by the uridine diphosphate glucuronosyltransferase (UGT) enzyme family.4 The 
main MPA metabolite, 7-hydroxy-glucuronide MPA (MPAG), is excreted in bile and  then 
contributes to the enterohepatic recirculation after deglucuronidation in the gastrointestinal 
tract.5 Finally, MPAG is eliminated by the kidneys. Zucker et al. reported significantly higher 
MPA predose plasma concentrations and MPA AUCs in renal transplant recipients treated 
with MMF and tacrolimus than in patients treated with MMF and cyclosporine.6 They also 
found a difference in MPAG concentrations between cyclosporine- and tacrolimus-treated 
patients. After all patients with impaired renal function were eliminated, MPAG AUC was 
significantly higher in the cyclosporine-treated group.7 Hübner et al. also found significantly 
higher MPA predose concentrations in renal transplant patients treated with tacrolimus 
than in a control group of cyclosporine-treated patients.8 Both Zucker et al. and Hübner 
et al. concluded that the difference in MPA concentrations was the result of a tacrolimus-
induced augmentation of the amount of MPA and that in the tacrolimus-treated patients the 
MPA concentrations were elevated compared with those in the cyclosporine group.7,8
These findings led to the hypothesis that the major cause for increased MPA concentrations 
during coadministration of tacrolimus is inhibition of the glucuronidation of MPA by 
tacrolimus.6 This hypothesis is supported by an in vitro study which showed that tacrolimus, 
but not cyclosporine, inhibits UGT-mediated formation of the major MPA metabolite, 
MPAG.9 For this study UGT was extracted from human liver and kidney tissue, and both 
the conversion of MPA to MPAG and the dose-dependent inhibition of this conversion by 
adding cyclosporine and tacrolimus were studied.
The pharmacokinetic data for both groups are, however, also consistent with the hypothesis 
that cyclosporine decreases MPA concentrations. The data from both studies are, in fact, 
insufficient to choose either explanation for the observed difference. What is missing is a 
control group of patients treated with MMF in the absence of cyclosporine or tacrolimus to 
more objectively indicate which group is “abnormal”.
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Table 3.2.1 Studies 
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In contrast to the design of the clinical studies by Zucker et al. and Hübner et al., a clinical 
study by Smak Gregoor et al. included a group of kidney transplant patients who were treated 
with MMF and steroids and no calcineurin inhibitors (Table 3.2.1).6,8,10 The pharmacokinetic 
data from these patients were very similar to those of patients treated with the combination 
of tacrolimus, MMF and prednisone.6 Mean MPA predose concentrations of the patients 
on a regimen of MMF and prednisone were 4.38 ± 0.4 mg/L versus 1.98 ± 0.12 mg/L in a 
control group of cyclosporine-, MMF- and prednisone-treated patients (all patients received 
2 g of MMF daily). Hübner et al. reported MPA predose concentrations of  3.4 ± 1.3 mg/L 
in tacrolimus-treated patients and 1.87 ± 1.1 mg/L in cyclosporine-treated patients, with 
slightly lower MMF doses (1.5 and 1.7 g daily, respectively).8 On the basis of our results, we 
concluded that cyclosporine reduces MPA predose concentrations. This conclusion contrasts 
with those of Zucker et al. and Hübner et al., who proposed that treatment with tacrolimus 
increases MPA exposure.6,8 
The data from the cross-sectional study reported by Smak Gregoor et al. were confirmed 
in a subsequent prospective longitudinal study.10,11 A cohort of patients treated with 
cyclosporine, MMF and prednisone during the first 6 months after kidney transplantation 
were randomized to either continuation of triple-drug treatment or discontinuation of either 
cyclosporine or prednisone at 6 months posttransplantation. MPA predose concentrations 
were measured at the time of randomization and at 9 months after transplantation. In the 
patients continuing triple-drug treatment and in the patients discontinuing prednisone, 
MPA predose concentrations did not change, whereas after discontinuation of cyclosporine 
a highly significant rise in MPA predose concentrations was observed. A similar rise in 
MPA concentrations was observed by Shipkova et al. in 5 patients with deteriorating 
renal function in whom cyclosporine was discontinued.12 The clinical studies showed that 
mean MPA predose concentrations in kidney transplant recipients treated with MMF 
and prednisone were significantly higher (3.16 mg/L) than in patients treated with MMF, 
cyclosporine, and prednisone (1.87 mg/L).10,11 This strongly indicates that cyclosporine 
does reduce MPA exposure, thus explaining the relative increase in MPA exposure after 
conversion from cyclosporine to tacrolimus as previously noted and ascribed solely to 
effects of tacrolimus on MPA metabolism.6,8 As indicated by our data, a comparison of MPA 
pharmacokinetics in patients treated with MMF and cyclosporine versus patients treated 
with  MMF and tacrolimus is misleading without a control group of patients treated with 
MMF monotherapy. In fact, the valuable observations from Hübner et al. and Zucker et al. 
are fully consistent with the hypothesis that cyclosporine decreases MPA concentrations.6,8
Filler et al. published their results on pharmacokinetics of MMF in pediatric renal transplant 
patients.13 They compared pharmacokinetic profiles from 13 patients who received MMF 
without calcineurin inhibitors with profiles from 14 patients treated with MMF and 
tacrolimus and 15 patients treated with MMF and cyclosporine.13 Also, in their study, dose-
normalized MPA AUC was higher in tacrolimus-treated patients than in cyclosporine-
treated patients. Surprisingly, dose-normalized MPA AUC in patients with no calcineurin 
inhibitor was significantly lower than dose-normalized MPA AUC in patients treated with 
tacrolimus and not significantly different from that in patients treated with cyclosporine.
More recently, Pou et al. studied MPA concentrations in kidney and lung transplant patients.14 
They observed significantly higher MPA trough levels in both tacrolimus-treated patients 
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(3.63 mg/L) and patients who were not treated with a calcineurin inhibitor (3.82 mg/L) 
compared with the cyclosporine-treated group (2.14 mg/L).14 Brown et al. studied pediatric 
liver transplant patients and found significantly higher MPA predose concentrations in 
tacrolimus-treated patients than in cyclosporine-treated patients.15
MECHANISM OF INHIBITORY EFFECT  
OF CYCLOSPORINE ON MPA PLASMA CONCENTRATIONS
In comparisons of clinical studies in transplant patients, different patient groups represent 
heterogeneous populations, leading to the influence of several variables on the interpretation 
of causes for pharmacokinetic drug-drug interactions. These variables include  time since 
transplantation, concomitant medication, and coexisting diseases.10,11
To understand the influence of tacrolimus and cyclosporine on MMF pharmacokinetics 
more completely, van Gelder et al. eliminated the influence of confounding variables in 
clinical studies by performing drug interaction studies in inbred Lewis rats under controlled 
conditions.17 In this study, 3 groups of rats were treated once daily with either MMF plus 
cyclosporine, MMF plus tacrolimus, or MMF plus vehicle. Rats in the MMF plus tacrolimus 
group and in the MMF plus vehicle group showed a second peak in the MPA AUC, which is 
consistent with enterohepatic recirculation of MPA. The MPA AUC for the animals treated 
MMF plus cyclosporine did not show this second MPA peak, resulting in a mean plasma 
MPA AUC at 24 h (AUC
0-24
) for the cyclosporine-treated animals that was significantly lower 
than that in rats treated with MMF plus tacrolimus and MMF plus vehicle. Furthermore, 
coadministration of cyclosporine and MMF significantly increased MPAG AUC
0-24
, 
suggesting that cyclosporine inhibits MPAG excretion into bile. This explains the well-
known increased MPA exposure in organ transplant patients caused by conversion from 
cyclosporine- to tacrolimus-based immunosuppression. Because cyclosporine increases 
the MPAG plasma concentrations and decreases the MPA/MPAG ratio, the most likely 
mechanism for the pharmacokinetic interaction between MMF and cyclosporine is the 
inhibition of MPAG excretion from the hepatocytes into bile by cyclosporine. Although 
potential species differences may restrict the extrapolation of the data from our rat study 
to patients, there is good evidence that enterohepatic recirculation in humans has a major 
role in the pharmacokinetics of MMF as well. Studies with oral carbon 14-labeled MMF in 
bile-cannulated rats showed that 24 h after study drug administration 77% and 21% of the 
dose was recovered from bile and urine, respectively.18 In humans, the mean contribution of 
the enterohepatic recirculation to the overall pharmacokinetic profile for MPA was found to 
be 37% (range 10%-61%).1 In healthy volunteers, disruption of enterohepatic recirculation 
by pretreatment with cholestyramine for 4 days before MMF treatment decreased the MPA 
AUC
0-24
 of a single dose of MMF by 40%.19
Hepatic uptake and biliary excretion are of importance for the disposition of a wide array of 
drugs. Transporters such as ABC proteins play important roles in the biliary elimination of 
xenobiotics, including many glucuronides.20 Cyclosporine is an inhibitor of P-glycoprotein 
and may also be responsible for the inhibition of a variety of other biliary ABC transporters, 
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including canalicular multiple organic anion transporter [cMOAT or multidrug resistance-
associated protein (MRP)-2].21-24 We speculate that cyclosporine inhibits active transport 
mechanisms in the biliary membrane responsible for the excretion of MPAG into bile. 
The hepatobiliary transport of MPAG, however, has not yet been studied. A further 
understanding of the hepatobiliary transport of MPAG can be obtained by studying animal 
models, isolated hepatocytes, or cell lines transfected with genes of the drug transporters 
under investigation.20 Animal models, consisting of specific strains of animals with a 
mutation (either spontaneous or transgenic) that gives rise to disturbances in transport, 
have the advantage that transport can be studied in an integrated model that is defined by 
the presence or absence of a single gene.20 The transport-deficient rat (TR-) is an example of 
an animal strain with a spontaneous mutation, resulting in a defect in cMOAT. Identification 
of the TR- rat has greatly contributed to the functional characterization of cMOAT. The 
most prominent substrate of this transporter is conjugated bilirubin, and TR- rats have 
often been used as a model for the human Dubin-Johnson syndrome.25 Dutch investigators 
have discovered a single-nucleotide deletion in the cMOAT gene responsible for the TR- 
phenotype.26 In cMOAT-transfected cell lines, cyclosporine was shown to inhibit apical 
transport.27 The hyperbilirubinemia associated with high-dose cyclosporine treatment is 
probably also caused by inhibition of cMOAT.25 It is interesting that cyclosporine is a more 
potent inhibitor than is its analogue PSC 833 and produces higher bilirubin levels, whereas 
PSC 833 is a more potent inhibitor of P-glycoprotein.28 It is our hypothesis that cyclosporine 
inhibits active transport of MPAG by cMOAT in the biliary membrane and thus inhibits 
the elimination of MPAG into bile. We are currently investigating the role of cMOAT in the 
pharmacokinetics of MPA by comparing  normal Wistar rats and a cMOAT-deficient mutant 
strain during in vivo treatment with MMF alone or in combination with cyclosporine.
CLINICAL RELEVANCE OF THE DRUG INTERACTION
In the 3 so-called pivotal trials that have led to the registration of MMF for the prevention 
of acute rejection after kidney transplantation, it was found that treatment with a standard 
dose of 2 g daily had similar efficacy and better tolerability compared with 3 g daily.29-31 
In all 3 studies, patients were receiving cyclosporine. These studies have also led to the 
recommendation to use a standard dose of 2 g daily in all patients. Although our data clearly 
show that MPA exposure is significantly higher in tacrolimus-treated patients, the dose 
recommendation for MMF in the context of tacrolimus treatment is the same.
In patients in whom MMF is combined with sirolimus, preliminary data show that MPA 
exposure is comparable to that of combined MMF and tacrolimus treatment.32 From 
these studies, it is clear that the MPA concentrations will increase in patients switched 
from cyclosporine- to tacrolimus-based therapy, even with unchanged MMF dose. It is 
not impossible that suddenly patients will have MMF-related side effects after they switch 
from cyclosporine to tacrolimus, although they may have been fine with that same dose 
before discontinuation of cyclosporine. We have seen such patients at our center. Clinicians 
should be aware of this effect of changing calcineurin inhibitor therapy. It is likely that the 
optimal maintenance dose for MMF therapy in a tacrolimus-based regimen is less than 
the recommended 1000 mg twice daily in cyclosporine-treated patients. Another clinically 
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relevant consequence of the described interactions occurs in patients on a regimen of MMF 
therapy in whom broad-spectrum antibiotics are started. Because antibiotics may change the 
bowel flora, their use can result in decreased deglucuronidation activity and interruption of 
enterohepatic recirculation. For kidney transplant patients, treatment with broad-spectrum 
antibiotics for prolonged time periods is unusual, but in bone marrow transplantation or 
lung transplantation this is a likely cause of reduced MPA exposure.
Clinically the difference in drug levels between regimens that do and do not contain 
cyclosporine is also important in view of the accumulating evidence relating drug 
concentrations to efficacy of MMF. Most published pharmacokinetic data come from 
patients within the first 6 months posttransplantation. The largest series of patients in whom 
repetitive MPA AUCs were determined is the randomized, concentration-controlled trial 
(RCCT) of MMF in the prevention of acute rejection after kidney transplantation, performed 
in 7 centers in The Netherlands and Belgium in 1994-1995.33 The aim of the study was to 
maintain the MPA AUC at 12 h (AUC
0-12
) at a predefined target value. Patients (n = 154) were 
randomized for low-, intermediate-, or high-target AUC groups. All patients were treated 
with cyclosporine, prednisone, and MMF. Blood samples were taken at regular intervals, 
MPA AUC
0-12
 was measured, and then, if necessary, the MMF dose was adjusted accordingly. 
This study showed a statistically significant correlation between drug concentrations (for 
MPA AUC
0-12
 and, to a lesser extent, also for MPA predose concentrations) and likelihood of 
developing an acute rejection episode.34
Other groups have also shown a relationship between pharmacokinetic markers and 
outcome in MMF treatment.35-40 Recently, a proposal for MPA target concentrations was 
published by Shaw et al.41 A target MPA AUC
0-12
 of at least 30 mg/L x h up to 60 mg/L x h was 
considered sufficient, both for the immediate posttransplant period and for  maintenance 
therapy. Corresponding MPA predose concentrations for this range are 1.0 to 3.5 mg/L. 
Independently from Shaw et al., in their recommendations, Oellerich et al. also recommend 
the interval between 30 and 60 mg/L x h as the optimal target values.37,41  Potentially, a 
strategy of adjusting MMF dose on the basis of MPA target concentrations could reduce the 
incidence of acute rejection by increasing the dose early after transplantation to reach target 
as soon as possible and by tapering the dose at later time points not to exceed target and to 
avoid toxicity.
Although several investigators have shown that drug exposure (either MPA AUC
0-12
 or  MPA 
predose concentrations) predicts outcome, a clinical trial comparing a group of patients 
receiving standard-dose therapy with a group of patients treated with concentration-
controlled MMF therapy has not yet been performed. A trial with this design would be able 
to determine the added value of performing therapeutic drug monitoring in MMF therapy. 
In March 2003, the so-called Fixed Dose versus Concentration Controlled trial was started. 
In the Fixed Dose versus Concentration Controlled trial, 900 patients will be randomized 
to either standard-dose therapy or concentration-controlled MMF therapy. The final results 
of this trial are expected in early 2006. Because both cyclosporine- and tacrolimus-treated 
patients will be entered into this trial, this study will also allow a further evaluation of the 
different effects of these drugs on MPA exposure. Subgroup analyses will include studies on 
the influence of renal function, co-medication, gene polymorphisms for enzymes involved 
in pharmacokinetics, and genes involved in the generation of an immune response. 
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ABSTRACT
In mycophenolate mofetil (MMF)-treated organ transplant recipients, lower mycophenolic 
acid (MPA) plasma concentrations have been found in cyclosporine- compared with 
tacrolimus-based immunosuppressive regimens. We previously demonstrated that 
cyclosporine decreases exposure to MPA and increases exposure to its metabolite MPA-
glucuronide (MPAG), possibly by interfering with the biliary excretion of MPAG. To 
elucidate the role of the multidrug resistance-associated protein (Mrp)-2 in the interaction 
between MMF and cyclosporine, we treated three groups of 10 Mrp2-deficient rats (TR- 
rat) for 6 days with either vehicle, cyclosporine (8 mg/kg) or tacrolimus (4 mg/kg) by oral 
gavage. Hereafter, co-administration with MMF (20 mg/kg) was started in all groups and 
continued through day 14. The 24-h MPA/MPAG area-under the concentration versus time-
curve (AUC) was determined after single (day 7) and multiple MMF doses (day 14). On both 
study days, there were no significant differences in the mean MPA and MPAG AUC between 
cyclosporine- and tacrolimus-treated animals. We conclude that the pharmacokinetics of 
MMF are comparable in Mrp2-deficient rats receiving either cyclosporine or tacrolimus as 
co-medication. This finding suggests that cyclosporine-mediated inhibition of the biliary 
excretion of MPAG by the Mrp2 transporter is the mechanism responsible for the interaction 
between cyclosporine and MMF.
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INTRODUCTION
Mycophenolate mofetil (MMF) is a pro-drug that is rapidly and almost completely 
absorbed from the gut where it is de-esterfied to form mycophenolic acid (MPA), the active 
immunosuppressant. MPA is converted by the uridine diphosphate glucuronosyl transferase 
(UGT) enzyme family into 7-hydroxy-glucuronide mycophenolic acid (MPAG) which is 
excreted into bile and is not pharmacologically active. In the gut, bacterial deconjugation 
transforms MPAG back into MPA, which is absorbed from the colon. Because of this 
enterohepatic circulation, the initial MPA plasma concentration peak at 1 h is followed by a 
second increase in the MPA plasma concentration, occurring 6-12 h after oral administration. 
In human subjects, interference with the enterohepatic circulation reduces the MPA area-
under the concentration versus time-curve (AUC) by 35% to 40%.1,2 Finally, the majority of 
the absorbed MMF is eliminated by the kidneys as MPAG.1,2
We and others previously demonstrated that co-administration of MMF with cyclosporine 
to solid organ transplant recipients leads to a reduction of MPA plasma concentrations and 
an increase in the plasma levels of MPAG as compared with patients treated with MMF 
plus tacrolimus or corticosteroids.3-6 These clinical findings were confirmed in an animal 
study that compared MPA and MPAG exposure between Lewis rats that were treated with 
MMF plus cyclosporine, MMF plus tacrolimus or MMF plus placebo.7 Rats in the MMF 
plus tacrolimus and MMF plus placebo groups showed a second peak in the plasma MPA 
AUC, consistent with enterohepatic recirculation. In contrast, animals treated with MMF 
plus cyclosporine showed a marked reduction of the second MPA peak, resulting in a 
significantly lower mean MPA AUC. Furthermore, co-administration of cyclosporine 
significantly increased the AUC of MPAG, suggesting a cyclosporine-induced inhibition of 
MPAG excretion into bile.7
At present, the exact mechanism responsible for the pharmacokinetic interaction between 
MMF and cyclosporine is unknown. We hypothesized that cyclosporine impairs biliary 
MPAG elimination through inhibition of the multidrug resistance-associated protein (MRP) 
2 (or ABCC2, previously known as canalicular multispecific organic anion transporter). 
MRP2 is expressed at the apical (canalicular) surface of hepatocytes, where it functions to 
excrete endogenous conjugates as well as conjugation products of drug metabolism into 
bile.8,9 Evidence for the implication of MRP2 in the MMF-cyclosporine interaction comes 
from the observation that cyclosporine can cause a conjugated hyperbilirubinemia (a MRP2 
substrate) in vivo and is an inhibitor of MRP2 function in vitro.10-12 Furthermore, it was 
recently demonstrated that Eisai hyperbilirubinemic rats (EHBRs), lacking Mrp2 due to 
a genetic mutation, can only excrete MPAG to a limited degree in bile after intravenous 
administration of MPA, resulting in high MPAG plasma concentrations.13
In this study, we aimed to elucidate the role of MRP2 in the interaction between MMF 
and cyclosporine by repeating our previous pharmacokinetic study that was performed in 
wildtype rats, in transport-deficient (TR-) Wistar rats.7 TR- rats have a mutation in the mrp2 
gene which results in the absence of functional Mrp2 protein. Phenotypically, TR- rats are 
characterized by a defective hepatobiliary excretion of bilirubin glucuronides and other 
amphiphilic anions.12,14,15 We show that in the absence of Mrp2, the previously described 
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effects of cyclosporine on MMF pharmacokinetics are no longer present, giving equal MPA 
and MPAG plasma concentrations as compared with rats treated with MMF and tacrolimus. 
For the first time, these in vivo data provide evidence for the hypothesis that inhibition 
of MRP2 by cyclosporine is the main mechanism responsible for the interaction between 
cyclosporine and MPA. 
MATERIALS AND METHODS
ANIMALS
Adult male TR- Wistar rats (HRD-AMC Abcc2) were purchased from Harlan (Horst, the 
Netherlands). The animals were housed in microisolation cages (three per cage) and had 
free access to food and water. Rats were acclimated under a 12-h light/dark cycle for 2 weeks 
before the start of the study. All rats were 12 weeks of age and weighed 250 g at the start of 
the experiment. 
DRUG FORMULATIONS
Vehicle: As placebo (hereafter called vehicle) we used Basis pro Suspension (Fagron 
Pharmaceuticals B.V., Nieuwerkerk a/d IJssel, the Netherlands) which consisted of 0.75 mg 
methylhydroxybenzoate, 0.20 mg propylhydroxybenzoate, 10.0 mg aluminiummagnesium
silicilate, 10.0 mg carmellose sodium 500 mPas.s, 0.75 mg citric acid 1 aq, 263.0 mg sirupus 
simplex, and 783.30 mg purified water per mL. 
Mycophenolate mofetil: MMF powder (Cellcept®, Roche Bioscience, Palo Alto, CA, USA) 
was suspended in vehicle for oral gavage every three days to produce a 2% solution which 
was stored at 4°C.
Cyclosporine: cyclosporine oral microemulsion formulation (100 mg/mL; Neoral®, Novartis 
Pharma AG, Basel, Switzerland) was freshly diluted in vehicle once daily to produce a 0.8% 
solution for oral gavage. 
Tacrolimus: tacrolimus solution for intravenous injection (10 mg/mL; Prograf®, Fujisawa 
Pharmaceutical Co. Ltd., Osaka, Japan) was diluted in vehicle once daily to produce a 0.4% 
solution which was administered by oral gavage. 
All drugs were kindly supplied by the manufacturers. 
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STUDY DESIGN
The study was a three-arm, two-period pharmacokinetic drug interaction study. Thirty 
adult, male TR- rats were allocated to three study groups (n = 10 each). The possible drug 
interactions between MPA and cyclosporine and between MPA and tacrolimus were studied 
after cyclosporine and tacrolimus reached steady-state, and after single and multiple MMF 
doses. The drug dosages used were chosen on the basis of previous experience demonstrating 
their ability to prevent the occurrence of acute rejection after kidney transplantation in 
rats.7 
Vehicle group: After daily oral gavage with vehicle on days 0-6, MMF treatment (20 mg/kg 
bodyweight) was started on day 7 and was administered daily through day 14. Blood samples 
for MPA and MPAG pharmacokinetic analysis were collected during the 24 h subsequent 
to dosing on day 7 (single dose pharmacokinetic profile). Additional MPA and MPAG 24-h 
pharmacokinetic profiles (multiple dose) were determined subsequent to dosing on study 
day 14. 
Cyclosporine group: From study day 0 through day 14, one group of rats was treated with 
8 mg/kg bodyweight cyclosporine daily. On day 7, co-administration of MMF (20mg/kg 
bodyweight) was started and continued through day 14. Blood samples for MPA and MPAG 
pharmacokinetic profiles were collected during 24 h subsequent to dosing on study days 7 
(single dose) and 14 (multiple dose). In addition, blood was collected at these time points for 
predose cyclosporine concentration measurements.
Tacrolimus: The dosing schedule and the schedule for the collection of samples for 
pharmacokinetic profiles was identical to those described for cyclosporine. The rats received 
a daily tacrolimus dose of 4 mg/kg bodyweight per day instead of cyclosporine. 
All drugs were given once daily by oral gavage at 9:00 am. When drugs were co-administered, 
they were given within 5 min. Blood samples were collected in ethylenediaminetetraacetic 
acid (EDTA)-containing tubes by tail bleeding under isoflurane (Rhodia Organique Fine 
Ltd., Bristol, United Kingdom) anesthesia before and 0.5, 1, 2, 6, 12 and 24 h after dosing. 
After collection, EDTA blood samples were immediately centrifuged at 11750 g, after which 
the plasma was frozen at –80 °C. 
ETHICS
The experimental protocol was approved by the Animal Experiments Committee of the 
Erasmus Medical Center under the national Experiments on Animals Act and adhered to 
the rules laid down in this national law that serves the implementation of “Guidelines on the 
protection of experimental animals” by the Council of Europe (1986), Directive 86/609/EC.
QUANTIFICATION OF PLASMA LEVELS OF  THE STUDY DRUGS
Cyclosporine and tacrolimus whole-blood concentrations were determined with the Emit 
2000 assay (Syva company, Dade Behring Inc., Cupertino, CA, USA) on a Cobas Mira Plus 
analyzer (Roche Diagnostic Systems, Basel, Switzerland). Details on the sensitivity and 
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reproducibility of the Emit assay in our laboratory were published previously.16 Proficiency 
samples were obtained from the United Kingdom Quality Assessment Scheme (Dr. Holt, St 
George’s Hospital Medical School, London, United Kingdom).   
MPA and MPAG in rat plasma were simultaneously measured with high-performance liquid 
chromatography (HPLC) according to the method described by Shipkova with several 
modifications.17 The assay was validated for determination of MPA and MPAG in rat plasma 
according to FDA guidelines.18 The limit of quantification was arbitrarily set at 0.25 mg/L 
for MPA and 2.5 mg/L for MPAG. The assay was found to be linear in a concentration range 
from 0.25 mg/L to 30 mg/L for MPA and from 2.5 mg/L to 100 mg/L for MPAG (correlation 
coefficient >0.99). In the same concentration range, the within-day CV ranged from 2.0% 
to 3.1% for MPA and from 1.5% to 3.9% for MPAG. The between-day CV ranged from 1.9% 
to 8.5% for MPA and from 3.0 to 6.9% for MPAG. The accuracy of the assay, defined as the 
percentage of recovery of MPA and MPAG from the control samples was for MPA in the 
range of 108-110% and for MPAG in the range of 98-113%.    
PHARMACOKINETIC ANALYSIS
The concentration-time data were analyzed using WinNonlin version 4.1 (Pharsight 
Corporation, Mountain View, CA, USA). A non-compartmental model with extravascular 
input for plasma data was used to obtain estimates for MPA and MPAG maximum 
concentration (C
max
), time to maximum concentration (t
max
) and AUC. Since the AUC on 
study day 7 was measured after the first MMF dose, AUC
0-∞
 was estimated. The decline 
of MPA or MPAG concentration between two subsequent time points that was most 
representative for elimination was used for extrapolation beyond 24 h. On day 14 steady-state 
was assumed and AUC
0-24
 was calculated. AUCs were calculated by using the logarithmic 
trapezoidal rule.
BIOCHEMISTRY
Before the start of the study and on study days 7 and 14, blood urea nitrogen, serum albumin 
and serum total bilirubin were determined on an ELAN analyzer (Eppendorf-Merck, 
Darmstadt, Germany) using the UV test/GIDH method, BCG method, and DPD method, 
respectively (Merck Diagnostica, Darmstadt, Germany).
STATISTICAL ANALYSIS
All data are expressed as means ± standard deviation unless otherwise stated. For comparisons 
between groups we used one-way ANOVA or Kruskal-Wallis test, as appropriate. Post-hoc 
analysis was performed using Bonferroni’s test for multiple comparisons or using the Mann 
Whitney U test. For comparisons within groups, the paired t-test was used. P values at α ≤ 
0.05 were considered statistically significant. Statistical analysis was performed using SPSS 
for Windows version 11.5.0 (SPSS, Chicago, IL, USA).
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RESULTS
MYCOPHENOLIC ACID AND GLUCURONIDATED  
MYCOPHENOLIC ACID PHARMACOKINETICS
A total of 30 MPA and MPAG pharmacokinetic profiles was obtained on study day 7 (single 
MMF dose). In all three treatment groups, the MPA concentration versus time profiles were 
characterized by a first peak within the first hour followed by a second peak at 6-12 h after 
drug administration, consistent with enterohepatic recirculation of MPA (Figures 3.3.1A 
and 3.3.2A).
On day 7, after the first MMF dose, the mean AUC
0-∞
 of MPA was significantly different 
between the three treatment groups: 32.0 ± 8.0 versus 24.5 ± 6.1 versus 21.8 ± 6.4 mg x h/L 
for the vehicle, cyclosporine and tacrolimus groups, respectively (P = 0.007; Figure 3.3.2A 
and Table 3.3.1). This overall difference resulted from a significantly higher AUC
0-∞
 of MPA 
in the vehicle group as compared with the tacrolimus group (P = 0.008). When the MPA 
exposure was compared between the vehicle and the cyclosporine groups a similar trend was 
observed, although this difference was not statistically significantly different (P = 0.065). The 
AUC
0-∞
 of MPA in the cyclosporine and tacrolimus groups were not different (P = 1.00). 
After the first week, two rats in the tacrolimus group died because of aspiration and 
therefore only 28 MPA and MPAG pharmacokinetic profiles were available for study day 
14 (after multiple MMF doses). Again, we found an overall difference in MPA exposure 
between the different study groups (P = 0.018) but there was no difference in the AUC
0-24
 
of MPA between rats receiving tacrolimus or cyclosporine: 28.1 ± 10.3 versus 30.0 ± 13.3 
mg x h/L, respectively (P = 1.00; Figure 3.3.2B and Table 3.3.1). When the MPA exposure 
in the tacrolimus and cyclosporine groups was compared with the vehicle group, only the 
difference between the tacrolimus and vehicle group was significant, although a similar 
trend was observed between the cyclosporine and vehicle groups (P = 0.033 and P = 0.056, 
respectively; Figure 3.3.2B and Table 3.3.1).
Table 3.3.1 summarizes the AUC
0-∞
 and AUC
0-24
 of MPAG values in the three different 
treatment groups at the two time points. Individual MPAG concentration versus time 
profiles are depicted in Figure 3.3.1B. In line with our observations for MPA, the MPAG 
exposure was never significantly different between the tacrolimus and cyclosporine groups. 
However, on study day 7, there was an overall difference in MPAG exposure between the 
three groups which was caused by a significantly lower AUC
0-∞
 of MPAG in the vehicle 
group as compared with the tacrolimus group but not the cyclosporine group (overall P 
= 0.022). On study day 14, this difference was no longer present, although the AUC
0-24
 of 
MPAG remained numerically highest in the rats treated with a calcineurin inhibitor 
(P = 0.28; Table 3.3.1, Figure 3.3.3).  
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Figure 3.3.1 Individual mycophenolic acid (A) and mycophenolic acid-glucuronide (B) 
pharmacokinetic profiles after once daily administration of 20 mg MMF/kg bodyweight to male 
Mrp2 transport-deficient (TR-) Wistar rats. Depicted are the concentration versus time profiles of 
the rats in the vehicle group that were obtained on study day 14 (after multiple MMF dosing).
Figure 3.3.2 Mean (± SEM) mycophenolic acid (MPA) plasma concentrations in Mrp2 transport-
deficient (TR-) rats after once daily administration of 20 mg MMF/kg bodyweight in combination 
with either vehicle (triangles), cyclosporine (solid circles) or tacrolimus (open circles)(n = 10 in 
each group). Depicted are the MPA pharmacokinetic profiles obtained on study day 7 (after a 
single MMF dose; panel A) and on day 14 (after multiple MMF doses; panel B).
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Table 3.3.1 Pharmacokinetic data of MPA and MPAG in Mrp2 transport-deficient (TR-) rats 
treated with MMF in combination with either vehicle, cyclosporine (CsA) or tacrolimus  
(Tac)(n = 10 in each group). Data represent the mean ± SD. 
Study Day Analyte Parameter Treatment Group
MMF + Vehicle MMF + CsA MMF + Tac
Day 7 
(single dose)
MPA AUC
0-∞
 (mg x h/L) 32.0 ± 8.0 24.5 ± 6.1 21.8 ± 6.4 ‡
C
max
 (mg/L) 7.9 ± 4.9 4.0 ± 1.3 † 4.0 ± 2.2 †
t
max
 § (h) 0.5 (0.5 - 6.0) 0.5 (0.5 - 12.0) 0.8 (0.5 - 24.0)
MPAG AUC
0-∞
 (mg x h/L) 324.4 ± 76.2 376.8 ± 87.2 422.3 ± 53.9 †
C
max
 (mg/L) 38.3 ± 13.3 27.8 ± 7.0 30.8 ± 7.4
t
max
 (h) 2.0 (0.5 - 12.0) 4.0 (1.0 - 24.0) 4.0 (1.0 - 12.0)
Day 14 
(multiple dose)
MPA AUC
0-24
 (mg x h/L) 41.7 ± 6.4 30.0 ± 13.3 28.1 ± 10.3 †
C
max
 (mg/L) 6.5 ± 3.4 5.1 ± 4.3 3.2 ± 1.8 †
t
max
 (h) 0.5 (0.5 - 6.0) 0.5 (0.5 - 2.0) 0.5 (0.5 - 2.0)
MPAG AUC
0-24
 (mg x h/L) 328.4 ± 30.1 365.0 ± 75.2 366.2 ± 58.3
C
max
 (mg/L) 36.9 ± 7.9 33.0 ± 11.3 30.7 ± 7.9
t
max
 (h) 2.0 (1.0 - 12.0) 7.0 (1.0 - 12.0) 12.0 (1.0 - 12.0)
§ For t
max
 data represent the median (range)
† P < 0.05, significantly different from the vehicle group
‡ P < 0.01, significantly different from the vehicle group
Figure 3.3.3 Mean (± SEM) mycophenolic acid glucuronide (MPAG) plasma concentrations in 
Mrp2 transport-deficient (TR-) rats after once daily administration of 20 mg MMF/kg bodyweight 
in combination with either vehicle (triangles), cyclosporine (solid circles) or tacrolimus (open 
circles)(n = 10 in each group). Depicted are the MPAG pharmacokinetic profiles obtained on study 
day 7 (after a single MMF dose; panel A) and on day 14 (after multiple MMF doses; panel B).
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Table 3.3.2 Serum biochemistries of transport-deficient rats treated with MMF in combination 
with either vehicle, cyclosporine or tacrolimus (n = 10 in each group). Data represent the mean 
± SD.
Vehicle Cyclosporine Tacrolimus
Albumin (g/L) day 0 31.2 ± 4.0 31.4 ± 0.7 30.8 ± 2.4
day 7 29.8 ± 1.8 § 27.6 ± 1.2 30.4 ± 1.2 §
day 14 29.7 ± 2.1 † 27.4 ± 1.8 30.0 ± 1.4 †
Total bilirubin (μmol/L) day 0 18.1 ± 10.2 29.1 ± 10.6 33.5 ± 9.6
day 7 18.9 ± 4.6 65.5 ± 24.3 ‡ 43.4 ± 18.7 §, ‡
day 14 24.5 ± 10.0 68.3 ± 15.2 ‡ 61.6 ± 23.3 #
Blood Urea Nitrogen (mmol/L) day 0 8.8 ± 0.3 8.8 ± 0.3 9.3 ± 0.7
day 7 8.4 ± 0.8 9.0 ± 0.7 8.9 ± 0.9
day 14 7.0 ± 0.7 7.2 ± 0.9 7.3 ± 0.3
§ P < 0.001, significantly different from the cyclosporine group
† P < 0.05, significantly different from the cyclosporine group
‡ P < 0.001, significantly different from the vehicle group
# P < 0.01, significantly different from the vehicle group
The MPA to MPAG-AUC
0-∞
 ratio was significantly different between the three treatment 
groups on study day 7: 0.10 ± 0.01 versus 0.07 ± 0.02 versus 0.05 ± 0.02 for  the vehicle, 
cyclosporine and tacrolimus groups, respectively (P < 0.001). The MPA to MPAG-AUC
0-24
 
ratio on study day 14 was also significantly different between the three groups: 0.13 ± 0.01 
versus 0.08 ± 0.03 versus 0.08 ± 0.03 for the vehicle, cyclosporine and tacrolimus groups, 
respectively (P = 0.001). On study days 7 and 14, this difference was caused by a significantly 
higher MPA:MPAG ratio in the vehicle group as compared to either the cyclosporine or the 
tacrolimus group (P < 0.001 and P = 0.002, for study days 7 and 14, respectively), whereas 
the cyclosporine and tacrolimus groups did not differ significantly on study days 7 or 14 (P 
= 0.17 and P = 1.00, respectively).
CYCLOSPORINE AND TACROLIMUS WHOLE-BLOOD CONCENTRATIONS
The mean cyclosporine predose concentrations at study days 7 and 14 were 456 ± 234 and 
367 ± 137 ng/mL, respectively and were not significantly different (P = 0.44). The tacrolimus 
predose concentrations were also comparable between the two time points: 3.1 ± 1.7 versus 
2.3 ± 0.8 ng/mL for day 7 and 14, respectively (P = 0.55). 
SERUM CHEMISTRIES
To exclude significant nephrotoxicity caused by cyclosporine or tacrolimus as a cause of 
possible differences in MPA and MPAG pharmacokinetics, we measured blood urea nitrogen 
concentrations at baseline and on study days 7 and 14. Throughout follow-up, the mean 
blood urea nitrogen was comparable between the three groups (Table 3.3.2). For serum 
albumin, there existed a significant overall difference between the three groups at study 
days 7 and 14 (overall P < 0.001 and P < 0.01, respectively; Table 3.3.2), which was caused 
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by a lower serum albumin in the cyclosporine group as compared with both the vehicle and 
tacrolimus groups. 
The serum total bilirubin concentrations at baseline were markedly elevated but not different 
between the three groups (P = 0.22; Table 3.3.2). However, on study days 7 and 14, the serum 
total bilirubin concentration was significantly higher in the cyclosporine and tacrolimus 
groups as compared with the vehicle group (Table 3.3.2 and Figure 3.3.4). On study day 
7, there also existed a difference in serum total bilirubin between the cyclosporine and 
tacrolimus group, but at the end of the study period, the bilirubin concentrations in the rats 
receiving a calcineurin inhibitor were comparable (Table 3.3.2 and Figure 3.3.4).    
Figure 3.3.4 Mean serum total bilirubin concentrations (± SEM) in Mrp2 transport-deficient 
(TR-) rats after once daily administration of 20 mg MMF/kg bodyweight in combination with either 
vehicle (triangles), cyclosporine (solid circles) or tacrolimus (open circles).
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DISCUSSION
Several authors have shown that MPA exposure is significantly lower in cyclosporine- 
compared with tacrolimus-based immunosuppressive regimens.3-6 The reported difference 
is as high as 30% to 40% and is clinically relevant. As a consequence of this difference in 
MPA exposure, the optimal MMF maintenance dose in cyclosporine-treated patients could 
be different from that in tacrolimus-treated patients. Also, discontinuation of cyclosporine 
treatment will lead to increased MPA exposure without a change in the MMF dose and can 
lead to the occurrence of new MMF-related side effects.4,19 With the increasing interest in 
therapeutic drug monitoring of MMF therapy, the calcineurin inhibitor of choice is of high 
relevance. 
In this study, we show that in the absence of the drug-transporting protein Mrp2, the 
pharmacokinetics of MPA and MPAG are comparable between rats receiving either 
cyclosporine or tacrolimus as co-medication. In addition, the ratio of the MPA to MPAG 
AUC of TR- rats treated with MMF and vehicle (which averaged around 1:9) was comparable 
to the MPA:MPAG ratio that we observed previously in wildtype rats treated with MMF 
and cyclosporine.7 In the current study, identical cyclosporine and tacrolimus doses on a 
bodyweight basis were used, resulting in similar predose concentrations. For the first time, 
these results demonstrate in vivo, that Mrp2 is the transporter mainly responsible for the 
excretion of MPAG into bile and that inhibition of Mrp2 by cyclosporine is the mechanism 
underlying the interaction between cyclosporine and MPA. Because the difference in MPA 
exposure between cyclosporine and tacrolimus co-administration appears to be present in 
both rats and transplanted patients, the results of the present experimental study are relevant 
for the human situation. There only appears to be a quantitative difference between both 
species. In humans, the contribution of enterohepatic recirculation to total MPA exposure 
averages around 40%, whereas in rats it can account for as much as 70%. 
Further evidence for the role of MRP2 in the excretion of MPAG comes from the results 
of Sallustio et al. who perfused isolated rat livers obtained from normal and TR- rats, with 
MPA and measured MPA and MPAG concentrations in both perfusate and bile.20 In normal 
rats, more than 90% of the administered MPA dose was recovered as MPAG in bile and no 
MPAG was present in the perfusate. In marked contrast, less than 1% of the MPA dose was 
recovered as MPAG from the bile of TR- rats, and around 80% was recovered as MPAG in 
the perfusate. Importantly, glucuronidation of MPA to MPAG appeared to be comparable 
between normal and Mrp2-deficient rats.20 A markedly reduced excretion of MPAG into bile 
was also demonstrated in EHBRs (that lack Mrp2) after intravenous MPA administration.13 
However, in this report, the interaction between MMF and calcineurin inhibitors was 
only directly studied in normal, but not in Mrp2-deficient animals. Moreover, all drugs 
were administered intravenously and were not in steady-state.13 For the current study, 
we compared the results of the Mrp2-deficient Wistar rat with those from our previous 
experiment in wildtype Lewis rats. Wildtype Wistar rats have been shown to metabolize 
several drugs by glucuronidation in the liver, with subsequent biliary excretion and 
enterohepatic recirculation. For diclofenac and valproic acid it was recently demonstrated 
that biliary excretion of their respective metabolites is mediated by Mrp2.21,22 This shows 
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that, similar to normal Lewis rats, wildtype Wistar rats possess a functional Mrp2-mediated 
enterohepatic recirculation of glucuronidated substances and obviates the need for a control 
group of wildtype Wistar rats.
Interestingly, in this study, we observed marked differences in the MPA and MPAG plasma 
concentrations between the vehicle group and the groups receiving a calcineurin inhibitor: 
the mean MPA exposure in the vehicle group was higher compared with rats receiving a 
calcineurin inhibitor, while the opposite was true for MPAG exposure. There are several 
possible explanations for this finding. First, in TR- rats, the absence of Mrp2 may be partly 
compensated for by (the induction of) other organic anion transporters. Alternative drug-
transporting enzymes that could theoretically provide an escape mechanism for MPAG 
excretion into bile may include the breast cancer resistance protein (or ABCG2), the bile 
salt export pump (or ABCB11) and others.23-25 Calcineurin inhibitors are known to inhibit 
a variety of these drug-transporters.26-29 P-glycoprotein (or ABCB1) is a less likely candidate 
as this transporter is not known to transport glucuronidated substances. If alternative 
MPAG-elimination pathways are operational in the liver of the TR- rat, then their blockade 
by cyclosporine or tacrolimus would theoretically lead to an increased MPAG exposure 
and, as less MPAG is available for enterohepatic recirculation, to a decreased MPA exposure 
compared with rats receiving vehicle. The observation that bilirubin concentrations were 
highest in rats who were treated with calcineurin inhibitors suggests that inhibition of 
alternative MPAG-excretory mechanisms may indeed have occurred in our experiment. 
Another, not mutually exclusive, escape mechanism would be that of an increased secretion 
of MPAG into sinusoidal blood in the calcineurin inhibitor groups. It may be speculated 
that (induction of) MRP3/Mrp3 is involved. Mrp3 has a high affinity for glucuronide 
substrates and is known to be overexpressed in the EHBR, as well as in humans with the 
Dubin-Johnson syndrome who are deficient for MRP2.30-32 MRP3/Mrp3 is located on the 
basolateral membrane of the hepatocyte and mediates the transport of organic anions from 
the hepatocyte into sinusoidal blood.32-34 Xiong et al. reported an increased basolateral egress 
of acetaminophen-glucuronide in the TR- rat, suggesting up-regulation of an organic anion 
transporter on the basolateral membrane of Mrp2-deficient rat livers.35
A second mechanism that may have contributed to the differences in MPA/MPAG exposure 
between the vehicle and cyclosporine/tacrolimus-treated rats, could be an increased MPA 
clearance in the latter group. The observation that the MPA peak concentrations were lower 
in the rats treated with a calcineurin inhibitor is suggestive in this respect. High bilirubin or 
elevated MPAG plasma concentrations may result in a decreased binding of MPA to plasma 
albumin, thus increasing the free fraction of MPA, resulting in a more rapid conjugation 
of MPA to MPAG.2,36,37 Alternatively, a lowering of serum albumin, as we observed in the 
cyclosporine-treated rats, could also have increased the free fraction of MPA. However, the 
reduction of serum albumin was limited and we feel that this mechanism is unlikely to have 
influenced the disposition of MPA or MPAG in our experiment to a significant degree.37
Finally, the observation that co-administration of MMF with cyclosporine or tacrolimus, 
lowered MPA peak concentrations compared with rats in the vehicle group, may also suggest 
that treatment with calcineurin inhibitors decreased the absorption of MPA. It has previously 
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been demonstrated that treatment with cyclosporine is associated with overexpression 
of P-glycoprotein in parenchymal cells of human kidney allografts.38 This indicates 
that cyclosporine may induce its own detoxification by upregulation of P-glycoprotein 
expression in the kidney. Although Koziolek et al. did not investigate the expression levels of 
P-glycoprotein in the small intestine, increased P-glycoprotein levels would in theory result 
in a lowering of the oral bioavailability of P-glycoprotein substrates.38 
In conclusion, our data provide evidence that the pharmacokinetic interaction between 
cyclosporine and MPA is caused by inhibition of Mrp2 by cyclosporine.      
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ABSTRACT
Background The calcineurin inhibitors cyclosporine (INN, ciclosporin) and tacrolimus 
have a narrow therapeutic index and show considerable interindividual variability in their 
pharmacokinetics. The low oral bioavailability of calcineurin inhibitors is thought to result 
from the actions of the metabolizing enzymes cytochrome P450 (CYP) 3A4 and CYP3A5 
and the multidrug efflux pump P-glycoprotein, encoded by MDR-1. Objective Our objective 
was to determine the role of genetic polymorphisms in CYP3A4, CYP3A5 and MDR-1 with 
respect to interindividual variability in cyclosporine and tacrolimus pharmacokinetics. 
Methods Kidney transplant recipients receiving cyclosporine (n = 110) or tacrolimus (n = 
64) were genotyped for CYP3A4*1B and *3, CYP3A5*3 and *6, and MDR-1 C3435T. Dose-
adjusted trough levels were determined and correlated with the corresponding genotype. 
Results Tacrolimus dose-adjusted trough levels were higher in CYP3A5*3/*3 patients (n = 45) 
than in *1/*3 plus *1/*1 patients (n = 17), as follows: median and range, 94 (34-398) ng/mL 
per mg/kg versus 61 (37-163) ng/mL per mg/kg (P < 0.0001, Mann-Whitney test). CYP3A4*1B 
allele carriers (n = 10) had lower tacrolimus dose-adjusted trough levels
 
compared with 
those in patients with the wildtype (*1/*1) genotype (n = 54): median and range, 57 (40-163) 
ng/mL per mg/kg versus 89 (34-398) ng/mL per mg/kg (P = 0.003, Mann-Whitney test). No 
evidence was found supporting a role for the MDR-1 C3435T polymorphism in tacrolimus 
dose-requirement. None of the polymorphisms studied correlated with cyclosporine dose-
adjusted predose concentrations. Conclusion As a group, patients with the CYP3A5*3/*3 
genotype require less tacrolimus to reach target predose concentrations compared with 
CYP3A5*1 allele carriers, whereas CYP3A4*1B carriers need more tacrolimus to reach target 
trough concentrations compared with CYP3A4*1 homozygotes.
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INTRODUCTION
The calcineurin inhibitors cyclosporine (INN, ciclosporin) and tacrolimus are highly 
effective in preventing acute rejection after solid organ transplantation. However, both drugs 
have a narrow therapeutic index and show highly variable pharmacokinetics. In addition, 
calcineurin inhibitors have interactions with many other widely prescribed drugs that can 
lead to altered blood concentrations of cyclosporine or tacrolimus.1-4 Cyclosporine and 
tacrolimus are dosed according to blood concentrations rather than bodyweight to avoid 
overimmunosuppression or underimmunosuppression. Currently, the parameter most 
widely used for therapeutic drug monitoring of calcineurin inhibitors is the predose, or 
trough, concentration (C
0
).5-7
The variability in the pharmacokinetics of calcineurin inhibitors is largely determined by 
differences in oral bioavailability. The oral bioavailability of cyclosporine and tacrolimus is 
poor and varies between patients or within a single patient over time.1-4 In recent years much 
research has focused on the possible causes of these interindividual and intraindividual 
differences in the pharmacokinetics of calcineurin inhibitors. It has become clear that the 
biologic activity of the permeability-glycoprotein and the cytochrome P450 (CYP) enzyme 
system play an important role in this respect.8,9 P-glycoprotein is the product of the multidrug-
resistance 1 (MDR-1) gene. The protein serves as a transporter and is capable of pumping 
a wide variety of endogenous substances, as well as drugs (including cyclosporine and 
tacrolimus), from the cytoplasm to the exterior of the cell.8-10 Physiologically, P-glycoprotein 
is present in the liver, kidney, adrenal gland, pancreas and the small intestine. In the small 
intestine P-glycoprotein is expressed at the apical surface of mature enterocytes, where it 
prevents the absorption of (possible toxic) xenobiotics from the intestinal lumen by active 
extrusion from the cell interior.8,9 The CYP system is an enzyme family that is responsible for 
the oxidative metabolism of many molecules and consists of more than 50 isozymes. CYP3A 
is the subfamily that accounts for the metabolism of many drugs, including cyclosporine 
and tacrolimus.11,12 The CYP3A subfamily consists of the isozymes CYP3A4,11 CYP3A5,12,13 
and CYP3A7,14,15 as well as the recently discovered CYP3A43.16 CYP3A4 and CYP3A5 have 
largely overlapping substrate specificities. CYP3A4 is, like P-glycoprotein, abundantly and 
constitutively expressed in hepatic and intestinal epithelium, whereas CYP3A5 appears to 
be more variably expressed.8,9,11-13,17,18 CYP3A7 is expressed mainly during fetal life.14,15,19 
CYP3A43 appears to have a low expression in the adult liver, but its relative contribution to 
drug metabolism is as yet unknown.16
Many drugs already undergo substantial metabolism in the intestine, after absorption from 
the gut lumen, in addition to metabolism in the liver.8,9,20 CYP3A and P-glycoprotein are jointly 
present in the gut, and it is believed that the low oral bioavailability of calcineurin inhibitors 
results largely from the actions of these 2 enzymes.8,9,17,20-25 The interindividual differences 
in the pharmacokinetics of calcineurin inhibitors have been attributed to interindividual 
heterogeneity in enzymatic activity of P-glycoprotein and CYP3A. However, the cause of 
this heterogeneity in enzymatic activity remains to be elucidated. Recently, a number of 
single-nucleotide polymorphisms (SNPs) were described for the MDR-1,26 CYP3A4,27,28 and 
CYP3A518,29,30 genes. The C3435T mutation in the MDR-1 gene has been associated with 
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a decreased protein expression, whereas the CYP3A5*3 and the CYP3A5*6 alleles were found 
to cause alternative splicing and protein truncation, resulting in the absence of functional 
CYP3A5 from liver tissue.29,30 For the CYP3A4*1B allele, an increased transcription was 
demonstrated in vitro, which would theoretically result in higher enzymatic activity in 
vivo.31 Therefore these genetic polymorphisms may provide an explanation for the observed 
variability in calcineurin inhibitor pharmacokinetics. To determine the effects of MDR-
1 and CYP3A SNPs on the pharmacokinetics of calcineurin inhibitors, we analyzed 174 
patients who underwent renal transplantation and were receiving maintenance treatment 
with either cyclosporine or tacrolimus. Cyclosporine and tacrolimus dose-adjusted C
0
 values 
were determined and correlated with the corresponding MDR-1, CYP3A4, and CYP3A5 
genotypes. Patients were analyzed for the MDR-1 C3435T,26 CYP3A4*1B,27 CYP3A4*3,28 
CYP3A5*3,29 and CYP3A5*629 variant alleles.
MATERIALS AND METHODS
PATIENTS
All renal transplant recipients visiting the outpatient clinic of the Erasmus Medical Center, 
Rotterdam, The Netherlands, who had received a renal graft at least 1 year before the start 
of the study were eligible for entry into this study. During routine visits, blood samples were 
drawn for genotyping. Cyclosporine and tacrolimus dose and predose concentrations, as 
well as demographic and clinical data were obtained at 3 and 12 months (±1 month) after 
transplantation. Both tacrolimus and cyclosporine were given in 2 equally divided doses. All 
patients treated with cyclosporine used the microemulsion formulation (Neoral; Novartis 
Pharmaceuticals Corporation, Hanover, NJ). Patients taking medication known to interact 
with calcineurin inhibitors, such as calcium channel blockers (diltiazem, nicardipine, and 
verapamil), antiepileptics (phenytoin and carbamazepine), antimycotics (fluconazole and 
ketoconazole), and macrolide antibiotics (erythromycin and clarithromycin), were not 
eligible for entry into the study. 
ETHICS
The study was performed in accordance with the declaration of Helsinki and its amendments. 
The protocol was approved by the Ethics Committee of the Erasmus Medical Center, and 
written informed consent was obtained from all subjects.
DRUG CONCENTRATION MEASUREMENTS
Cyclosporine and tacrolimus C
0
 values were determined in whole blood with the Emit 2000 
assay (Syva company, Dade Behring Inc, Cupertino, CA) on a Cobas Mira Plus analyzer 
(Roche Diagnostic Systems, Basel, Switzerland). Details on the sensitivity and reproducibility 
of the Emit assay in our laboratory were published previously.32 Proficiency samples were 
obtained from the United Kingdom Quality Assessment Scheme (Dr Holt, St George’s 
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Hospital Medical School, London United Kingdom). Dose-adjusted predose concentrations 
were calculated by dividing the C
0
 by the corresponding 24-h dose on a milligrams per 
kilogram basis. 
DEOXYRIBONUCLEIC ACID ISOLATION AND GENOTYPE DETERMINATION
Genomic deoxyribonucleic acid was isolated from 200 µL ethylenediaminetetraacetic 
acid-treated whole blood using a MagnaPure LC (Roche Diagnostics GmbH, Mannheim, 
Germany). 
POLYMERASE CHAIN REACTION-RESTRICTION FRAGMENT LENGTH 
POLYMORPHISM ANALYSIS FOR CYP3A4*1B AND *3, CYP3A5*3 AND *6,  
AND MDR-1 (C3435T) VARIANT ALLELES
Polymerase chain reaction (PCR)-restriction fragment length polymorphism analyses 
for CYP3A4*1B and *3 and CYP3A5*3 and *6 were performed as described previously.33-
35 In brief, 50 ng of genomic deoxyribonucleic acid was used in a PCR volume of 50 µL 
containing 1x buffer [10-mmol/L Tris-hydrochloric acid, pH 8.3; 1.5-mmol/L magnesium 
chloride; 50-mmol/L potassium chloride; and 0.001% (wt/vol) gelatin (Perkin-Elmer Inc, 
Wellesley, MA)], 0.2-mmol/L each deoxyribonucleoside triphosphate (Roche), 1.25 U of 
AmpliTaq Gold (Perkin-Elmer), and 40 pmol of each of forward and reverse primer. For 
MDR-1, forward primer 5’-CATGCTCCCAGGCTGTTTAT-3’ and reverse primer 5’-
GTAACTTGGCAGTTTCAGTG-3’ were used. PCR conditions were as follows: 7 minutes 
at 94 °C; 35 cycles of 1 minute at 94 °C, 1 minute at 55 °C, and 1 minute at 72 °C; and finally 
7 minutes at 72 °C. The PCR product (10 µL) was digested with PstI (CYP3A4*1B), SspI 
(CYP3A5*3), or DpnII (MDR-1) in a total volume of 15 µL for 2 h at 37 °C, and subsequently 
analyzed on agarose/Tris-borate-ethylenediaminetetraacetic acid gel with ethidium bromide 
staining.
STATISTICAL ANALYSIS
Between-group differences were calculated by use of the Mann-Whitney U test and one-way 
ANOVA (Kruskal-Wallis test), followed by the Dunn post hoc test for multiple comparisons. 
A P value of ≤ 0.05 was considered statistically significant. All values are expressed as median 
and range unless stated otherwise.
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RESULTS
A total of 174 patients were included, of whom 110 were treated with cyclosporine and 64 were 
treated with tacrolimus. The characteristics of these patients are summarized in Table 4.1.1.
Table 4.1.1 Characteristics of 174 renal transplant recipients  
treated with cyclosporine or tacrolimus
Cyclosporine Tacrolimus All patients
Patients (male : female) 110 (69:41) 64 (34:30) 174 (103:71)
Transplantation number
     First 89 47 136
     Second 15 14 29
     Third or more 6 3 9
Primary kidney disease 
     Glomerulonephritis 23 11 34
     Chronic pyelonephritis 8 3 11
     Immunoglobulin A nephropathy 6 4 10
     Diabetic nephropathy 9 6 15
     Hypertensive nephropathy 8 5 13
     Polycystic kidney disease 15 13 28
     Unknown 14 12 26
     Other 27 10 37
Race
     Asian 12 6 18
     Black 11 9 20
     White 87 49 136
MDR-1 GENOTYPE
Of the 110 patients treated with cyclosporine, the MDR-1 genotype was determined in 109. 
The wildtype genotype (3435CC) was observed in 22 patients (20.2%), whereas 56 (51.4%) 
were heterozygous (3435CT) and 31 (28.4%) homozygous (3435TT) for the variant allele. 
There were no significant differences among the 3 groups in cyclosporine dose (mg/kg), 
cyclosporine C
0
 (ng/mL), or cyclosporine dose-adjusted C
0
 (ng/mL per mg/kg) at month 3 
or 12 (Table 4.1.2). Of the 64 patients treated with tacrolimus, the wildtype genotype was 
present in 15 patients (23.4%), whereas 34 (53.2%) were heterozygous and 15 (23.4%) were 
homozygous for the variant allele. Again, no significant differences were observed among 
the 3 groups in tacrolimus dose (mg/kg), tacrolimus C
0
 (ng/mL) or tacrolimus dose-adjusted 
C
0
 (ng/mL per mg/kg) at month 3 or 12 (Table 4.1.2). 
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Table 4.1.2 MDR-1 genotype and dose requirement for cyclosporine (n = 109) or tacrolimus (n 
= 64) in 173 renal transplant recipients 
MDR-1 genotype
3435 CC 3435 CT 3435 TT
Patients taking cyclosporine (No.) 22 56 31
   Cyclosporine C
0
 (ng/mL)
      3 months 217.5 (80-400) 217.5 (40-370) 210 (90-380)
      12 months 145 (80-430) 140 (20-320) 125 (75-290)
   Cyclosporine C
0
/dose (ng/mL per mg/kg)
      3 months 45.3 (16.0-82.6) 41.5 (10.4-78.0) 40.2 (19.1-87.6)
      12 months 37.3 (14.9-84.3) 38.3 (9.2-142.9) 38.8 (22.0-79.5)
Patients taking tacrolimus (No.) 15 34 15
   Tacrolimus C
0
 (ng/mL)
      3 months 9.2 (4.7-19.7) 9.1 (5.1-17.5) 10.0 (7.2-14.5)
      12 months 7.1 (4.3-9.4) 6.8 (4.0-19.2) 7.1 (3.0-17.1)
   Tacrolimus C
0
/dose (ng/mL per mg/kg)
      3 months 66.8 (46.2-369.4) 86.8 (33.8-397.8) 91.2 (53.4-270.1)
      12 months 80.4 (40.9-202.5) 96.8 (27.5-432.0) 100.9 (26.0-192.1)
No significant differences in dose requirement of either drug were observed between patients with the 3 MDR-1 
genotypes. All values are expressed as median with range in parentheses. C
0
, Predose or trough concentration.
CYP3A4 GENOTYPE
For patients treated with cyclosporine, the CYP3A4 wildtype genotype (*1/*1) was 
observed in 94 patients (87.1%), whereas 9 (8.3%) were heterozygous and 5 (4.6%) were 
homozygous for the CYP3A4*1B allele. The CYP3A4*3 allele was not found among patients 
taking cyclosporine. For the CYP3A4*1/*1B polymorphism, no significant differences in 
cyclosporine dose (mg/kg), cyclosporine C
0
 (ng/mL), or cyclosporine dose-adjusted C
0
 (ng/
mL per mg/kg) were observed among individuals with the CYP3A4*1/*1, CYP3A4*1/*1B and 
CYP3A4*1B/*1B genotypes at 3 and 12 months after transplantation (Table 4.1.3). 
Of the 64 patients treated with tacrolimus, 7 (10.9%) were heterozygous and 3 (4.7%) were 
homozygous for the variant CYP3A4*1B allele. A trend was observed toward a lower dose-
adjusted C
0
 in patients heterozygous or homozygous for the CYP3A4*1B allele, as compared 
with the CYP3A4*1/*1 genotype (P = 0.01, one-way ANOVA; data not shown). When patients 
carrying the CYP3A4*1B allele were compared to patients with the CYP3A4*1/*1 genotype, a 
significant difference in tacrolimus dose-adjusted C
0
 was found, as follows: 57.0 ng/mL per 
mg/kg versus 89.3 ng/mL per mg/kg, respectively; P = 0.003 (Table 4.1.3 and Figure 4.1.1A). 
This difference remained statistically significant at month 12 (Table 4.1.3). These findings are 
in line with the assumption that carriers of a CYP3A4*1B allele will display higher CYP3A4 
activity as a result of increased expression of this allele. Because tacrolimus C
0
 was similar in 
both groups at month 3 and month 12 (P = 0.84 and P = 0.57, respectively)(Table 4.1.3), the 
observed differences in tacrolimus dose-adjusted C
0
 are explained by a significantly higher 
tacrolimus dose requirement in patients with the CYP3A4*1B allele compared with patients 
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with the CYP3A4*1/*1 genotype at month 3 [0.18 (0.04-0.27) mg/kg versus 0.09 (0.03-0.23) 
mg/kg, P = 0.01] and at month 12 [0.10 (0.04-0.23) mg/kg versus 0.06 (0.03-0.21) mg/kg, 
P = 0.03]. Two patients taking tacrolimus carried the CYP3A4*3 allele. The tacrolimus dose-
adjusted C
0
 in these 2 patients was higher than that in patients with the wildtype genotype 
(n = 62), as follows: 134.9 (106.6-163.2) ng/mL per mg/kg versus 83.83 (33.83-397.8) ng/mL 
per mg/kg, respectively. This difference was also observed at 12 months after transplantation, 
as follows: 147.3 (117.0-177.5) ng/mL per mg/kg versus 88.8 (26.0-432.0) ng/mL per mg/
kg. Because of the small number of CYP3A4*3 variant alleles, the relationship between 
tacrolimus dose-adjusted C
0
 and the CYP3A4*3 allele could not be analyzed statistically. 
Table 4.1.3 CYP3A4 genotype and dose requirement for cyclosporine (n = 108) or tacrolimus (n 
= 64) in 172 renal transplant recipients 
CYP3A4 genotype
*1/*1 *1/*1B plus *1B/*1B P value §
Patients taking cyclosporine (No.) 94 14
   Cyclosporine C
0
 (ng/mL)
      3 months 210 (40-400) 217 (65-370) NS
      12 months 137.5 (20-430) 135 (85-190) NS
   Cyclosporine C
0
/dose (ng/mL per mg/kg)
      3 months 41.5 (10.4-87.6) 41.7 (17.9-68.2) NS
      12 months 38.3 (9.2-142.9) 35.4 (21.1-69.0) NS
Patients taking tacrolimus (No.) 54 10
   Tacrolimus C
0
 (ng/mL)
      3 months 9.2 (5.1-19.7) 10.3 (4.7-13.9) NS
      12 months 7.0 (3.0-19.2) 7.5 (4.0-9.4) NS
   Tacrolimus C
0
/dose (ng/mL per mg/kg)
      3 months 89.3 (33.8-397.8) 57.0 (39.5-163.2) 0.003
      12 months 107.0 (26.0-432.0) 65.5 (28.0-177.5) 0.027
A significant difference in tacrolimus dose requirement was observed between patients carrying the variant 
CYP3A4*1B allele and patients with the CYP3A4*1/*1 genotype. For cyclosporine no such difference was 
observed. All values are expressed as median with range in parentheses.
NS, Not significant.
§ Two-tailed, Mann-Whitney U test. 
CYP3A5 GENOTYPE
The majority of the patients who were treated with cyclosporine were homozygous for the 
CYP3A5*3 variant allele [n = 78 (71.6%)] and are thus expected to lack CYP3A5 activity. It 
was determined that 26 patients (23.8%) carried 1 CYP3A5*1 allele, and the CYP3A5*1/*1 
genotype was observed in 5 patients (4.6%). Of the 31 CYP3A5*1 allele carriers, 5 were 
also heterozygous for the CYP3A5*6 variant allele. It is difficult to assess whether these 
patients are compound heterozygotes (with no active CYP3A5) or whether they carry both 
polymorphisms on the same allele (leaving 1 active CYP3A5 allele). Therefore, we excluded 
these 5 patients from further analysis. There were no significant differences between the 3 
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CYP3A5 genotypes in cyclosporine dose (mg/kg), cyclosporine C
0
 (ng/mL) or cyclosporine 
dose-adjusted C
0
 (ng/mL per mg/kg) at month 3 or 12 (Table 4.1.4). Moreover, no significant 
differences were found when we compared carriers of the CYP3A5*1 allele to CYP3A5*3 
homozygotes.
The CYP3A5*1/*1 genotype was observed in 3 (4.7%) of the 64 tacrolimus-treated patients, 
whereas 16 patients (25%) were heterozygous and 45 homozygous (70.3%) for the CYP3A5*3 
variant allele. Of the 19 patients carrying a wildtype allele, 2 were heterozygous for the 
CYP3A5*6 allele. These patients were not analyzed further. A significant difference was found 
in tacrolimus dose (mg/kg) and tacrolimus dose-adjusted C
0
 (ng/mL per mg/kg) among 
the 3 groups, as shown in Table 4.1.4 and Figure 4.1.1B. A significantly lower tacrolimus 
dose-adjusted C
0
 was found in patients carrying a CYP3A5*1 allele compared to patients 
with the CYP3A5*3/*3 genotype, both at month 3 and month 12 after transplantation. 
Again, because the tacrolimus C
0
 was not significantly different among the 3 groups, the 
observed differences in tacrolimus dose-adjusted C
0 
can only be explained by a higher 
dose requirement for patients carrying a wildtype allele. According to the expectation that 
CYP3A5*1 allele carriers have CYP3A5 enzyme activity, the CYP3A5*1/*1 and *1/*3 groups 
were analyzed against the CYP3A5*3/*3 group. The earlier observed difference in tacrolimus 
dose-adjusted C
0
 remained highly significant: 61.0 ng/mL per mg/kg versus 94.4 ng/mL per 
mg/kg, P < 0.0001 (Table 4.1.4 and Figure 4.1.1B).
Table 4.1.4 CYP3A5 genotype and dose requirement for cyclosporine (n = 104) or tacrolimus (n 
= 62) in 166 renal transplant recipients (patients carrying a CYP3A5*6 allele were excluded) 
CYP3A5
*1/*1 *1/*3 *3/*3
Patients taking cyclosporine (No.) 4 22 78
   Cyclosporine C
0
 (ng/mL)
      3 months 205 (160-340) 217.5 (40-370) 207.5 (45-400)
      12 months 170 (145-225) 132.5 (75-270) 135 (20-430)
   Cyclosporine C
0
/dose (ng/mL per mg/kg)
      3 months 42.6 (33.2-57.0) 41.3 (10.4-78.0) 40.7 (14.4-87.6)
      12 months 46.3 (33.7-59.4) 33.1 (14.9-70.2) 38.3 (9.2-143.0)
Patients taking tacrolimus (No.) 2 15 45
   Tacrolimus C
0
 (ng/mL)
      3 months 9.7 (7.7-11.7) 9.1 (5.7-15.7) 9.4 (4.7-19.7)
      12 months 7.5 (6.9-8.0) 7.2 (4.0-10.6) 7.0 (3.0-19.2)
   Tacrolimus C
0
/dose (ng/mL per mg/kg)
   3 months 67.3 (56.8-77.8) 61.0 (36.8-163.2) 94.4 (33.8-397.8) §
   12 months 78.8 (73.6-84.0) 57.6 (27.5-177.5) 124.2 (26-432.0) §
Patients carrying a CYP3A5*1 allele require a significantly higher tacrolimus dose to reach similar tacrolimus 
predose concentrations as compared with patients homozygous for the CYP3A5*3 allele. For cyclosporine no 
such difference was observed. All values are expressed as median with range in parentheses.
§ P < 0.001, CYP3A5*1/*3 versus CYP3A5*3/*3, Kruskal-Wallis test with Dunn’s multiple comparison test.
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Figure 4.1.1 Tacrolimus (TRL) dose-
adjusted predose concentration 
(C0) and CYP3A genotype at 
month 3 after transplantation in 
64 renal transplant recipients. A 
significant difference in tacrolimus 
dose requirement was observed 
between patients carrying the 
CYP3A4*1B allele and patients 
with the CYP3A4*1/*1 genotype (P 
= 0.003, Mann-Whitney U test; 
panel A). A significant difference in 
tacrolimus dose-adjusted C0 was 
also observed between patients 
carrying the CYP3A5*1 allele and 
patients homozygous for CYP3A5*3 
(P < 0.0001, Mann Whitney U 
test; panel B)(patients carrying a 
CYP3A5*6 allele were excluded 
from the analysis). When white 
patients were analyzed separately, 
this difference in tacrolimus dose 
requirement was still present (P 
= 0.021, Mann Whitney U test; 
panel C).
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INFLUENCE OF ETHNICITY
The Dutch transplant patient population consists mainly of patients of Caucasian descent. 
This is reflected by the large cohort of white patients in our study population [136/174 patients 
(78.2%)]. Only 20 patients (11 in the cyclosporine and 9 in the tacrolimus group) were black, 
with the remaining 18 patients being of Asian descent. The low number of patients in the 
last 2 groups indicates that conclusions regarding the influence of ethnicity should be 
interpreted with caution. Nevertheless, we performed all previously mentioned analyses for 
each ethnic group separately. With ethnic diversity taken into account, no influence of the 
MDR-1 genotype was found, for either cyclosporine or tacrolimus. The previously discovered 
correlation of the CYP3A4*1B allele with tacrolimus dose requirement was lost, probably 
because of the limited number of CYP3A4*1B allele carriers (3 white and 7 black patients, 
respectively; data not shown). However, the reported correlation of the CYP3A5 genotype 
with tacrolimus dose requirement remained significant in the white population, both at 
month 3 and at month 12 after transplantation (P = 0.021 and P = 0.01, respectively)(Figure 
4.1.1C). It is interesting that, for white patients taking cyclosporine, a significant influence 
of CYP3A5 genotype on cyclosporine dose requirement was now found but only at month 12 
after transplantation, whereas this difference was not present for the whole study population 
[CYP3A5*1/*3 (n = 14) versus CYP3A5*3/*3 (n = 71); median and range, 27.85 (14.93-69.0) 
ng/mL per mg/kg versus 38.03 (9.2-142.9) ng/ml per mg/kg; P = 0.03]. 
DISCUSSION
The clinical use of calcineurin inhibitors is complicated by their narrow therapeutic index 
and highly variable and unpredictable pharmacokinetics in individual patients. Although 
therapeutic drug monitoring is routinely performed for this class of drugs, both acute and 
chronic calcineurin inhibitor toxicity occur in everyday clinical practice. Moreover, some 
patients do not reach target concentrations with recommended starting doses of calcineurin 
inhibitors and therefore have an increased risk of underimmunosuppression and acute 
rejection.1-4 The role of P-glycoprotein and the CYP3A enzymes in calcineurin inhibitor 
pharmacokinetics has been recognized for some time, but until the recent identification 
of a number of SNPs in the MDR-1 and CYP3A genes, the (genetic) basis for the observed 
interindividual differences in pharmacokinetics was unclear.8,9,26,27,29
We observed a highly significant association between tacrolimus dose requirement
 
and the 
CYP3A5*1/*3 polymorphism. Our results show that a lower tacrolimus dose is required to 
reach target concentrations in patients homozygous for CYP3A5*3 compared with CYP3A5*1 
allele carriers. This is in agreement with the fact that the CYP3A5*3 allele results in the loss 
of hepatic CYP3A5 activity.29,30 Moreover, it may explain the recently published findings of 
MacPhee et al.36 who suggested that a SNP in the CYP3AP1 pseudogene (A/G
-44
) is strongly 
correlated with tacrolimus dose requirement. Although the CYP3AP1 pseudogene is strongly 
associated with hepatic CYP3A5 activity, being a pseudogene, it cannot be responsible for 
polymorphic expression. In fact, the results of MacPhee et al. may have been caused by linkage 
of the CYP3AP1 pseudogene to the CYP3A5*1/*3 SNP we studied.29,36 Our findings could be 
of clinical importance because patients carrying the CYP3A5*1 allele may theoretically run 
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the risk of underimmunosuppression and, subsequently, of acute rejection. In our patient 
cohort the incidence of biopsy-proven acute rejection was not significantly different between 
CYP3A5*1 allele carriers and patients with the CYP3A5*3/*3 genotype (23.5% versus 20.0%, 
respectively; P = 0.74 Fisher’s exact test). However, this was a cross-sectional study in a 
selected group of patients with a graft survival of at least 1 year and no severe drug toxicity 
necessitating discontinuation of tacrolimus. A prospective study is needed to further address 
these possible clinical consequences. Eventually, determination of the CYP3A5 genotype 
before transplantation may identify patients at risk for underimmunosuppression or toxicity 
and alert clinicians to a high likelihood of development of drug levels outside target ranges. It 
is tempting to speculate that our results provide a genetic basis for the poorer outcome after 
transplantation in black patients. One of the factors that possibly explains this observation is 
the fact that the oral bioavailability of tacrolimus (and cyclosporine) is lower in black kidney 
transplant recipients as compared with white patients.37,38 Indeed, in our study group the 
allelic frequency of CYP3A5*1 was much higher in patients of African origin compared with 
white patients, which is fully consistent with the literature.29,30 
A relationship between CYP3A4 genotype and cyclosporine dose requirement could not be 
demonstrated in our study, confirming the results of 2 previous studies.39,40 These findings 
argue against a major influence of the CYP3A4*1B promoter variant allele on cyclosporine 
pharmacokinetics. In contrast, our results are the first to show that patients carrying the 
CYP3A4*1B allele require a higher tacrolimus dose to reach target concentrations. Until 
now, the effect of the CYP3A4*1B allele on CYP3A4 activity remained controversial. From 
clinical studies, it was postulated that the CYP3A4*1B allele results in a decreased enzymatic 
activity.27,41 However, subsequent microsomal studies could not confirm an effect of the 
CYP3A4*1B allele on enzymatic function,42,43 whereas a higher CYP3A4 expression of the 
CYP3A4*1B allele was reported in vitro.31 The fact that we observed a correlation between 
the CYP3A4 genotype and tacrolimus, but not cyclosporine, dose requirement, could be 
explained by the fact that the molecular structure of these 2 drugs is entirely different.4 We 
believe that this is an unlikely mechanism, because the CYP3A4*1/*1B SNP  is located in 
the 5’ transcriptional regulatory element of the CYP3A4 coding region, more likely causing 
changes in protein expression rather than activity. Alternatively, we may not have detected 
an effect of the CYP3A4*1B allele on cyclosporine pharmacokinetics. The variability in 
the pharmacokinetics of orally administered calcineurin inhibitors is largely determined 
by interindividual differences in first-pass elimination. However, the (dose-adjusted) C
0
 
value reflects clearance from the systemic circulation rather than first-pass extraction. An 
effect of the CYP3A4*1B allele on tacrolimus, but not cyclosporine, dose requirement, could 
have been found because the tacrolimus C
0
 correlates better with total drug exposure (as 
measured by the tacrolimus 12-h area-under the concentration versus time-curve) than does 
the cyclosporine C
0.
6,7
Another issue that needs to be addressed is the combined effect of the genetic polymorphisms 
in CYP3A4 and CYP3A5 on tacrolimus pharmacokinetics. Because tacrolimus is metabolized 
by both CYP3A4 and CYP3A5, this dual pathway partially obscures the (clinical) effects of 
genetic polymorphisms of either enzyme. In our population, 80% of the patients homozygous 
for CYP3A5*3 were homozygous for CYP3A4*1 (associated with a lower tacrolimus dose 
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requirement in comparison with that of CYP3A4*1B allele carriers). It is interesting that we 
also found linkage between the CYP3A5*3 and CYP3A4*1 alleles in 500 white patients who 
were described previously (references 33 and 35; van Schaik et al., unpublished observations). 
Recently, linkage between these two SNPs was described by a second group.44
Finally, our results do not demonstrate an association between cyclosporine or tacrolimus 
dose requirement and the C3435T polymorphism in exon 26 of the MDR-1 gene. Although 
it was originally associated with lower duodenal P-glycoprotein expression in patients 
homozygous for the variant allele,26 a later study found no significant correlation between 
the C3435T polymorphism and cyclosporine C
0
.39 Nevertheless, these results should be 
interpreted with some caution. Intestinal P-glycoprotein content accounts for 30% of the 
interindividual variability in peak blood concentrations of orally administered cyclosporine 
but has markedly less effect on the variation in oral cyclosporine clearance.45 By analyzing 
the full pharmacokinetic profiles of 14 healthy volunteers, Min and Ellingrod46 found 
that individuals carrying the variant MDR-1 C3435T allele had a 15% higher peak blood 
concentration and a 22% higher area-under the concentration versus time-curve from 0 to 
24 h.46 However, these differences failed to reach statistical significance, possibly because of 
the limited number of MDR-1 3435TT homozygotes. 
In conclusion, our study demonstrates for the first time that a strong correlation exists between 
the CYP3A genotype and tacrolimus dose requirement. Patients carrying a CYP3A5*1 allele 
require significantly more tacrolimus to reach target concentrations compared to CYP3A5*3 
homozygotes and may thus have a higher likelihood of underimmunosuppression and acute 
rejection. Carriers of the CYP3A4*1B allele also required more tacrolimus to reach adequate 
whole blood levels compared with patients with the CYP3A4*1/*1 genotype, although its 
exact contribution needs to be elucidated because of linkage of the CYP3A4*1 allele to the 
CYP3A5*3 allele. No evidence was found supporting a role for the MDR-1 C3435T SNP in 
the pharmacokinetics of calcineurin inhibitors. 
None of the authors has any financial or personal relationships that could potentially be 
perceived as influencing our described research.
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ABSTRACT
Objective Our objective was to determine the relationship between single-nucleotide 
polymorphisms (SNPs) in the multidrug resistance 1 (MDR-1) gene and the cytochrome 
P450 (CYP) genes CYP3A4 and CYP3A5 and the pharmacokinetics of cyclosporine (INN, 
ciclosporin). Methods Cyclosporine pharmacokinetics of 151 kidney and heart transplant 
recipients undergoing maintenance therapy was described by use of nonlinear mixed-effects 
modeling (NONMEM) according to a 2-compartment pharmacokinetic model with first-
order absorption and elimination. All patients were genotyped for the CYP3A4*1B and *3, 
CYP3A5*3 and *6, and MDR-1 3435C→T SNPs. Results For a typical 70-kg white patient, the 
following parameters were estimated: absorption rate constant, 1.27 h-1; absorption time lag, 
0.47 h; oral volume of distribution of the central and peripheral compartment, 56.3 and 185.0 
L, respectively; oral clearance (Cl/F), 30.7 L/h; and oral intercompartmental clearance, 31.7 
L/h. Estimated interpatient variability of Cl/F was 28%. Cl/F was significantly correlated 
with weight and ethnicity; Cl/F was 13% higher (95% confidence interval, 8%-18%; P < 0.005) 
in white patients than in black and Asian patients. In carriers of a CYP3A4*1B variant allele, 
Cl/F was 9% (95% confidence interval, 1%-17%; P < 0.05) higher compared with CYP3A4*1 
homozygotes, and this effect was independent of ethnicity or weight. Incorporation of these 
covariates into the NONMEM model did not markedly reduce interpatient variability of 
Cl/F. None of the other SNPs studied significantly influenced any of the pharmacokinetic 
parameters. Conclusion Patients carrying a CYP3A4*1B variant allele have a significantly 
higher oral cyclosporine clearance compared with patients homozygous for CYP3A4*1. 
However, this genetic effect on cyclosporine disposition was small, and genotyping of 
transplant recipients for CYP3A4 is thus unlikely to assist in planning initial cyclosporine 
dosing. 
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INTRODUCTION
The clinical use of the immunosuppressive agent cyclosporine (INN, ciclosporin) is hampered 
by its many side effects, narrow therapeutic index, and highly variable and unpredictable 
pharmacokinetics, as well as the frequent occurrence of drug interactions.1 Therapeutic 
drug monitoring has, therefore, been adopted by most transplant physicians as a means to 
improve the efficacy and reduce the toxicity of cyclosporine treatment. Pharmacogenetics 
has the potential to assist in determining the starting dose of immunosuppressive drugs.2 
For renal transplant recipients, it has been demonstrated that early adequate exposure to 
such agents is critical and that failure to reach target concentrations as early as the third 
postoperative day may result in acute rejection.3 
The multidrug resistance 1 (MDR-1) gene encodes P-glycoprotein, an adenosine triphosphate-
dependent transmembrane transporter that is capable of pumping a wide variety of 
endogenous substances, xenobiotics, and drugs from the cytoplasm to the exterior of the 
cell. Cytochrome P450 (CYP) 3A4 and CYP3A5 are enzymes with overlapping substrate 
specificities that are largely responsible for the phase I metabolism of the majority of drugs 
currently in use.2 Physiologically, P-glycoprotein and the CYP3A enzymes are expressed 
in human liver and gut, where they act synergistically to limit systemic exposure to a large 
number of xenobiotics and drugs. In the small intestine, P-glycoprotein limits the absorption 
of these substances by active extrusion from the enterocyte interior back into the gut lumen. 
The oral bioavailability of many drugs is reduced further by intestinal metabolism by 
CYP3A. In addition, CYP3A and MDR-1 expression in liver and biliary canaliculi is largely 
responsible for systemic drug clearance.4 
There exist marked interindividual differences in MDR-1 and CYP3A expression that may 
be attributed to a number of recently discovered single-nucleotide polymorphisms (SNPs) 
in the MDR-1 and CYP3A genes. The MDR-1 3435C→T SNP was originally associated 
with a decreased protein expression in individuals carrying a T allele, resulting in higher 
probe drug blood concentrations.5-7 A large number of drugs, including anticancer agents, 
antiarrhythmics, and antiviral drugs, are P-glycoprotein substrates; therefore polymorphic 
expression of this drug transporter potentially has an important clinical impact. However, 
the exact functional significance of this SNP is still a matter for debate (for a review, see 
reference 8). For CYP3A5, the CYP3A5*3 and the CYP3A5*6 variant alleles have been 
described, which cause alternative splicing and protein truncation, resulting in the absence 
of functional CYP3A5 from liver tissue.9,10 For the CYP3A4*1B variant allele, an increased 
transcription has been demonstrated in vitro.11 
Cyclosporine and its counterpart tacrolimus are both P-glycoprotein and CYP3A 
substrates,12-14 and their well-recognized pharmacokinetic variability is explained in part 
by marked interindividual heterogeneity in intestinal and hepatic MDR-1 and CYP3A 
expression.15-19 Several groups have studied the association between the above-mentioned 
SNPs and tacrolimus dose requirement in renal,20-24 heart,25 liver,26 and lung transplant 
recipients.27 In summary, the tacrolimus dose requirement was consistently found to be 
higher in CYP3A5 expressors, whereas the MDR-1 genotype appears to have a minor or no 
effect on tacrolimus pharmacokinetics. Interestingly, several large cohort studies in renal 
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transplant recipients could not detect a correlation between these SNPs and the cyclosporine 
dose requirement.22,28-30 A possible explanation for these conflicting results could be that in 
most studies the effect of genotype on cyclosporine dose requirement was investigated by 
use of the cyclosporine predose concentration (C
0
), which has a notoriously poor correlation 
with total drug exposure.3 For tacrolimus, the C
0 
appears to reflect total tacrolimus exposure 
much better.31 A possible effect of the MDR-1 or CYP3A genotype on cyclosporine dose 
requirement could thus have remained undetected.
In this study we investigated the relationship between cyclosporine pharmacokinetics and MDR-
1 and CYP3A genotypes in more detail. The presence of the MDR-1 3435C→T,5 CYP3A4*1B,32 
CYP3A4*3,33 CYP3A5*3, and CYP3A5*6,9,10 variant alleles was determined in 151 kidney and 
heart transplant recipients who were all treated with cyclosporine. Pharmacokinetic analysis 
was carried out by use of nonlinear mixed-effects modeling (NONMEM). In contrast to 
more classic pharmacokinetic analysis methods (i.e., noncompartmental method), this 
technique has the advantage that individual pharmacokinetic parameters can be assessed 
when only a limited number of blood concentrations are available for each patient.  
METHODS
PATIENTS
All patients described herein participated in 1 of 2 studies. For the current study, the 
demographic, clinical, pharmacokinetic, and pharmacogenetic data of these patients were 
pooled and analyzed together. The design and aims of these 2 studies were as follows:
Study 1. The aim of study 1 was to investigate the relationship between cyclosporine 
exposure and the presence of cyclosporine-related side effects in solid organ transplant 
recipients receiving maintenance therapy (Hesselink DA, unpublished data, 2004). All 
heart, kidney, and liver transplant recipients visiting our outpatient clinic were asked to 
participate in the study. Inclusion criteria were (1) unchanged cyclosporine dose within the 
last 3 months before entry into the study, (2) stable graft function, (3) use of the cyclosporine 
microemulsion formulation (Neoral; Novartis Pharmaceuticals Corporation, Hanover, 
NJ), and (4) no treatment with drugs known to interact with cyclosporine at the CYP3A 
or MDR-1 level. The use of azathioprine, mycophenolate mofetil, or prednisone as part of 
the immunosuppressive regimen was allowed. In all patients the cyclosporine exposure was 
determined by drawing blood at 0, 1, 2, 3 and 4 h after oral administration of the normal 
morning dose. Cyclosporine pharmacokinetics was then compared between patients with 
and patients without cyclosporine-related side effects. In addition, genotyping for MDR-1, 
CYP3A4, and CYP3A5 was performed in all patients as an integral part of the study. The 
CYP3A and MDR-1 genotype of the transplanted organs was not determined. Because 
cyclosporine is metabolized by hepatic and intestinal CYP3A enzymes and its metabolites 
are almost exclusively excreted by the biliary route (around 95%), we only included the data 
from the heart (n = 28) and renal allograft recipients (n = 26) in this study. 
147
Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the 
influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes
Study 2. The objective of study 2 was to determine the role of SNPs in MDR-1, CYP3A4, 
and CYP3A5 with respect to interindividual variability in cyclosporine and tacrolimus dose 
requirement. The results of this study were published recently.22 In brief, all renal transplant 
recipients who were examined in the outpatient clinic of our hospital and had received a 
renal allograft at least 1 year before the start of the study were asked to participate. During 
routine visits, blood samples were drawn for genotyping. Cyclosporine and tacrolimus 
dose and predose concentrations, as well as demographic and clinical data, were recorded 
at 3 and 12 months (±1 month) after transplantation. Again, all patients were treated 
with microemulsified cyclosporine and did not take any drugs known to interact with 
cyclosporine. Patients were included if their cyclosporine dose remained unchanged for at 
least 1 week before predose concentration sampling at the 3- and 12-month time points.
ETHICS
Both studies were performed in accordance with the declaration of Helsinki and its 
amendments. Protocols were approved by the Ethics Committee of the Erasmus Medical 
Center, Rotterdam, The Netherlands, and written informed consent was obtained from all 
subjects.
DEOXYRIBONUCLEIC ACID ISOLATION AND POLYMERASE CHAIN  
REACTION-RESTRICTION FRAGMENT LENGTH POLYMORPHISM ANALYSIS
Polymerase chain reaction (PCR)-restriction fragment length polymorphism analysis for 
CYP3A4*1B and *3, CYP3A5*3 and *6, and MDR-1 3435C→T variant alleles was performed 
as described previously.22,34-36 In brief, genomic deoxyribonucleic acid was isolated from 
200 µL ethylenediaminetetraacetic acid-treated-whole blood by use of a total nucleic acid 
extraction kit on a MagnaPure LC (Roche Diagnostics GmbH, Mannheim, Germany). Next, 
50 ng of genomic deoxyribonucleic acid was used in a PCR volume of 50 µL containing 
1x buffer [10-mmol/L Tris-hydrochloric acid, pH 8.3; 1.5-mmol/L magnesium chloride; 
50-mmol/L potassium chloride; and 0.001% (wt/vol) gelatin (Perkin-Elmer Inc, Wellesley, 
MA)], 0.2-mmol/L each deoxyribonucleoside triphosphate (Roche Diagnostics GmbH), 1.25 
U of AmpliTaq Gold (Perkin-Elmer), and 40 pmol of each of forward and reverse primer 
(described in references 22 and 34-36). PCR conditions were as follows: 7 minutes at 94°C; 
35 cycles of 1 minute at 94°C, 1 minute at 55°C, and 1 minute at 72°C; and finally, 7 minutes 
at 72°C. The PCR product (10 µL) was digested with PstI (CYP3A4*1B), SspI (CYP3A5*3), 
or DpnII (MDR-1) in a total volume of 15 µL for 2 h at 37°C and subsequently analyzed on 
agarose/Tris-borate-ethylenediaminetetraacetic acid gel with ethidium bromide staining. 
Because the CYP3A5*3 and CYP3A5*6 variant alleles both result in the absence of functional 
CYP3A5 protein from liver,9,10 the CYP3A5*6 allele was only determined when patients 
carried at least 1 CYP3A5*1 (wildtype) allele.
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CYCLOSPORINE CONCENTRATION MEASUREMENTS
Cyclosporine whole-blood concentrations were determined with the Emit 2000 assay 
(Syva company, Dade Behring Inc, Cupertino, CA) on a Cobas Mira Plus analyzer (Roche 
Diagnostic Systems, Basel, Switzerland). Proficiency samples were obtained from the United 
Kingdom Quality Assessment Scheme (Dr Holt, St George’s Hospital Medical School, 
London, United Kingdom). 
PHARMACOKINETIC ANALYSIS
Pharmacokinetic models were fitted to data from all individuals simultaneously by use of 
NONMEM. The NONMEM model accounts for interpatient and residual pharmacokinetic 
variability (random effects), as well as pharmacokinetic differences predicted by patient 
factors (fixed effects). The typical population parameters, interpatient and residual variances, 
were estimated by use of the NONMEM software program (double precision; version V, level 
1.1). The first-order method was used throughout the analysis. The pharmacokinetics of 
cyclosporine was described according to compartmental models, which were parameterized 
in terms of clearance and volume with rate constants used only to describe the absorption 
process. For instance, for a 2-compartment pharmacokinetic model with first-order 
absorption and elimination, the following parameters were estimated: absorption rate 
constant (K
a
), time lag between intake and start absorption (T
lag
), volume of distribution 
of the central compartment (V1), clearance from the central compartment (Cl), volume 
of distribution of the peripheral compartment (V2), and intercompartmental clearance 
(Q). Because cyclosporine was administered orally, the terms volume of distribution and 
clearance represent the ratios of these parameters to the unknown bioavailability [oral 
volume of distribution of central compartment (V1/F), oral volume of distribution of 
peripheral compartment (V2/F), oral clearance from central compartment (Cl/F), and oral 
intercompartmental clearance (Q/F)]. Simultaneous analysis of the data from all patients 
requires statistical models for interpatient and residual variances. Interpatient variability of 
the pharmacokinetic parameters was estimated by use of a proportional error model. For 
instance, interindividual variability in Cl/F was estimated as follows: 
Cl/F
i
 = Cl/F
pop
 (1 + η
i
) 
in which i represents the number of the individual, Cl/F
i
 is the clearance of the ith individual, 
Cl/F
pop 
is the Cl/F value of a typical individual, and η is the interindividual random effect 
with mean 0 and variance ω2. In addition to interpatient variability of the pharmacokinetic 
parameters, the covariance between those parameters was also estimated.
For a NONMEM model, the residual variance corresponds to the difference between the 
observed concentration (C
obs
) and the predicted concentration (C
pred
). The latter is predicted 
on the basis of individual parameters (Cl/F
i
, V1/F
i
, and so on). Residual variance was 
modeled with an additive error model as follows:
 ln (C
obs
 i) = ln (C
pred
 i) + ε
where ε is an independent random variable with mean 0 and a variance of σ2. 
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On the basis of the derived population model and the observed individual concentrations, 
individual pharmacokinetic parameter estimates were obtained by Bayesian (POSTHOC) 
analysis. The individual estimates were plotted against demographic factors (sex, ethnicity, 
weight, daily dose, time after transplantation) and the tested genotypes (MDR-1, CYP3A4, 
CYP3A5) for visual inspection according to the method described by Maitre et al.37 
Covariates that showed a correlation with a pharmacokinetic parameter were entered into 
the population pharmacokinetic model. In the NONMEM model the relationship between 
categoric covariates (genotype, sex, ethnicity) and pharmacokinetics was statistically 
tested by use of the log-likelihood test.38 For instance, a change in the cyclosporine Cl/F in 
CYP3A4*1B carriers was evaluated by use of the following equation:
Cl / F = θ1 x θ2FLAG
where the indicator variable FLAG has the value 0 [wildtype (*1/*1)] or 1 (CYP3A4*1B allele 
carrier), θ1 is the typical cyclosporine Cl/F with CYP3A4*1/*1 (FLAG = 0), and θ2 is the 
fractional change in θ1 with CYP3A4*1B carriers. The minimum value of the objective 
function (MVOF) generated by NONMEM was used to evaluate the increase in goodness of 
fit of the model. The MVOF is approximately proportional to -2 times the logarithm of the 
likelihood of the data. The model was first evaluated with FLAG fixed to 0 for all genotypes 
(wildtype and *1B carriers) and subsequently with FLAG equal to 0 or 1 as explained. A 
decrease in the MVOF of at least 3.8 identified a covariate as being significant (P < 0.05). This 
criterion is based on the objective function having an approximate chi square distribution 
with 1 df.
Relationships between continuous covariates and pharmacokinetic parameters were 
evaluated in a similar manner. For instance, the relationship between Cl/F and weight was 
described as follows:
were Cl/F
pop
 is a typical population value of Cl/F, θ3 is Cl/F
pop
 of a patient with weight of 70 
kg, and θ4 is an exponent.
STATISTICAL ANALYSIS
For comparisons between groups, 1-way ANOVA was performed with SPSS for Windows, 
version 11.5.0 (SPSS, Chicago, IL).
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RESULTS
The demographic, clinical, pharmacokinetic and pharmacogenetic data of the 151 transplant 
recipients are depicted in Tables 4.2.1 and 4.2.2. For 2 typical patients, cyclosporine plasma 
concentration versus time profiles are given in Figure 4.2.1. Because the cyclosporine dose 
was not changed during a period of at least 1 week immediately before blood sampling, 
steady-state pharmacokinetics was assumed. Consequently, the predose concentration 
reflects the concentration at the end of the dosing interval. By use of a 1-compartment model, 
adequate population estimates were obtained for T
lag
, K
a
, V1/F and Cl/F and the interpatient 
variability of the latter 3 parameters. However, the diagnostic plot of weighted residuals 
(WRES) versus time showed a U-shaped trend, which is indicative of model misspecification 
(plot not shown). The addition of a peripheral compartment improved the goodness of fit. 
The residual error decreased, the objective function was approximately 180 units lower, and 
WRES versus time plots showed no trend. The objective function for a 3-compartment model 
did not further improve the fit. Estimation of interpatient variability of T
lag
 further improved 
the fit of the 2-compartment model. Typical population values for the pharmacokinetic 
parameters are summarized in Table 4.2.3 (model 1). Interpatient variability of K
a
 and V1/F 
was high (with corresponding values of 152% and 128%, respectively), whereas interpatient 
variability of Cl/F was moderate (28%). Correlations between K
a
 and V1/F, K
a
 and Cl/F, and 
V1/F and Cl/F were high, with corresponding values of 0.98, 0.74 and 0.81, respectively. No 
interpatient variability could be estimated for V2/F and Q/F. This should not be interpreted 
to indicate an absence of variability but simply that the data did not contain enough 
information to quantify the variance of these parameters. Several plots were produced to 
judge the goodness of fit of the derived model (plots not shown). In plots of model-predicted 
and Bayesian individually predicted concentrations versus observed concentrations, the data 
points were symmetrically distributed around the line of unity (predicted concentration 
equal to observed concentration), indicating the adequacy of the derived NONMEM 
model. The model slightly underestimated the observed maximal concentrations. Several 
models accounting for a more complex absorption process (e.g., time-dependent absorption, 
Weibull absorption and a dual-sequential first-order absorption process) were tried but did 
not improve the fit significantly. 
Plots of the individual pharmacokinetic parameters K
a
, V1/F, and Cl/F versus the covariates 
sex, ethnicity, weight, daily dose, and time after transplantation indicated the following 
relationships: ethnicity, sex, and weight with Cl/F and weight with V1/F. After the black 
and Asian patients were combined, Cl/F in this group was 13% (95% confidence interval, 
8%-18%) lower than in white patients (Figure 4.2.2). The MVOF was reduced by 8.9 points 
(P < 0.005). Subsequently, a possible difference in Cl/F between black and Asian patients 
was evaluated by inclusion of an extra parameter in the population model. Oral clearance 
in Asian patients was slightly lower than in black patients (reduction of 15% and 12%, 
respectively, compared with white patients). This difference was not significant, however, 
because the MVOF of the population model was reduced with only 1.2 points. Therefore the 
extra parameter was not included in the model. To continue the population analysis, the 
MVOF was further reduced with 7.8 points when the relationship between weight and Cl/F 
was introduced in the NONMEM model (P < 0.005). Mean bodyweight was not different 
among the 3 different ethnic groups (P = 0.35, 1-way ANOVA). Introduction of relationships 
between sex and Cl/F and between weight and V1/F did not further improve the model.
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Table 4.2.1 Demographic, clinical, and pharmacokinetic characteristics of 151 renal and heart 
transplant recipients
                   Kidney Heart
Characteristic Study 1 Study 2 Study 1
No. of patients 26 109§ 28
Male/female 17/9 67/42 22/6
Ethnicity (white/black/Asian) 20/6/0 87/11/11 27/0/1
Age at time of transplantation (y) 46.2 ± 14.4 44.9 ± 12.6 45.7 ± 14.3
Time after transplantation (mo) 86.9 ± 71.2 3.0 ± 1.0 12.0 ± 1.0 80.6 ± 44.4
CsA dose (mg/d) 239 ± 61 372 ± 127 286 ± 84 229 ± 76
Body weight (kg) 81.4 ± 21.9 73.5 ± 14.0 76.9 ± 14.7 80.3 ± 17.9
CsA dose per bodyweight (mg ∙ kg -1 · d -1) 3.06 ± 0.88 5.13 ± 1.72 3.80 ± 1.22 2.94 ± 1.03
CsA C
0
 (ng/mL) 144 ± 50 210 ± 76 150 ± 60 122 ± 50
CsA C
2
 (ng/mL) 884 ± 191 ND 729 ± 290
CsA AUC
0-4
 (ng/mL ∙ h) 2718 ± 671 ND 2321 ± 827
C
max
 (ng/mL) 1116 ± 365 ND 975 ± 303
t
max
 (h) 1.39 ± 0.50 ND 1.25 ± 0.44
Primary kidney disease
          Glomerulonephritis 2 24
          Polycystic kidney disease 4 15
          Unknown 8 14
          Diabetic nephropathy 1 9
          Chronic pyelonephritis 0 8
          Hypertensive nephropathy 6 7
          Immunoglobulin A nephropathy 0 6
          Focal segmental glomerulosclerosis 0 5
          Other 5 21
Primary heart disease
          Ischemic heart disease 13
          Cardiomyopathy 14
          Congenital abnormality 1
All values are depicted as mean ± SD or number of patients.
CsA, Cyclosporine; C
0
, trough concentration; C
2
, concentration at 2 hours, AUC
0-4
, area under the concentration 
versus time-curve between 0 and 4 hours; C
max
, peak concentration; ND, not determined; t
max
, time to peak 
concentration.
§ Twelve patients participated in studies 1 and 2.
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Table 4.2.2 Allele frequencies of MDR-1 and CYP3A single-nucleotide polymorphisms in 151 
renal and heart transplant recipients receiving cyclosporine maintenance therapy
             Ethnicity and frequency
Single-nucleotide polymorphism Allele White (n = 126) Asian (n = 13) Black (n = 12)
MDR-1 3435C→T C 0.42 0.50 0.65
T 0.58 0.50 0.35
CYP3A4*1/*1B *1 0.96 1.00 0.54
*1B 0.04 0.00 0.46
CYP3A4*1/*3 *1 0.99 1.00 1.00
*3 0.01 0.00 0.00
CYP3A5*1/*3 *1 0.08 0.42 0.42
*3 0.92 0.58 0.58
Table 4.2.3 Population pharmacokinetic parameter estimates for cyclosporine
Model 1:
Estimate and CV%
Model 2:
Mean and CV%
Population parameters
     K
a
 (1/h) 1.39 (11%) 1.27 (9%)
     V1/F (L) 55.7 (6%) 56.3 (5%)
     Cl/F (L/h) 30.5 (3%) 30.7§ (3%)
     V2/F (L) 166 (11%) 185 (16%)
     Q/F (L/h) 35.4 (8%) 31.7 (11%)
     T
lag
 (h) 0.551 (9%) 0.470 (16%)
Fractional change in oral clearance (Cl/F)†
     Ethnicity = black or Asian - 0.870 (3%)
     CYP3A4 genotype = *1/*1B or *1B/*1B - 1.09 (4%)
     Exponent clearance - weight - 0.172 (35%)
Interpatient variability
     K
a
 (%) 152 (22%) 155 (32%)
     V1/F (%) 128 (22%) 125 (29%)
     Cl/F (%) 28 (23%) 29 (29%)
     T
lag
 (%) 75 (53%) 110 (89%)
Residual error
     ε 0.225 (8%) 0.222 (8%)
Minimal value objective function
     Value -633.7 -654.4
CV, Coefficient of variation; K
a
, absorption rate constant; V1/F, oral volume of distribution of central 
compartment; Cl/F, oral clearance from central compartment; V2/F oral volume of distribution of peripheral 
compartment; Q/F, oral intercompartmental clearance; T
lag
, time lag between intake and start absorption; ε, 
residual error.
§Typical Cl/F in a 70-kg white patient with CYP3A4*1/*1 genotype. 
† The typical Cl/F can be calculated  as follows: Cl/F
pop
 = 30.7 x (Weight/70) 0.172. For black and Asian patients 
and carriers of a CYP3A4*1B variant allele, Cl/F
pop
 can be obtained by multiplication with the factors 0.870 and 
1.09, respectively.
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Figure 4.2.1 Cyclosporine plasma concentration versus time profiles for 2 typical patients. The 
solid circles represent observed concentrations. The solid line represents the Bayesian fit obtained 
on the basis of the individual concentrations and population model 2.
Figure 4.2.2 Bayesian oral cyclosporine clearance 
versus ethnicity. Individual estimates were obtained 
on basis of the final NONMEM model and individual 
concentrations. The solid circles represent the 
individual patients. The solid line represents the 
median.
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Figure 4.2.3 Bayesian oral cyclosporine 
clearance versus CYP3A4 genotype. The 
solid circles represent the *1/*1 patients, 
and the open circles represent the *1/*1B 
and *1B/*1B patients. The solid line 
represents the median.
Figure 4.2.4 Bayesian oral cyclosporine 
clearance versus CYP3A5 genotype. The 
solid circles represent the *1/*1 and *1/*3 
patients, and the open circles represent the 
*3/*3 patients. The solid line represents the 
median.
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Individual Bayesian estimates of the pharmacokinetic parameters were generated on the 
basis of the intermediate NONMEM model and plotted versus the different genotypes. The 
plot of Cl/F versus CYP3A4*1/*1B genotype indicated an increased Cl/F in patients carrying 
a CYP3A4*1B variant allele compared with CYP3A4*1 homozygotes. Evaluation of this 
hypothesis in the NONMEM model demonstrated a small (9%; 95% confidence interval, 
1%-17%) but significant (P < 0.05) increase in Cl/F; the MVOF was reduced with 4.0 points 
on introduction of CYP3A4*1/*1B genotype into the model (Figure 4.2.3). The effect of the 
CYP3A4*1/*1B genotype appeared to be different for white and black patients (Figure 4.2.3). 
However, no statistical significance was obtained when this difference was evaluated in the 
population model. On further inspection of the plots, Cl/F appeared to be slightly lower 
in patients who were homozygous for CYP3A5*3. However, this small difference (6%) was 
not statistically significant (P = 0.06) when CYP3A5*1/*3 genotype was implemented in the 
population model (Figure 4.2.4). One white patient carried a CYP3A4*3 variant allele. The 
cyclosporine Cl/F of this individual was 33.8 L/h, which was not markedly different from 
the median cyclosporine Cl/F of white patients (Table 4.2.3). No other significant changes 
in any of the pharmacokinetic parameters were detected in patients with MDR-1 3435C→T, 
CYP3A4*3, or CYP3A5*6 variant alleles. 
The final population pharmacokinetic parameters are summarized in Table 4.2.3 (model 
2). The diagnostic plots of predicted versus observed concentrations indicated adequacy 
of the derived NONMEM model (plot not shown). Inclusion of the covariates (sex, 
ethnicity, weight, daily dose, and time after transplantation) did not improve the slight 
underprediction of maximal concentrations. Figure 4.2.1 represents Bayesian individually 
predicted concentrations for 2 typical patients. No trend was observed in the plot of the 
WRES versus time (not shown). 
DISCUSSION
There has been much controversy about the effects of genetic polymorphisms in MDR-1 and 
CYP3A on the pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. 
Several association studies have reported effects of the MDR-1 3435C→T,20,25 CYP3A4*1B,22 
and CYP3A5*3,21-25,27 SNPs on the disposition of tacrolimus, whereas most studies reported 
to date have not found a correlation between MDR-1, CYP3A4, or CYP3A5 genotype and 
the pharmacokinetics of cyclosporine.22,28-30,39,40 We hypothesized that these contrasting 
results may have arisen through underdetection of an effect of genotype on cyclosporine 
pharmacokinetics through the use of a too crude pharmacokinetic analysis (dose-adjusted 
C
0
)22,28,29 or underpowering in the studies that performed more detailed pharmacokinetic 
profiling.39,40
With the use of NONMEM, a sensitive and precise method to describe population 
pharmacokinetics, we did indeed find a significant, albeit numerically small, effect of 
the CYP3A4*1B SNP on cyclosporine pharmacokinetics. Patients carrying the variant 
CYP3A4*1B allele were found to have an increased oral cyclosporine clearance (+9%). This 
finding is in agreement with our previous observation that renal transplant recipients with 
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the CYP3A4*1/*1B or *1B/*1B genotype require a higher tacrolimus dose to reach target C
0
 
compared with patients homozygous for CYP3A4*1.22 The current findings are supported by 
the results of the in vitro study by Amirimani et al.,11 who described in eukaryotic luciferase 
reporter constructs that the CYP3A4*1B promoter sequence caused a higher expression 
compared with the CYP3A4*1 promoter. This expression was found to be 1.4-fold higher 
in HepG2 cells carrying the variant promoter, and was 1.9-fold higher in MCF7 cells.11 
Min and Ellingrod41 reported an association between the CYP3A4*1B polymorphism and 
cyclosporine pharmacokinetics in healthy volunteers. By use of noncompartmental analysis 
(WinNonLin program; Pharsight Corporation, Mountain View, CA), the mean area-under 
the concentration versus time-curve between 0 and 24 h divided by dose was found to 
be significantly higher in CYP3A4 wild-type (*1/*1) subjects compared with individuals 
homozygous for the variant allele (*1B/*1B) (21.5 ng ∙ h/mL ∙ mg-1 versus 11.7 ng ∙ h/mL ∙ mg-1, 
respectively). Oral clearance was lower in wildtype individuals compared with CYP3A4*1B 
allele homozygotes (49.4 L/h versus 83.5 L/h, respectively), suggesting increased enzymatic 
activity or expression in individuals with the variant *1B allele.41 
Although the effect of CYP3A4 genotype on cyclosporine pharmacokinetics was statistically 
significant, one could argue about its clinical relevance for the individual patient. 
Incorporation of CYP3A4 genotype into the final NONMEM model did not markedly 
reduce interpatient variability of K
a
, Cl/F, V1/F, or T
lag
, indicating that the CYP3A4 genotype 
made only a limited contribution to the observed marked interindividual differences in 
cyclosporine pharmacokinetics. The influence of environmental factors, such as smoking 
habits, diet, and comedication, or perhaps not-yet-identified genetic factors may, therefore, 
be more important factors determining the pharmacokinetics of this drug. Because the 
current study population consisted of stable transplant patients receiving maintenance 
therapy, the results may be different in patients in the early phase after transplantation when 
adequate immunosuppressive drug dosing is most critical. Furthermore, this study used a 
cross-sectional design, and the possibility of a selection bias must, therefore, be considered. 
We believe, however, that several points argue against a significant selection bias. First, all 
the allele frequencies in the different ethnic groups were in Hardy-Weinberg equilibrium 
and were in agreement with published allele frequencies.5,9,10,32-36 Second, therapeutic drug 
monitoring for cyclosporine was performed in all patients. Patients with drug concentrations 
well outside the target range (possibly as a result of extremely high or low clearance) are, 
therefore, likely to have been identified, resulting in appropriate dose adjustments. Third, 
cyclosporine-related side effects were quite common among the “stabilized” patients of the 
study group. Moreover, our current practice in cases of cyclosporine toxicity is to reduce the 
dosage of this drug and not to withdraw cyclosporine until the first year after transplantation. 
Fourth, with modern triple immunosuppression, the percentage of patients who lose their 
graft within the first year after renal transplantation is below 10% and is largely a result of 
either technical failure (thrombosis of vessels) or grafts that never functioned.
An alternative explanation for these findings could be that the observed correlation 
between CYP3A4 genotype and oral cyclosporine clearance may, in fact, have been caused 
by differences in CYP3A5 expression. Several authors have suggested that it is CYP3A5 
rather than CYP3A4 that determines an individual’s CYP3A enzymatic activity and there is 
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substantial evidence that the CYP3A4*1B and the CYP3A5*1 alleles are linked.9,22,35,36,42 In the 
our study 67% of the white patients carrying the CYP3A4*1B allele also carried the CYP3A5*1 
allele. In the black patients, all of the CYP3A4*1B carriers had a CYP3A5*1 allele, suggesting 
linkage disequilibrium between these 2 alleles. The importance of CYP3A5 for tacrolimus 
disposition has been reported by several independent research groups. Renal and heart 
transplant recipients with a genetic inability to express CYP3A5 (homozygous for CYP3A5*3 
or *6) required less of the drug to reach target concentrations.20,22-25 Recently, a similar 
CYP3A5 effect on tacrolimus dose requirement was found in lung transplant recipients.27 In 
our study, patients homozygous for the CYP3A5*3 allele (nonexpressors) did have a reduced 
oral cyclosporine clearance (-6%) compared with carriers of the CYP3A5*1 allele, but this 
difference was not statistically significant (P = 0.06). In agreement with this finding, Haufroid 
et al.24 reported a small effect of the CYP3A5*3 polymorphism on cyclosporine C
0
 adjusted 
for the last dose in 50 stable renal transplant recipients. However, this genotype effect was 
much smaller than that observed for the tacrolimus dose requirement. In a stepwise multiple 
regression analysis, Haufroid et al.24 showed that CYP3A5 genotype only explained 9% of 
the total variance in cyclosporine dose-adjusted C
0
 in their study population.   
The MDR-1 3435C→T SNP was not related to cyclosporine pharmacokinetics, confirming 
earlier reports in kidney and heart transplant recipients.22,29,39,40 This SNP is a silent 
polymorphism, which means that it does not cause an amino acid change.5 However, there 
is substantial evidence that the 3435C→T polymorphism is linked to other, nonsynonymous 
SNPs in MDR-1 (among others, the 2677G→T/A SNP in exon 21).8 Haplotype analysis of 
MDR-1 may, therefore, be a superior method to analyze the effects of genetic variability in 
this gene on drug pharmacokinetics.8 An effect of MDR-1 haplotype has been described 
for tacrolimus21 and for cyclosporine43 in a small number (n = 9) of Asian heart transplant 
recipients. However, in a larger study (n = 98) in renal transplant recipients,30 the latter 
finding could not be confirmed, suggesting that genetic variability in MDR-1 is unlikely to 
contribute much to interindividual differences in cyclosporine pharmacokinetics.30
Finally, a remarkable finding was the observed effect of ethnicity on oral cyclosporine 
clearance. Black and Asian transplant recipients were found to have a reduced oral cyclosporine 
clearance, independent of their CYP3A genotype. This finding may seem in contradistinction 
with the literature, because several authors have previously reported a higher cyclosporine 
clearance and a lower oral bioavailability in black transplant recipients.44-46 However, these 
studies were conducted in de novo renal transplant recipients who used the older oil-based 
cyclosporine formulation44,45 or were conducted in healthy volunteers without controlling 
for diet.46 Administration of microemulsified cyclosporine to white and black volunteers 
under controlled (dietary) conditions did not result in statistically significant differences 
in cyclosporine pharmacokinetics between ethnic groups.47 Comparable cyclosporine 
exposure between black and white patients after administration of either the oil-based or the 
microemulsified preparation has also been observed in de novo renal transplant recipients.48 
In this study patients fasted overnight and later ate a standardized meal.48 On the basis of 
the findings of our study, the comparable cyclosporine pharmacokinetics between black and 
white patients may be explained by the fact that the reduced oral cyclosporine clearance (-
13%) in black patients is counterbalanced by the greater presence of the CYP3A4*1B variant 
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allele (resulting in a +9% higher Cl/F) in this patient group (allelic frequency of 0.46 versus 
0.04 in black and white patients, respectively). The finding that Asian patients had a slightly 
lower oral cyclosporine clearance compared with white individuals may seem surprising, 
because the transplant survival in the former group has been reported to be comparable 
or even superior to that of white patients.49 However, the influence of immunologic, 
physiologic, and socioeconomic factors on long-term allograft survival may well outweigh 
small interethnic differences in cyclosporine pharmacokinetics. Moreover, to the best of 
our knowledge, no studies have been published that were primarily designed to compare 
the pharmacokinetics of microemulsified cyclosporine between white and Asian subjects. 
In addition, the ancestry of “Asians” is often not specified in clinical trials. In our study 
all of the Asian patients were of Indian or Indonesian descent, and there exist important 
differences in genetic background, as well as in dietary habits, between these populations 
and Chinese and Japanese patients.
In summary, we found a statistically significant effect of the CYP3A4*1/*1B genotype on the 
pharmacokinetics of cyclosporine in stable renal and heart transplant recipients. Patients 
carrying a CYP3A4*1B variant allele had a higher oral cyclosporine clearance, whereas no 
effect of the MDR-1 3435C→T SNP or the CYP3A4*3 or CYP3A5*3 and *6 variant alleles was 
observed. However, because the effect of the CYP3A4*1B polymorphism on cyclosporine 
disposition was small, genotyping of transplant recipients for CYP3A is unlikely to assist in 
planning initial dosing of this immunosuppressant.  
None of the authors has any financial or personal relationships that could potentially be 
perceived as influencing the described research.
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ABSTRACT
The immunosuppressive drugs cyclosporine and tacrolimus are widely used to prevent 
acute rejection following solid organ transplantation. However, the clinical use of these 
agents is complicated by their many side effects, a narrow therapeutic window, and highly 
variable pharmacokinetics. The variability in cyclosporine and tacrolimus disposition has 
been attributed to interindividual differences in the expression of the metabolizing enzymes 
cytochrome P450 (CYP) 3A4 and 3A5, and in the expression of the drug transporter P-
glycoprotein (encoded by the ABCB1 gene, formerly known as the multidrug resistance 
1 gene). Variation in the expression of these genes could in turn be explained by several 
recently-identified single-nucleotide polymorphisms (SNPs). Determination of these 
SNPs in (future) transplant recipients has the potential to identify individuals who 
are at risk of underimmunosuppression or the development of adverse drug reactions. 
Ultimately, genotyping for CYP3A and ABCB1 may lead to a further individualization of 
immunosuppressive drug therapy for the transplanted patient. 
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INTRODUCTION
Since the first human kidney was successfully transplanted half a century ago, transplantation 
has grown from an experimental therapy to become the treatment of choice for patients with 
end-stage organ failure.1,2 A large part of this success can be attributed to the development 
of powerful and more specific immunosuppressive drugs during the past three decades. 
With the availability of these agents, the incidence of acute rejection has been reduced 
dramatically, and presently this is a rare cause for allograft loss.1,2
However, the introduction of modern immunosuppressive drug therapy has not resulted in a 
comparable improvement in the long-term transplantation outcomes. Late allograft loss most 
often results from the death of a patient with a functioning graft, or from chronic allograft 
nephropathy (CAN), which is an incompletely understood process characterized clinically 
by a slowly progressive decline in transplant function.2 Paradoxically, immunosuppressive 
drug treatment itself negatively influences long-term patient and allograft survival. First, by 
its very nature, immunosuppressive therapy promotes the development of malignancy and 
infectious disease. Second, transplant recipients have an increased risk of cardiovascular 
disease, which is the leading cause of death in this population. The use of immunosuppressive 
drugs, such as cyclosporine and tacrolimus, contributes to this risk, as their side effects 
include the induction of glucose intolerance, hypertension and hyperlipidemia.3 Third, some 
immunosuppressants appear to be directly involved in the development of CAN.2 Finally, 
most immunosuppressive drugs have specific side effects that compromise the quality of life 
of transplanted patients. 
At the present time, the main challenge facing transplant physicians involves further 
improving the long-term transplantation outcomes, while maintaining the excellent short-
term results that are currently achieved. As the benefits of modern immunosuppressive 
therapy are partially outweighed by its adverse effects, there has been an ongoing search 
for more specific and less toxic immunosuppressive agents.4 However, a more immediate 
option that could reduce iatrogenic morbidity may be the further individualization of the 
currently-available immunosuppressive treatment strategies. Pharmacogenetics offers great 
promise in this respect, as it has the potential to assist in “identifying the right drug and 
the right dose for an individual patient”.5 In this paper we discuss the current status of 
pharmacogenetics in solid organ transplantation. As pharmacogenetic research in this field 
has mainly focused on the immunosuppressants cyclosporine and tacrolimus, the discussion 
is limited to these two agents and the genes that play a central role in their disposition, the 
adenosine triphosphate (ATP)-binding cassette (ABC)B1 gene [in the older nomenclature 
known as the multidrug resistance 1 (MDR1) gene], and the genes encoding the cytochrome 
P450 (CYP) isoenzymes 3A4 and 3A5. 
166
Chapter 4.3
CALCINEURIN INHIBITORS
The immunosuppressive actions of the calcineurin inhibitors (CNIs) cyclosporine and 
tacrolimus were first described in 1976 and 1987, respectively.6,7 Both drugs exert their 
immunosuppressive effect by inhibiting several signaling processes in T cells, most 
importantly by blocking the phosphatase calcineurin, which leads to a decreased transcription 
of the interleukin (IL)-2, IL-4, CD40 ligand and interferon-γ genes, which finally results 
in the inhibition of T cell activation and proliferation.8,9 The clinical introduction of 
cyclosporine in the early 1980s led to a marked reduction in the incidence and severity of 
acute rejection, and with the availability of cyclosporine, heart and lung transplantation 
first became realistic options.10 In the 1990s, tacrolimus proved to be equally effective, and 
possibly even superior to cyclosporine.11 At present, in most transplant centers, CNIs form 
the cornerstone of immunosuppressive therapy after organ transplantation. Generally, 
in such therapy, either cyclosporine or tacrolimus is used in combination with an anti-
proliferative agent, such as azathioprine or mycophenolate mofetil (MMF), with or without 
the addition of corticosteroids. 
Despite their effectiveness, the clinical use of CNIs is hampered by many side effects, which 
include nephrotoxicity, hypertension, the induction of diabetes mellitus and dyslipidemia, 
and cosmetic side effects. Moreover, both drugs have a narrow therapeutic window, highly 
variable and unpredictable pharmacokinetics, and interactions with many other drugs.8,9 
Attempts to improve CNI therapy have resulted in the widespread application of therapeutic 
drug monitoring (TDM). TDM is the practice of monitoring blood drug concentrations and 
adjusting the drug dose, in order to reach a predefined target concentration that has been 
associated with the optimal balance between efficacy and toxicity.12 
Although TDM of CNIs has resulted in a more individualized therapy, there are several 
limitations to this practice. First, there is still uncertainty regarding the best parameter for 
pharmacokinetic monitoring of CNIs. Traditionally, these drugs are dosed according to the 
predose concentration (C
0
). However, it has become clear that the correlation between the 
cyclosporine C
0
 and total drug exposure is poor, and that the predictive value of this parameter 
for the occurrence of acute rejection or nephrotoxicity is limited.13 This is explained by the 
fact that cyclosporine pharmacokinetics are most variable during the absorption phase, 
whereas the C
0
 mainly reflects systemic clearance. Therefore, the cyclosporine area-under 
the concentration versus time-curve during the first 4 h after oral administration (AUC
0-4
) 
and the cyclosporine 2-h postdose concentration (C
2
) have recently been advocated as more 
appropriate tools for TDM.13-15 Second, TDM can only be performed after the start of drug 
treatment. Therefore, TDM has no predictive value and is of no aid when determining the 
starting dose of a drug for an individual patient. This is especially relevant for transplant 
recipients, as failure to reach target cyclosporine concentrations as soon as three days 
after renal transplantation, is critical in order to prevent acute rejection.15 Third, TDM is 
performed invasively and requires considerable effort to reliably draw blood at the correct 
time point. Finally, TDM does not provide any mechanistic information regarding the 
factors that underlie a drug’s pharmacokinetics. 
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PHARMACOKINETICS OF CALCINEURIN INHIBITORS
The pharmacokinetics of CNIs are characterized by a highly variable, unpredictable, and, in 
general, poor oral bioavailability, which has an average value of 30%, ranging from 4%-89%.8,9 
Following absorption from the gut, both drugs are metabolized in the intestine and liver into 
15-30 metabolites. Elimination of CNIs is mainly biliary, with renal clearance accounting for 
< 1 and 6% of total body clearance for tacrolimus and cyclosporine, respectively.8,9 Besides 
a low oral bioavailability, the pharmacokinetics of CNIs are characterized by marked 
interindividual differences in first-pass metabolism and systemic clearance. Recently, it has 
become clear that much of the interindividual differences in CNI pharmacokinetics result 
from variability in the activity of the permeability glycoprotein (P-glycoprotein) and the 
CYP isoenzymes 3A4 and 3A5 (Figure 4.3.1).
P-GLYCOPROTEIN
P-glycoprotein is encoded by the ABCB1 gene located on chromosome 7q21.1, and belongs 
to the family of the ABC membrane transporters (subfamily B). P-glycoprotein is an ATP-
dependent transporter capable of pumping many endogenous substances, as well as a wide 
variety of drugs (including CNIs, sirolimus, and glucocorticoids), from the cytoplasm or 
cell membrane to the extracellular space.5,16-20 Physiologically, P-glycoprotein is expressed 
in the liver (at the canalicular surface of hepatocytes), kidney (brush border of proximal 
tubular cells), pancreas, and at the apical surface of mature enterocytes in the small intestine 
and colon.21 The specific tissue expression of P-glycoprotein suggests that the protein 
functions as a protective barrier, by actively extruding xenobiotics and metabolites from 
the cell interior into bile, urine or gut lumen. P-glycoprotein is also expressed in testes, 
placenta (trophoblasts), on the luminal surface of capillaries in the brain, and at the choroid 
plexus where it serves to maintain the blood-testis, maternal-fetal, blood-brain and blood-
cerebrospinal fluid barriers, respectively.21 In addition, P-glycoprotein is expressed on 
various leukocytes, including T and B lymphocytes and dendritic cells (Figure 4.3.1).22,23
CYP3A
The CYP enzyme family consists of more than 50 isozymes that are responsible for the 
oxidative metabolism of many endogenous and exogenous compounds (Figure 4.3.1).5 
The CYP3A subfamily, which represents the majority of CYP proteins in the human liver, 
metabolizes more than 50% of all drugs currently in use (including CNIs, sirolimus and 
glucocorticoids)5,24-26 and consists of the isozymes CYP3A4, CYP3A5, CYP3A7, and 
CYP3A43.24,26,27 CYP3A4 and CYP3A5 have largely overlapping substrate specificities and, 
based on the amount of protein, are considered the most important CYP3A family members. 
CYP3A4 is constitutively expressed in liver, jejunum, colon, kidney, and pancreas, but 
marked interindividual differences in its activity exist, which may vary by up to 40-fold.28 
For stable kidney transplant recipients, a ten-fold variation in enterocyte CYP3A4 content 
was reported.29,30 CYP3A5 is also present in the liver, kidney, and small intestine, although 
its expression is even more variable, and in general much lower, compared with CYP3A4. 
In Caucasian livers, the CYP3A5 protein was only detectable in 10%-40% of all samples.31 
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However, CYP3A5 may account for up to 50% of total hepatic CYP3A content in some 
individuals.32 The functional significance of the other two CYP3A family members, CYP3A7 
and CYP3A43, is incompletely understood. CYP3A7 appears to be most important during 
fetal life. However, in approximately 3% of adults, CYP3A7 is expressed due to inheritance of 
the CYP3A7*1C allele. In this allele, part of the CYP3A4 promoter has replaced the CYP3A7 
promoter, thereby preventing downregulation after birth.33 CYP3A43 accounts for less than 
1% of CYP3A transcripts in adult human liver, and therefore, its contribution to CYP3A-
mediated metabolism is thought to be minimal.27 
P-GLYCOPROTEIN AND CYP3A AS BARRIERS  
TO CALCINEURIN INHIBITOR EXPOSURE
Several studies have established the importance of P-glycoprotein and CYP3A in the 
disposition of CNIs (Figure 4.3.1). First, P-glycoprotein limits the absorption of these drugs by 
active extrusion from the enterocyte interior back into the gut lumen. Kaplan and colleagues34 
described a small bowel transplant recipient with an extremely low oral bioavailability of 
both tacrolimus and cyclosporine. This patient was found to have a high small bowel P-
glycoprotein content. Administration of fluconazole, an inhibitor of P-glycoprotein, resulted 
in an increase in CNI concentrations in whole-blood. A similar relationship between CNI 
dose requirement and intestinal ABCB1 expression has been described for small bowel,35,36 
liver,37,38 and kidney30 transplant recipients. Besides extrusion by P-glycoprotein, systemic 
exposure to CNIs is limited by substantial intestinal metabolism. Kolars and co-workers39 
introduced cyclosporine into the small bowel of patients during the anhepatic phase of liver 
transplant surgery. Cyclosporine metabolites were readily detectable in portal venous blood, 
indicating that the small intestine is a major site of cyclosporine breakdown. More recently, 
Tuteja and colleagues40 provided evidence for intestinal tacrolimus metabolism. In stable 
renal transplant recipients, coadministration of tacrolimus and ketoconazole (an inhibitor 
of CYP3A and P-glycoprotein, like fluconazole ) resulted in a decrease in tacrolimus 
clearance and an increase in the tacrolimus bioavailability. This effect was greater following 
oral ketoconazole administration, compared with intravenous dosing, suggesting intestinal 
CYP3A-mediated tacrolimus metabolism.40 The importance of intestinal CNI metabolism 
has been substantiated further in animal and human-volunteer studies.41-44 Finally, the 
interindividual variability in CNI disposition correlates with variation in hepatic CYP3A 
activity.29 
In summary, the pharmacokinetics of CNIs are influenced by the synergistic actions 
of intestinal and hepatic P-glycoprotein and CYP3A. In the gut, these enzymes act as a 
barrier to absorption by active extrusion into the gut lumen and through intestinal phase I 
metabolism, whereas hepatic CYP3A and P-glycoprotein activity are responsible for systemic 
drug clearance.18 
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Table 4.3.1 Cyclosporine pharmacokinetics and single-nucleotide polymorphisms in the ABCB1 gene.
Au
th
or
 [r
ef
er
en
ce
]
Su
bj
ec
ts
n
SN
P(
s)
PK
 p
ar
am
et
er
Ef
fe
ct
vo
n
 A
h
se
n
 [
66
]
R
en
al
 t
ra
n
sp
la
nt
 r
ec
ip
ie
nt
s
12
4
34
35
C
>T
C
0
N
o 
eff
ec
t o
n
 C
sA
 d
os
e 
re
qu
ir
em
en
t
H
es
se
li
n
k 
[6
7]
R
en
al
 t
ra
n
sp
la
nt
 r
ec
ip
ie
nt
s
10
9
34
35
C
>T
C
0
N
o 
eff
ec
t o
n
 C
sA
 d
os
e 
re
qu
ir
em
en
t
M
ai
 [
72
]
R
en
al
 t
ra
n
sp
la
nt
 r
ec
ip
ie
nt
s
98
26
77
G
>T
/A
C
0, 
C
2, 
A
U
C
0-
4
N
o 
eff
ec
t o
f h
ap
lo
ty
pe
s 
on
 C
sA
 
ph
ar
m
ac
ok
in
et
ic
s
34
35
C
>T
A
n
gl
ic
he
au
 [
73
]
R
en
al
 t
ra
n
sp
la
nt
 r
ec
ip
ie
nt
s
10
6
12
36
C
>T
C
al
cu
la
te
d 
A
U
C
0-
12
N
o 
eff
ec
t o
f h
ap
lo
ty
pe
s 
on
 C
sA
 
ph
ar
m
ac
ok
in
et
ic
s
26
77
G
>T
/A
34
35
C
>T
H
au
fr
oi
d 
[7
4]
R
en
al
 t
ra
n
sp
la
nt
 r
ec
ip
ie
nt
s
50
12
36
C
>T
C
0
N
o 
eff
ec
t o
f h
ap
lo
ty
pe
s 
on
 C
sA
 
ph
ar
m
ac
ok
in
et
ic
s
26
77
G
>T
/A
34
35
C
>T
K
u
zu
ya
 [
68
]
R
en
al
 t
ra
n
sp
la
nt
 r
ec
ip
ie
nt
s
97
-1
29
T
>
C
C
2
N
o 
eff
ec
t o
f i
n
d
iv
id
u
al
 S
N
P
s 
on
 C
sA
 
do
se
 r
eq
u
ir
em
en
t
12
36
C
>T
26
77
G
>T
/A
34
35
C
>T
Y
at
es
 [
75
]
R
en
al
 t
ra
n
sp
la
nt
 r
ec
ip
ie
nt
s
10
34
35
C
>T
A
U
C
0-
12
H
ig
he
r 
C
sA
 d
os
e 
re
qu
ir
em
en
t i
n
 T
 
al
le
le
 c
ar
ri
er
s
H
es
se
li
n
k 
[6
9]
R
en
al
 a
n
d 
he
ar
t t
ra
n
sp
la
nt
 
re
ci
pi
en
ts
15
1
34
35
C
>T
A
U
C
0-
4
N
o 
eff
ec
t o
n
 o
ra
l C
sA
 c
le
ar
an
ce
 o
r 
do
se
 r
eq
u
ir
em
en
t
B
al
ra
m
 [
71
]
H
ea
rt
 t
ra
n
sp
la
nt
 r
ec
ip
ie
nt
s
10
34
35
C
>T
A
U
C
0-
4
N
o 
eff
ec
t o
n
 C
sA
 p
ha
rm
ac
ok
in
et
ic
s
C
ho
w
ba
y 
[5
4]
H
ea
rt
 t
ra
n
sp
la
nt
 r
ec
ip
ie
nt
s
14
12
36
C
>T
A
U
C
0-
12
L
ow
er
 C
sA
 e
xp
os
u
re
 in
 C
-G
-C
 
co
m
pa
re
d 
w
it
h 
T-
T-
T
 h
ap
lo
ty
pe
26
77
G
>T
/A
34
35
C
>T
M
in
 [
77
]
H
ea
lt
hy
 v
ol
u
nt
ee
rs
14
34
35
C
>T
A
U
C
0-
24
N
o 
eff
ec
t o
n
 C
sA
 p
ha
rm
ac
ok
in
et
ic
s
B
on
ho
m
m
e 
-F
ai
vr
e 
[7
6]
L
iv
er
 t
ra
n
sp
la
nt
 r
ec
ip
ie
nt
s
44
34
35
C
>T
C
2
L
ow
er
 C
sA
 d
os
e 
re
qu
ir
em
en
t i
n
 T
T
 
ho
m
oz
yg
ot
es
 
H
eb
er
t [
70
]
L
iv
er
 t
ra
n
sp
la
nt
 r
ec
ip
ie
nt
s
89
26
77
G
>T
/A
C
0
N
o 
eff
ec
t o
f i
n
d
iv
id
u
al
 S
N
P
s 
on
 C
sA
 
do
se
 r
eq
u
ir
em
en
t 
34
35
C
>T
A
U
C
, a
re
a-
u
n
de
r 
th
e 
co
n
ce
nt
ra
ti
on
 v
er
su
s 
ti
m
e-
cu
rv
e;
 C
0, 
pr
ed
os
e 
co
n
ce
nt
ra
ti
on
, C
2, 
2-
h 
po
st
do
se
 c
on
ce
nt
ra
ti
on
; C
sA
, c
yc
lo
sp
or
in
e;
  
P
K
, p
h
ar
m
ac
ok
in
et
ic
; S
N
P,
 s
in
gl
e-
nu
cl
eo
ti
de
 p
ol
ym
or
ph
is
m
.
170
Chapter 4.3
GENETIC VARIABILITY IN ABCB1 AND CYP3A
Interindividual variability in CYP3A and P-glycoprotein activity can be partly explained by 
differences in age, gender, environmental factors (concomitant medication, smoking, and 
diet), and co-morbidity. In addition, the possibility that this variability has an important 
genetic basis has been recognized for a long time, but it was not until the recent identification 
of several single-nucleotide polymorphisms (SNPs) in the ABCB1, CYP3A4, and CYP3A5 
genes that further evidence for this hypothesis was provided (for a review see references 16 
and  27).  
To date, more than 25 SNPs have been discovered in ABCB1. The best-studied SNP is the 
3435C→T transition located in exon 26. This is a silent SNP, meaning that it does not lead 
to an amino acid change. In the original report by Hoffmeyer and co-workers45, individuals 
homozygous for the T allele were found to have a lower duodenal P-glycoprotein content 
and higher plasma digoxin (a P-glycoprotein substrate) concentrations under noninduced, 
as well as under rifampin-induced, conditions. These findings suggested reduced P-
glycoprotein activity in T allele carriers45, and this was confirmed by several other studies.46-
48 Healthy Caucasian volunteers with the 3435TT genotype had higher AUC
0-4
 and C
max
 
values for digoxin than those with the 3435CC genotype.46 In a study of Japanese volunteers, 
P-glycoprotein expression was numerically lower in placentas of 3435TT individuals.47 A 
reduced P-glycoprotein activity associated with the T allele was also demonstrated in an in 
vitro study. Hitzl and colleagues48 showed that rhodamine (a P-glycoprotein substrate) efflux 
from CD56+ natural killer cells and leukocyte ABCB1 mRNA levels were significantly lower in 
3435TT subjects as compared with CC and CT individuals. However, the functionality of the 
3435C→T SNP is controversial, as some investigators have reported a higher P-glycoprotein 
activity in association with the T allele. For example, ABCB1 mRNA levels in the proximal 
small bowel of healthy Japanese volunteers were significantly higher in 3435TT individuals 
compared with 3435CC individuals, whereas heterozygotes (CT) had intermediate mRNA 
expression levels.49 In addition, the fexofenadine AUC
0-4
 after single-dose administration 
was significantly lower in 3435TT individuals compared with CC subjects, suggesting a 
higher P-glycoprotein expression in vivo.50 Finally, others have not found a relation between 
the 3435C→T SNP and intestinal ABCB1 expression/P-glycoprotein content38,51 or the 
pharmacokinetics of various drugs, including digoxin, talinolol, and fexofenadine.51-53
There is substantial evidence that the exon 26 SNP is linked to other SNPs in ABCB1.16 
Linkage disequilibria have been established between ABCB1 3435C→T and 1236C→T in exon 
12, and with 2677G→T/A in exon 21.46,51,54,55 Therefore, effects ascribed to 3435C→T may have 
been caused by the fact that this SNP is inherited together with other causative SNP(s). 
The 2677G→T/A SNP is a good candidate for such a relationship. This SNP is a missense 
mutation resulting in an 893Ala to 893Ser or 893Thr amino acid change. However, the 
reported functional consequences of this 2677G→T/A transition are also far from clear, as 
the absence of 2677G has been associated with both increased and decreased expression.16 A 
difference in the contribution of either the T or A allele may effectively obscure the effects 
of the 2677G→T/A SNP because the 2677T variant is correlated with decreased ABCB1 
expression, whereas the 2677A variant has been associated with an increased activity.56 It 
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may be that a marked phenotypic effect only arises when an individual possesses a specific 
combination of SNPs (haplotype), meaning that assessment of a patient’s haplotype could 
prove to be a superior method to be used in investigating genotype-phenotype relationships. 
With haplotype analysis, even the functional consequences of as yet unidentified SNPs can 
be detected once the key polymorphisms representative of a certain haplotype (which do not 
necessarily have to be the SNPs responsible for phenotypic differences) have been defined.55 
The number of studies using ABCB1 haplotype analysis is still limited but it has become clear 
that important inter-racial differences in the frequencies of such haplotypes exist.16,55,57,58
The human CYP3A gene cluster on chromosome 7q21-q22.1 consists of four genes and two 
pseudogenes: CYP3A4, CYP3A5, CYP3A7, CYP3A43, CYP3AP1, and CYP3AP2.27 At present, 
more than 30 SNPs have been identified in CYP3A4 (see http://www.imm.ki.se/CYPalleles). 
The first CYP3A4 SNP described in the literature was CYP3A4-V, later renamed CYP3A4*1B, 
which is encoded by -290A→G in the nifedipine-specific element of the CYP3A4 promoter. 
This variant allele was originally identified by linkage to a worse presentation of prostate 
cancer59, and CYP3A4*1B was hypothesized to cause a decreased CYP3A4 transcription. 
However, in vitro, the CYP3A4*1B allele resulted in a 1.5-fold increase in transcription60, 
whereas other investigators did not observe a change in enzyme activity.61 
CYP3A5, the second important CYP3A subfamily member, is highly homologous to CYP3A4 
(83%). Recently, a SNP in intron 3 of the CYP3A5 gene, genomic 6986A→G, showed 100% 
linkage with the absence of CYP3A5 protein. This variant, referred to as the CYP3A5*3 
allele,31,32 occurred homozygously in 80% of the Caucasian and 30% of the African-
American population.31,32,62,63 The CYP3A5*3 allele encodes a splice variant mRNA resulting 
in only a small amount of normally-spliced CYP3A5 mRNA.32 Interestingly, linkage was 
observed between the CYP3A4*1B and CYP3A5*1 alleles,32,64 which makes it difficult to 
assign increased CYP3A activity to either of these SNPs. In addition, another splice variant 
was identified, leading to deletion of exon 7: CYP3A5*6.32 This deletion causes a frameshift, 
resulting in a truncated protein at amino acid 184. This CYP3A5*6 allele was found in 3 out 
of 20 African-Americans,32 and in 1 out of 500 Caucasians.62 
The -44G→A SNP in CYP3AP1  (originally identified as a -45A→G) was initially believed 
to represent a variant allele of CYP3A5, in which the -44A allele correlated with absence 
of CYP3A5 activity.65 However, this observation was later explained by genetic linkage of 
CYP3AP1 -44G→A with CYP3A5*3.32 Although the CYP3AP1 -44G→A SNP has been used 
as an indicator for CYP3A5 activity, this does not seem to be a reliable predictor as the 
linkage is incomplete.64
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PHARMACOGENETICS OF CALCINEURIN INHIBITORS
ABCB1
Von Ahsen and colleagues66 were the first to study the relationship between the ABCB1 
genotype and cyclosporine dose requirement. In a cohort of 124 stable renal transplant 
recipients, the ABCB1 3435C→T SNP was not associated with cyclosporine dose requirement 
(determined by dividing the cyclosporine C
0
 by the corresponding dose per bodyweight), a 
finding which was subsequently confirmed by other studies in renal,67-69 liver,70 and heart 
transplant recipients69,71 (Table 4.3.1).54,66-77 More recently, the effect of ABCB1 genotype 
on cyclosporine disposition was studied in more detail with the use of ABCB1 haplotype 
analysis. Nevertheless, in the largest cohort studies,72-74 no significant correlation between 
ABCB1 haplotype and cyclosporine pharmacokinetics was identified, although in several 
smaller study groups both a higher75 and lower54,76 cyclosporine dose requirement has been 
associated with possession of a T allele at position 3435 (Table 4.3.1).   
The effect of genetic variation in ABCB1 on tacrolimus pharmacokinetics has also been 
investigated extensively (Table 4.3.2).38,67,70,74,78-84 As in the case of cyclosporine, a large number 
of studies have not reported an association between ABCB1 genotype and tacrolimus phar
macokinetics.38,67,70,74,81-83 These studies were conducted among kidney and liver transplant 
recipients, and a possible ABCB1 genotype effect was studied using both individual SNP, as well 
as haplotype analysis. However, in the largest cohort of kidney transplant recipients studied 
to date (n = 180), MacPhee and co-workers78 did find an association between tacrolimus 
dose requirement and the ABCB1 3435C→T SNP. Patients with the ABCB1 3435CC genotype 
were found to have the highest tacrolimus dose requirement but this genotype effect was 
relatively small. Anglicheau and co-workers80 determined ABCB1 haplotypes in 81 renal 
transplant recipients. The majority of patients in this cohort had the 1236C–2677G–3435C 
haplotype (haplotype 1) or the 1236T–2677T/A–3435T haplotype (haplotype 2). In line with 
the observations of MacPhee and colleagues78, haplotype 1 individuals were found to have 
a significantly higher tacrolimus dose requirement compared with haplotype 2 individuals: 
0.18 mg/kg per day versus 0.15 mg/kg per day.80 A higher tacrolimus dose requirement of 
patients homozygous for ABCB1 2677GG or 3435CC was also described for pediatric heart 
and adult lung transplant recipients.79,84 These results may be explained by differences in 
the pharmacokinetic (C
0
, C
2
 or AUC) or genetic (single SNP versus haplotype) analyses 
that were performed in the various studies. Moreover, the sample size of the study cohorts 
and the time (after transplantation) points at which a possible ABCB1 genotype effect was 
assessed, differed between studies. However, taken together, it appears that the variability in 
the pharmacokinetics of CNIs is, at most, only explained to a limited degree by the various 
ABCB1 SNPs that have been studied to date.
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Table 4.3.2 Tacrolimus pharmacokinetics and single-nucleotide polymorphisms in the ABCB1 gene.
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Table 4.3.3  Calcineurin inhibitor pharmacokinetics and 
single-nucleotide polymorphisms in cytochrome P450 3A4.
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Table 4.3.4 Calcineurin 
inhibitor pharmacokinetics 
and single-nucleotide 
polymorphisms in 
cytochrome P450 3A5.
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CYP3A4
A limited number of studies has investigated the effect of the CYP3A4*1B promoter variant 
allele on the pharmacokinetics of CNIs (Table 4.3.3).66,67,69,85,86 In renal transplant recipients, 
the CYP3A4*1B allele was not associated with cyclosporine dose requirement, nor with 
the incidence of biopsy-proven acute rejection or the occurrence of cyclosporine-related 
nephrotoxicity.66,67,85 Interestingly, we found that renal transplant recipients carrying a 
CYP3A4*1B allele had an approximately one-third higher tacrolimus dose requirement 
compared with CYP3A4*1 homozygotes.67 It is possible that the CYP3A4*1B allele also 
affected cyclosporine pharmacokinetics, but this effect may have been obscured as only the 
cyclosporine C
0
 was investigated in these studies. This parameter correlates poorly with 
total cyclosporine exposure, whereas the tacrolimus C
0
 better reflects total tacrolimus 
exposure.13-15,87 To test this hypothesis, we described cyclosporine pharmacokinetics of 151 
kidney and heart transplant recipients undergoing maintenance therapy by use of nonlinear 
mixed-effects modeling.69 By use of this sensitive method, the oral clearance of cyclosporine 
(clearance divided by bioavailability or Cl/F) of CYP3A4*1B allele carriers was indeed found 
to be 9% higher compared with CYP3A4*1 homozygotes, an effect independent of ethnicity. 
These observations suggest a higher CYP3A4 expression in patients carrying a CYP3A4*1B 
allele, which is in accordance with the reported increased expression of the CYP3A4*1B 
promoter sequence in vitro.60 In a healthy volunteer study, and using a noncompartmental 
analysis, Min and Ellingrod86 also found that the mean cyclosporine Cl/F was significantly 
higher in CYP3A4*1B homozygotes compared with wildtype individuals.86 
Although these results indicate that the CYP3A4*1B allele may have functional effects in vivo, 
one could argue about its clinical relevance. The CYP3A4 genotype only explains a small 
part of the interindividual variability in cyclosporine pharmacokinetics, and genotyping 
for CYP3A4*1B is thus unlikely to assist in planning initial cyclosporine dosing.69 Moreover, 
the observed correlation between CYP3A4 genotype and cyclosporine clearance may have 
been caused by differences in CYP3A5 expression. There is evidence that the CYP3A4*1B and 
the CYP3A5*1 alleles are linked and, therefore, differences in CYP3A5 rather than CYP3A4 
activity could explain the observed differences in cyclosporine pharmacokinetics.27,32,62,64,67,69 
CYP3A5
In contrast to the various ABCB1 and CYP3A4 SNPs, the correlation between tacrolimus 
dose requirement and CYP3A5 genotype has been established more clearly (Table 
4.3.4).67,69,73-75,78,79,81-84,88,89 Studies in kidney, liver, lung, and heart transplant recipients 
have demonstrated that patients who do not express functional CYP3A5 (for instance, 
individuals homozygous for CYP3A5*3, representing 80% of the Caucasian population62) 
require significantly less tacrolimus to reach target concentrations compared with patients 
who do express CYP3A5 (CYP3A5*1 allele carriers).67,74,79,82-84,88,89 In addition, the  -44G→
A SNP in the CYP3A pseudogene CYP3AP1 was also associated with tacrolimus dosing in 
renal transplant recipients.78 This SNP is (incompletely) linked to the CYP3A5*3 allele, which 
explains the observed correlation with tacrolimus dose requirement.64 The patient cohort of 
MacPhee and colleagues was recently directly genotyped for CYP3A5*3, confirming that 
individuals genetically predicted to express CYP3A5 required twofold higher tacrolimus 
doses to achieve target concentrations.89 
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Most studies published to date have not found significant associations between the 
CYP3A5*3 SNP and cyclosporine pharmacokinetics (Table 4.3.4). In one study69, patients 
homozygous for the CYP3A5*3 SNP (nonexpressors) did have a reduced cyclosporine Cl/
F (-6%) compared with carriers of the CYP3A5*1 allele. However, this small difference 
was not statistically significant (P = 0.06). Yates and co-workers75 reported a higher 
cyclosporine Cl/F in renal transplant recipients with a genetic inability to express CYP3A5. 
The pharmacokinetic analysis used in this study was sensitive, but its results are in marked 
contrast with the findings of many other studies. In particular, CYP3A5 nonexpressors had 
the highest cyclosporine dose requirement, which is exactly the opposite of what might have 
been expected. 
DISEASE OUTCOME
In addition to the direct effect on the pharmacokinetics of CNIs, genetic variation in ABCB1 
and CYP3A may also influence transplantation outcomes. MacPhee and colleagues89,90 
assessed the time to achieve tacrolimus target concentrations among renal transplant 
recipients. Despite the use of TDM, patients who expressed CYP3A5 had a significantly lower 
mean tacrolimus C
0
 during the first two weeks after transplantation and experienced a delay 
in achieving target concentrations. Acute rejection episodes occurred earlier in CYP3A5 
expressors than in nonexpressors (median of day 8 versus day 13), although there was no 
statistically significant difference in the overall rate of biopsy-confirmed acute rejection.89,90 
The absence of a relation between ABCB1 or CYP3A genotype and the incidence of acute 
rejection has also been described by other authors.66,67 However, these studies were all 
retrospective and were not designed nor powered to detect such an effect. Larger studies are 
needed to answer this question, as with modern immunosuppressive protocols the incidence 
of acute rejection has fallen below 20%. 
One of the major limitations of CNI treatment is the frequent occurrence of nephrotoxicity. 
Evidence for a role of P-glycoprotein in the pathogenesis of CNI-related nephrotoxicity 
was provided by Koziolek and co-workers91 who demonstrated in a histological study that 
treatment with cyclosporine was associated with increased expression of P-glycoprotein 
in arterial endothelia, proximal tubules, and endothelial cells of the Bowman’s capsule 
in kidney transplants with acute tubular necrosis, acute rejection or CAN. By contrast, 
in kidney biopsies from patients suffering from cyclosporine-related nephrotoxicity, P-
glycoprotein expression was not increased when compared with controls. These findings 
suggest that cyclosporine treatment induces P-glycoprotein expression, in order to facilitate 
cyclosporine detoxification. Failure to adequately upregulate P-glycoprotein expression, 
or a constitutively low P-glycoprotein expression in renal parenchymal cells, may lead 
to intrarenal accumulation of cyclosporine, and predispose patients to the occurrence of 
cyclosporine-related nephrotoxicity (Figure 4.3.1).91 
The influence of ABCB1 genotype on the occurrence of CNI-related nephrotoxicity was 
studied in a case-control study among liver transplant recipients.70 Patients treated with CNIs, 
who were homozygous for the ABCB1 2677T allele, were less than 50% as likely to experience 
symptoms of chronic renal dysfunction compared with 2677GT or 2677GG individuals. 
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The cause for this observation is at present unclear, but could possibly be explained by a 
lower renal P-glycoprotein efflux activity in G allele carriers, leading to a higher intrarenal 
CNI exposure.70 However, the genotype of the liver transplant itself was not determined in 
this study, and an alternative explanation for these findings may be a difference in hepatic 
cyclosporine metabolism and exposure between patients with and without cyclosporine-
related nephrotoxicity. In another case-control study, Hauser and colleagues92 recently 
reported the influence of ABCB1 genotype on the occurrence of cyclosporine-related 
nephrotoxicity after renal transplantation. In this study, the ABCB1 genotype of the donor 
was also determined and proved to be a major risk factor for the occurrence of cyclosporine-
related nephrotoxicity.92 Among patients with cyclosporine-related nephrotoxicity, kidney 
transplants of the ABCB1 3435TT genotype were over-represented compared with patients 
without toxicity [odds ratio (OR) = 3.2; 95% confidence interval (CI) 1.4-7.6]. The donor’s but 
not the recipient’s, ABCB1 genotype was highly predictive as 2½ years after transplantation, 
approximately 40% of all patients who received a kidney transplant from a donor homozygous 
for the 3435T allele developed cyclosporine-related nephrotoxicity, compared with only 10% 
of patients who received a kidney with the 3435 CT or CC genotype. To determine whether 
the ABCB1 genotype was an independent risk factor for cyclosporine-related nephrotoxicity, 
a multivariate logistic regression analysis was performed. In the final model, which included 
several nongenetic factors, only the donor’s ABCB1 3435TT genotype was strongly associated 
with cyclosporine-related nephrotoxicity (OR = 13.4; 95% CI 1.2-148).92 Although the 
seemingly contradictory findings of the latter two studies require further investigation, they 
do indicate that it may become possible to perform a risk assessment for the occurrence of 
CNI-related nephrotoxicity by utilizing pharmacogenetics. Patients receiving a transplant 
from a donor with a genotype that renders them more susceptible to the development of 
CNI-related nephrotoxicity should then be (more) closely monitored, and might benefit 
from early CNI dose reduction or conversion to a CNI-free immunosuppressive regimen.    
Finally, possession of a ABCB1 2677T/A allele has been associated with an increased risk 
of tacrolimus-induced neurotoxicity.93 In addition, kidney transplant recipients with the 
ABCB1 3435TT genotype had a lower risk of developing corticosteroid-induced necrosis of 
the femoral head,94 but this SNP was not related to the development of cyclosporine-induced 
gingival overgrowth (Figure 4.3.1).95 
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Figure 4.3.1 The effects of P-glycoprotein and cytochrome P450 3A on the pharmacokinetics of 
calcineurin inhibitors and transplantation outcomes
A. In the gut, P-glycoprotein and CYP3A form a barrier to the absorption of the CNIs cyclosporine 
and tacrolimus. B. Following absorption, cyclosporine and tacrolimus are metabolized in the liver 
and excreted into bile. C. A small amount of absorbed cyclosporine and tacrolimus is eliminated by 
the kidneys. In addition, the ABCB1 genotype of the kidney (allograft) may predict the development 
of CNI-related nephrotoxicity. D. P-glycoprotein also maintains the blood-brain barrier and the 
ABCB1 genotype appears to be a risk factor for CNI-related neurotoxicity. E. Furthermore, P-
glycoprotein limits entry of CNIs into various leukocytes. F. The ABCB1 genotype is not related to 
the development of cyclosporine-induced gingival hyperplasia but does appear to predict the risk 
of corticosteroid-induced necrosis of the femoral head (G).
ABC, Adenosine triphosphate-binding cassette; CNI, Calcineurin inhibitors; CsA, cyclosporine; 
CYP, cytochrome P450; P-gp, P-glycoprotein; Tac, tacrolimus
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EXPERT COMMENTARY 
In summary, most pharmacokinetic studies in transplantation have not identified a 
substantial effect of the various SNPs in ABCB1, CYP3A4 or CYP3A5 on the pharmacokinetics 
of cyclosporine. In contrast, tacrolimus dose requirement has been repeatedly found to be 
30-50% higher in patients expressing CYP3A5, whereas SNPs in ABCB1 appear to contribute 
little, if at all, to the interindividual variability in tacrolimus pharmacokinetics. The role of 
the CYP3A4*1B allele is still controversial as the reported association with tacrolimus dose 
requirement may have arisen through linkage with CYP3A5*1.
The most important promise of pharmacogenetics, namely to provide the genetic basis for 
the interindividual variability in the pharmacokinetics of CNIs, has not yet been fulfilled. 
It may have been too optimistic to expect that cyclosporine or tacrolimus pharmacokinetics 
would depend on a single SNP in only one gene. More likely, the causes of the variability 
in the pharmacokinetics of CNIs are multifactorial, to which multiple SNPs in different 
genes may contribute. In addition, the polymorphic expression of ABCB1 and CYP3A 
not only depends on genetic polymorphisms, but also on variation in transcriptional 
regulation. Nevertheless, pharmacogenetics has made some important contributions 
to our understanding of the pharmacokinetics of tacrolimus. The association between 
tacrolimus dose requirement and CYP3A5 genotype has been most significant in this 
respect, and indicates that pharmacogenetic analysis before transplantation may assist in 
guiding individual tacrolimus dosing. Although this remains to be formally tested, some 
transplant centers have already adopted the strategy to give a twofold higher tacrolimus dose 
to CYP3A5 expressors (MacPhee IA, personal communication). Second, the high frequency 
of the CYP3A5*1 allele among black people31,32 may explain the low oral bioavailability of 
tacrolimus in this ethnic group, and could help to reduce the incidence of acute rejection 
in black patients.96 Finally, the ABCB1 genotype of the (transplanted) kidney appears to 
predict the risk for the development of CNI-related nephrotoxicity, which is one of the major 
limitations to the successful long-term use of these immunosuppressants. 
Future clinical studies are needed to further characterize the complex interplay between 
inherited factors and individual variation in CNI response and transplantation outcomes. 
Such studies should investigate the combined effect of different SNPs in ABCB1 and CYP3A 
on the pharmacokinetics of CNIs, preferably by use of haplotype analysis and the most 
advanced pharmacokinetic assessment. In addition, as all studies conducted to date are of 
a cross-sectional or retrospective design and generally have a limited sample size, there is 
a need for larger numbers of well-characterized patients who have been uniformly treated 
and systematically evaluated, to make it possible to quantify drug response objectively. In 
order to limit spurious genotype-phenotype relationships, the possibility of co-medication 
interfering with CNI pharmacokinetics should also be carefully monitored in such 
studies.34,40,44,97-99 A pharmacogenetic (sub)study as an integral part of a large prospective 
immunosuppressive drug trial would be most appropriate in this respect. Such trials may also 
answer questions regarding the efficacy, safety, and cost effectiveness of pharmacogenetics-
guided immunosuppressive therapy. In the mean time, fundamental research will continue 
to provide deeper insights into the transcriptional regulation of CYP3A and ABCB1, and will 
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hopefully discover more specific activity probes for the individual CYP3A isozymes.27 The 
recent elucidation of the crystal structure of human CYP3A4 is likely to be helpful in this 
respect.100 Finally, there are other questions left unanswered. For example, it is not clear why 
CYP3A5 genotype affects tacrolimus, but not cyclosporine, pharmacokinetics. The relative 
contribution of CYP3A4 and CYP3A5 to the metabolism of each of these two drugs should 
therefore be better defined. Moreover, the recently reported effect of the CYP3A genotype 
on the novel immunosuppressant sirolimus requires confirmation.101 It is also to be expected 
that the genetic basis of the variability in the pharmacokinetics of the immunosuppressive 
drug MMF will be investigated. 
OUTLOOK
Pharmacogenetics has generated considerable enthusiasm in transplantation medicine. 
Drug therapy in this field is characterized by the frequent occurrence of toxicity and drug 
interactions, and the need for close monitoring of drug concentrations in order to ensure 
adequate immunosuppression. Pharmacogenetic studies in transplant recipients have 
recently led to a further understanding of the genetic basis of the variable pharmacokinetics 
of immunosuppressants, although its full complexity is only beginning to be understood. 
In order to meet the ultimate goal of pharmacogenetics (i.e., to realize a further 
individualization of immunosuppressive drug treatment) future study is needed. It is most 
likely that pharmacogenetics will not replace traditional TDM, but will have an additional 
value. Nonetheless, it is to be expected that pharmacogenetics will influence our everyday 
practice of medicine in the near future. It will become possible to perform genotype screens 
that identify patients with a smaller chance of an effective response, or an increased risk of 
adverse reactions. Ultimately, for transplanted patients the genetic profile may be added to 
well-known risk factors, such as the recipient’s ethnicity, panel reactive antibody titers and 
previous transplant history, when selecting immunosuppressive drug protocols. 
HIGHLIGHTS
• Cyclosporine and tacrolimus are critical-dose immunosuppressive agents that display 
highly variable pharmacokinetics.
• Cyclosporine and tacrolimus are metabolized by the cytochrome P450 (CYP) isozymes 
3A4 and 3A5 and are a substrate for P-glycoprotein, which is encoded by the adenosine 
triphosphate-binding cassette (ABC)B1 gene.
• Interindividual differences in cyclosporine and tacrolimus pharmacokinetics have been 
attributed to variability in the expression and activity of P-glycoprotein and the CYP3A 
enzymes.
• Several recently-identified single-nucleotide polymorphisms (SNPs) may form the  
genetic basis for the polymorphic expression of CYP3A and ABCB1. 
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• The ABCB1 3435C→T and 2677G→T SNPs do not appear to contribute much to the  
interindividual variability in cyclosporine- and tacrolimus pharmacokinetics, but may 
be associated with the occurrence of cyclosporine- or tacrolimus-related nephrotoxity.
•  The CYP3A4*1B variant allele has been associated with a higher tacrolimus, and to a 
lesser extent cyclosporine, dose requirement but these observations may have been 
caused by linkage to the CYP3A5*1 allele
• The CYP3A5*3 allele, which results in the absence of functional CYP3A5 protein, 
has  been strongly associated with a lower tacrolimus, but not cyclosporine, dose 
requirement.
• Patients who do express CYP3A5 (*1 allele carriers) not only need more tacrolimus, but 
are also slower to reach their target concentration when compared with non-expressors, 
despite the use of therapeutic drug monitoring. 
• Carriers of a CYP3A5*1 allele may have an increased risk of the development of  
acute rejection. 
• Screening transplant recipients for CYP3A5 expression has the potential to optimize  
tacrolimus therapy, although this needs to be confirmed prospectively.
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SUMMARY
The calcineurin inhibitor (CNI) cyclosporine revolutionized transplantation medicine. 
Its potent immunosuppressive activity resulted in a dramatic decrease in the incidence 
of acute rejection after solid organ transplantation. As a result, kidney allograft survival 
improved markedly and other forms of solid organ transplantation first became realistic 
options with the availability of this drug. In the nineties, tacrolimus was approved for the 
prevention of acute rejection after solid organ transplantation and like cyclosporine, exerts 
its immunosuppressive effect by inhibiting the enzyme calcineurin. Today, more than 25 
years after CNIs were first introduced into the clinic, these agents remain the cornerstone of 
immunosuppressive therapy after solid organ transplantation.1
However, cyclosporine and tacrolimus are not ideal drugs. Most important, they are toxic 
and can cause, among others, renal insufficiency, hypertension, hyperlipidemia, and 
diabetes mellitus. These side effects have a negative influence on graft and patient survival, 
and decrease the quality of life of transplant recipients. Furthermore, the pharmacokinetics 
of CNIs are highly variable both between and within individuals, which makes these agents 
difficult to use and close monitoring of CNI therapy necessary.1  
The overall aim of this dissertation was to explore ways of optimizing treatment with CNIs. 
In this regard, several questions were addressed which are formulated in Chapter 1. In 
addition, the history of CNIs, their pharmacokinetics and pharmacodynamics, as well as 
current CNI treatment strategies are reviewed in the first chapter.
In the second part of the dissertation, (new strategies for) therapeutic drug monitoring 
(TDM) of cyclosporine was investigated. More specifically, we studied (1) the relationship 
between cyclosporine exposure and the occurrence of cyclosporine-related side effects in 
stable heart, kidney, and liver transplant recipients on maintenance cyclosporine therapy 
(Chapter 2.1), and (2) the benefits and drawbacks of cyclosporine dosing based on the 
cyclosporine whole-blood concentration 2 h after oral administration (C
2
) compared with 
conventional predose (C
0
) concentration monitoring (Chapter 2.1 and Chapter 2.2). The 
rationale for these studies was the following:2-6
1. Cyclosporine exposure (within a dosing interval) correlates with the occurrence of its 
side effects and its efficacy.
2. The cyclosporine C
0
 poorly reflects total cyclosporine exposure and does not adequately 
predict its efficacy (i.e., absence of acute rejection) nor the occurrence of adverse clinical 
events (toxicity). 
3. The cyclosporine area-under the concentration versus time-curve within the first 4 h after 
oral administration (AUC
0-4
) and the cyclosporine C
2
 better reflect total cyclosporine 
exposure than C
0
.
4. The cyclosporine AUC
0-4
 and C
2
 correlate with clinical events.
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Because of the above, it has recently been propagated that TDM of cyclosporine should 
be based on cyclosporine AUC
0-4
 or C
2
 levels.7 However, this recommendation is based on 
studies that were mostly performed in de novo transplant recipients. In addition, side effects 
other than nephrotoxicity have not been studied intensively.8 Importantly, there have been 
no studies that have demonstrated improved graft or patient survival when cyclosporine 
was monitored (and dosed) according to AUC
0-4
 or C
2
 levels.5,6,9 Given the fact that AUC
0-4
 
and C
2
 level monitoring are more expensive and time-consuming than C
0
 level monitoring, 
and pose logistic problems, further study of these new strategies for TDM of cyclosporine 
was justified.10,11
In Chapter 2.1, we investigated the relationship between cyclosporine exposure and 
the occurrence of cyclosporine-related side effects [renal insufficiency, hypertension, 
hyperlipidemia, neurotoxicity (polyneuropathy and tremor of the hands), and cosmetic side 
effects (gingival hyperplasia, hirsutism and hypertrichosis)]. A total of 49 liver, 28 heart, 
and 26 kidney transplant recipients, all stable and on cyclosporine maintenance therapy (>6 
months after transplantation) were included in the study. In all patients, the cyclosporine 
AUC
0-4
 was measured. Cyclosporine exposure was compared between patients with and those 
without a particular cyclosporine-related side effect. In addition, the correlation coefficients 
between C
0
, C
2
, and AUC
0-4
 were calculated. The correlation between the cyclosporine C
0
 
and AUC
0-4
 was weaker than the correlation between the latter and the cyclosporine C
2
 
(r2 of 0.59 and 0.84, respectively). However, cyclosporine exposure (as measured by AUC
0-
4
) was not significantly different between patients with and those without toxicity, and as 
such, we could not demonstrate a cyclosporine concentration-effect relationship in patients 
on maintenance therapy. Possibly, the negative findings in this study can be explained by 
previous cyclosporine dose reductions in patients experiencing side effects.
In Chapter 2.2, we investigated the effect of cyclosporine dose reduction based on C
2
 levels, 
on renal function in long-term liver transplant recipients. Cyclosporine C
2
 levels were 
measured in 60 stable liver transplant recipients (>1 year after transplantation) and dose 
reduction was performed if C
2
 levels exceeded the recommended target range of 600 ng/
mL ± 20%.7 In twenty-three patients (38%), C
2
 levels were above the upper limit of the C
2
 
target range, whereas C
2
 levels were within the target range in 27% of the patients. Twenty 
of the 23 patients with cyclosporine “overexposure” agreed to have their cyclosporine dose 
reduced. Although cyclosporine C
2
 target levels were reached rapidly in these patients and 
cyclosporine dose was reduced by a mean of 25%, at 6 months follow-up, no improvement 
of renal function, lipid levels or systolic blood pressure was observed. However, after 
dose reduction, 1 patient experienced an episode of acute cellular rejection, in 2 patients 
primary biliary cirrhosis recurred, and 1 patient had a recurrence of autoimmune hepatitis. 
We concluded that according to current recommendations, cyclosporine overexposure is 
common among stable liver transplant recipients. However, cyclosporine dose reduction 
aimed at reaching recommended C
2
 levels did not result in an improvement of renal function 
and posed a risk of immune activation.
In part 3 of the dissertation, pharmacokinetic drug interactions with CNIs were studied. 
In addition to CNIs, most transplant recipients are also treated with several other 
immunosuppressive drugs. The rationale for using a “cocktail” of immunosuppressive agents 
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is to ensure adequate immunosuppression (through the synergistic actions of multiple, 
differently-acting agents), while limiting the toxicity of an individual drug.1 Because 
pharmacokinetic interactions can result in increased or decreased blood concentrations of 
an individual drug, such interactions may be clinically relevant.    
In Chapter 3.1, we studied the effect of corticosteroids on the pharmacokinetics of tacrolimus. 
In a randomized, controlled trial, de novo kidney transplant recipients were treated with 
tacrolimus plus mycophenolate mofetil (MMF) in combination with either daclizumab (n 
= 31) or 3 months of prednisone (n = 34). Tacrolimus dose-adjusted C
0
 at months 1-6 were 
compared between and within the 2 groups. The tacrolimus dose-adjusted C
0
 at months 
1-3 was lower in the corticosteroid group compared with the daclizumab group, although 
the overall difference was not statistically significant (P = 0.06). Within the corticosteroid 
group, a lower tacrolimus dose-adjusted C
0
 was observed at months 1 and 2 compared with 
months 4-6 (after corticosteroid withdrawal). These findings demonstrate that tacrolimus 
dose requirement is higher when tacrolimus is used in combination with corticosteroids. 
Changes in corticosteroid dosage may thus result in altered tacrolimus exposure causing 
toxicity or underimmunosuppression. 
In Chapter 3.2, we reviewed the pharmacokinetic interaction between CNIs and 
mycophenolic acid (MPA), the active metabolite of MMF. There is controversy regarding 
the effects of cyclosporine and tacrolimus on MPA concentrations.12-15 We conclude that co-
administration of cyclosporine and MMF leads to a decreased MPA concentration, whereas 
tacrolimus does not have a clinically relevant effect on MPA concentrations. In addition, we 
propose that cyclosporine decreases exposure to MPA by inhibiting the biliary excretion of 
its metabolite MPA-glucuronide (MPAG).
The mechanism of the interaction between cyclosporine and MPA was investigated in 
Chapter 3.3. We hypothesized that cyclosporine impairs biliary elimination of MPAG through 
inhibition of the multidrug resistance-associated protein 2 (MRP2). Three groups of 10 rats 
deficient for Mrp2 were treated for 6 days with either placebo, cyclosporine or tacrolimus. 
Hereafter, co-administration with MMF was started in all groups and continued through 
day 14. The 24 h AUC (AUC
0-24
) of MPA and MPAG was determined after single (day 7) and 
multiple MMF doses (day 14). On both study days, there were no significant differences in 
the mean MPA and MPAG AUC
0-24
 between cyclosporine and tacrolimus-treated animals. 
In a previous study in normal rats (i.e., rats expressing Mrp2), significant differences in MPA 
and MPAG exposure between cyclosporine and tacrolimus-treated rats had been observed 
(MPA being lower and MPAG higher in the cyclosporine-treated animals).16 Therefore our 
findings suggest that cyclosporine-mediated inhibition of the biliary excretion of MPAG by 
MRP2 is the mechanism responsible for the interaction between cyclosporine and MPA. 
Nonetheless other mechanisms may also be important. MRP2 is expressed in proximal renal 
tubular cells and cyclosporine-mediated inhibition of renal MPAG clearance could explain 
the higher MPAG concentrations observed in cyclosporine-treated patients, although such 
a mechanism does not readily explain their reduced exposure to MPA.17 In addition, recent 
data suggest that cyclosporine may also inhibit hepatic glucuronidation of MPA in Wistar rats.18
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Part 4 of the dissertation focused on the pharmacogenetics of CNIs. The pharmacokinetics of 
these drugs vary widely between individuals and this has been attributed to interindividual 
differences in the expression of the CNI-metabolizing enzymes cytochrome P450 (CYP) 
3A4 and CYP3A5, as well as the drug transporter P-glycoprotein.19 Recently, several 
single-nucleotide polymorphisms (SNPs) in the genes encoding CYP3A4, CYP3A5, and P-
glycoprotein have been described.20,21 We hypothesized that these SNPs may lead to altered 
CYP3A or P-glycoprotein activity or expression, which in turn may result in differences in 
CNI pharmacokinetics. 
The aim of Chapter 4.1 was to determine the role of genetic polymorphisms in CYP3A4, 
CYP3A5, and MDR-1 (encoding P-glycoprotein) with respect to interindividual variability 
in cyclosporine and tacrolimus pharmacokinetics. Kidney transplant recipients receiving 
cyclosporine (n = 110) or tacrolimus (n = 64) were genotyped for CYP3A4*1B and *3, 
CYP3A5*3 and *6, and MDR-1 3435C→T. Dose-adjusted C
0
 were determined and correlated 
with the corresponding genotype. Tacrolimus dose-adjusted C
0
 were significantly higher 
in CYP3A5*3/*3 patients than in *1/*3 plus *1/*1 patients, being roughly one-third higher 
in CYP3A5 non-expressors (patients with the CYP3A5 *3/*3 genotype). CYP3A4*1B allele 
carriers had lower tacrolimus dose-adjusted C
0 
compared with those in patients with the 
wildtype (*1/*1) genotype. No evidence was found supporting a role for the MDR-1 3435C→T 
SNP in tacrolimus dose-requirement. None of the SNPs studied correlated with cyclosporine 
dose-adjusted C
0
. We concluded that as a group, patients with the CYP3A5*3/*3 genotype 
require less tacrolimus to reach target C
0
 compared with CYP3A5*1 allele carriers, whereas 
CYP3A4*1B carriers need more tacrolimus to reach target C
0
 compared with CYP3A4*1 
homozygotes.
In Chapter 4.2, we aimed to elucidate why tacrolimus dose requirement was found to 
correlate with SNPs in CYP3A4 and CYP3A5, whereas cyclosporine dose requirement 
did not (the main finding of Chapter 4.1). We hypothesized that these contrasting results 
arose by using a (too) crude pharmacokinetic analysis (dose-adjusted C
0
) resulting in 
underdetection of an effect of genotype on cyclosporine pharmacokinetics. We therefore 
described cyclosporine pharmacokinetics of 151 kidney and heart transplant recipients 
undergoing maintenance therapy by use of nonlinear mixed-effects modeling (NONMEM) 
according to a 2-compartment pharmacokinetic model with first-order absorption and 
elimination. All patients were genotyped for the CYP3A4*1B and *3, CYP3A5*3 and *6, and 
MDR-1 3435C→T SNPs. Oral cyclosporine clearance was found to be 9% higher in carriers 
of a CYP3A4*1B variant allele compared with CYP3A4*1 homozygotes, and this effect was 
independent of ethnicity. Incorporation of CYP3A4 genotype into the final NONMEM model 
did not markedly reduce interpatient variability of oral clearance, indicating that CYP3A4 
genotype made only a limited contribution to the observed interindividual differences in 
cyclosporine pharmacokinetics. None of the other SNPs studied significantly influenced 
any of the pharmacokinetic parameters. We concluded that patients carrying a CYP3A4*1B 
variant allele have a significantly higher oral cyclosporine clearance compared with patients 
homozygous for CYP3A4*1. However, this genetic effect on cyclosporine disposition was 
small, and genotyping of transplant recipients for CYP3A4 is therefore unlikely to assist in 
planning initial cyclosporine dosing. 
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In Chapter 4.3, we discussed the current status of pharmacogenetics in transplantation 
medicine. Drug therapy in this field is characterized by the frequent occurrence of drug 
interactions and toxicity, and the need for close monitoring of drug concentrations in order 
to ensure adequate immunosuppression. Pharmacogenetics has generated considerable 
enthusiasm among transplant physicians as it has the potential to identify “the right drug and 
the right dose for an individual patient”. In this respect, polymorphisms in the MDR-1 and 
CYP3A5 genes appear at present to be the most promising. Although the MDR-1 3435C→T 
and 2677G→T SNPs do not appear to contribute much to the interindividual variability in 
CNI pharmacokinetics, they may predict the risk of developing CNI-related nephrotoxicity. 
The CYP3A5*3 allele, which results in the absence of functional CYP3A5 protein, is strongly 
correlated with tacrolimus, but not cyclosporine, dose requirement. Therefore, patients who 
express CYP3A5 (*1 allele carriers) need more tacrolimus to reach target concentrations and 
are at risk of developing acute rejection. 
CLINICAL IMPLICATIONS
What are the (clinical) implications of our findings for the individual transplant recipient? 
First of all, our findings demonstrate that after 20 years of clinical use, the optimal strategy 
for TDM of cyclosporine remains to be determined. Although it was recently recommended 
in an international consensus statement,7 to dose cyclosporine according to C
2
 levels (or 
some other limited sampling strategy), the studies on which these recommendations were 
based have been criticized heavily.10,11,22 The most important argument against C
2
 monitoring 
has been that to date, no controlled clinical trial has demonstrated unequivocally that it 
leads to improved clinical outcomes.10,22 In our studies, no cyclosporine concentration-
effect relationship was observed. Due to the cross-sectional study design the relationship 
between drug exposure and adverse events may have been obscured as patients not 
tolerating cyclosporine may already have been switched to tacrolimus-based therapy or have 
been subject to dose reductions. Adoption of C
2
 monitoring did not result in any clinically 
relevant benefit and in certain patients possibly even caused immune reactivation. Although 
our findings may be limited by the fact that a relatively small number of (selected) patients 
was studied, it appears that cyclosporine dosing based on C
2
 or AUC
0-4
 holds no advantage 
over conventional C
0
 level monitoring, at least in stable patients on maintenance therapy. As 
such, we agree with Campbell and Johnson10 that “there is not enough science yet to justify 
the practice of C
2
 monitoring”. 
Second, until recently, the only evidence for a pharmacokinetic interaction between 
corticosteroids and tacrolimus came from in vitro and animal studies.23,24 We demonstrate 
that in humans, co-administration of these drugs is indeed associated with a higher dose 
requirement of tacrolimus. This finding is in line with the recently published observations 
of two other research groups.25,26 In addition, evidence for the proposed mechanism of 
this pharmacokinetic interaction, namely induction of CYP3A-mediated tacrolimus 
metabolism by corticosteroids, comes from the work of Lemahieu and colleagues.27 The 
interaction between tacrolimus and corticosteroids appears to be clinically relevant as 
tapering of the latter (which is nowadays common practice in many transplant centers) may 
197
Summary and Conclusions
cause an increase in tacrolimus exposure and subsequently nephrotoxicity, which may be 
misinterpreted as acute rejection. Vice versa, treatment of an episode of acute rejection with 
high-dose corticosteroids may reduce tacrolimus exposure which may then lead to so-called 
“steroid-resistant” acute rejection. Therefore, monitoring of tacrolimus concentrations is 
necessary in corticosteroid-weaning protocols and during episodes of acute rejection.  
Third, we show that co-administration of cyclosporine and MMF leads to a decreased 
exposure to MPA. No clinically important pharmacokinetic interaction appears to exist 
between MMF and tacrolimus. In addition, we elucidated the mechanism underlying this 
interaction, namely cyclosporine-mediated inhibition of the biliary excretion of MPAG 
by the MRP2 transporter. The corollary of these findings is that the MMF dose should be 
higher in patients treated with cyclosporine than in patients treated with tacrolimus, in 
order to ensure adequate MPA exposure. Cessation of cyclosporine treatment or a switch 
from cyclosporine to tacrolimus-based immunosuppression may cause increased exposure 
to MPA and MPA-related toxicity. Finally, inhibition of MRP2 by cyclosporine may have 
important clinical consequences for the (co-) administration of other drugs.28  
Lastly, our pharmacogenetic studies demonstrated that this rapidly evolving field may help 
to individualize and optimize treatment with CNIs. Genetic screening of (future) transplant 
recipients may identify patients at risk for adverse drug reactions or underimmunosuppression. 
However, this hypothesis remains to be tested prospectively in clinical trials. One possibility 
is to genotype patients on the waiting list for CYP3A5 polymorphisms and adjust the 
starting tacrolimus dose accordingly. Based on our data, CYP3A5 expressors should start 
with a tacrolimus dose that is between 30% and 50% higher compared with non-expressors. 
This approach may result in a more rapid achievement of tacrolimus target concentrations 
and thus in a reduction of the incidence of acute rejection. Given the low allelic frequency 
of these polymorphisms among white and Asian individuals, as well as the low rejection 
rates that are achieved with modern immunosuppressive regimens, such a trial would 
require a considerable number of patients in order to have adequate discriminative power. 
Hopefully, the transplant community will unite and perform such a study. Moreover, it is at 
present unclear why polymorphisms in CYP3A and MDR-1 are associated with tacrolimus 
but not with cyclosporine pharmacokinetics. The relative contribution of the different 
CYP3A isozymes and MDR-1 polymorphisms to the pharmacokinetics of CNIs, which has 
hitherto only been studied in vitro and by use of liver microsomes, should therefore also 
be investigated in human transplant recipients under the conditions of everyday clinical 
practice.29-32 
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CONCLUSIONS
1. In solid organ transplant recipients on cyclosporine maintenance therapy, cyclosporine 
exposure as measured by AUC
0-4
, is not correlated with the occurrence of cyclosporine-
related side effects.
2. Cyclosporine dosing based on C
2
 levels in stable liver transplant recipients does not 
lead to an improvement of renal function and is associated with the risk of immune 
activation. 
3. Co-administration of corticosteroids and tacrolimus increases tacrolimus dose 
requirement.
4. Co-administration of cyclosporine and mycophenolate mofetil leads to a decreased 
mycophenolic acid concentration, whereas tacrolimus does not have a clinically relevant 
effect on mycophenolic acid concentrations.  
5. Cyclosporine interacts with mycophenolic acid by impairing the biliary excretion 
of mycophenolic acid-glucuronide through inhibition of the multidrug resistance-
associated protein 2. 
6. Patients expressing CYP3A5 require more tacrolimus to reach target concentrations 
than CYP3A5 non-expressors. Genetic screening of transplant recipients for CYP3A5 
expression may thus guide individual tacrolimus dosing.
7. Single-nucleotide polymorphisms in CYP3A4, CYP3A5, and MDR-1 have no clinically 
relevant effects on cyclosporine pharmacokinetics, and genotyping of transplant 
recipients for CYP3A or MDR-1 is unlikely to assist in planning initial cyclosporine 
dosing. 
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SAMENVATTING
De calcineurineremmer ciclosporine veroorzaakte een revolutie binnen de transplantatiegen
eeskunde, omdat het gebruik van dit krachtige immunosuppressieve geneesmiddel leidde tot 
een sterke afname van het aantal acute afstotingen na orgaantransplantatie. Dientengevolge 
trad er een aanzienlijke verbetering op van de overleving van niertransplantaten en met 
het beschikbaar komen van dit geneesmiddel werd transplantatie van andere organen voor 
het eerst een realistische behandelingsmogelijkheid. Tacrolimus werd in de jaren negentig 
geregistreerd voor de preventie van acute afstoting na orgaantransplantatie en oefent, 
net als ciclosporine, zijn immunosuppressieve werking uit door remming van het enzym 
calcineurine. Vandaag de dag, meer dan 25 jaar na hun klinische introductie, vormen de 
calcineurineremmers nog steeds de hoeksteen van de immunosuppressieve behandeling na 
solide orgaantransplantatie.1   
Ciclosporine en tacrolimus zijn echter verre van ideale geneesmiddelen. In de eerste plaats zijn 
zij toxisch en kan het gebruik ervan leiden tot, onder andere, nierinsufficiëntie, hypertensie, 
hyperlipidemie, en diabetes mellitus. Deze bijwerkingen hebben een ongunstige invloed 
op de overleving van het getransplanteerde orgaan en de patiënt, en kunnen de kwaliteit 
van leven van de ontvanger van een orgaan verminderen. Daarnaast is de farmacokinetiek 
van calcineurineremmers zeer variabel, zowel tussen individuen als binnen één persoon 
in de tijd. Dit maakt het klinische gebruik van deze geneesmiddelen moeilijk aangezien 
éénzelfde dosis bij de ene patiënt kan resulteren in het gewenste effect maar bij een ander 
kan leiden tot het optreden van bijwerkingen. Het nauwgezet vervolgen van de behandeling 
met calcineurineremmers is dan ook noodzakelijk.1  
Het doel van het onderzoek zoals beschreven in dit proefschrift was om te onderzoeken óf 
en hoe de behandeling met calcineurineremmers zou kunnen worden verbeterd. Hiertoe 
werden enkele onderzoeksvragen bedacht welke zijn geformuleerd in Hoofdstuk 1. 
Daarnaast worden in het eerste hoofdstuk de geschiedenis van calcineurineremmers, hun 
farmacokinetiek en farmacodynamiek, alsmede de huidige behandelingstrategieën met 
deze geneesmiddelen uiteen gezet.
In het tweede gedeelte van dit proefschrift, werd het doseren van ciclosporine op geleide 
van bloedspiegels, het zogenaamde “therapeutic drug monitoring” (TDM), onderzocht. Wij 
onderzochten hiertoe het volgende: (1) de relatie tussen ciclosporine expositie en het optreden 
van ciclosporine-gerelateerde bijwerkingen in stabiele hart-, lever-, en niertransplantaaton
tvangers die een onderhoudsbehandeling met ciclosporine kregen (Hoofdstuk 2.1); (2) de 
voor- en nadelen van het doseren van ciclosporine op geleide van de ciclosporine volbloed 
concentratie 2 uur na inname van het geneesmiddel (C
2
) in vergelijking met de traditioneel 
gebruikte dalspiegel (C
0
) (Hoofdstuk 2.1 en Hoofdstuk 2.2). De uitgangspunten voor deze 
onderzoeken waren de volgende:2-6
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1. De ciclosporine blootstelling (binnen een doseringsinterval) correleert met het risico op 
het krijgen van ciclosporine-gerelateerde bijwerkingen en het risico op het doormaken 
van een acute afstoting.
2. De ciclosporine C
0
 vormt een povere afspiegeling van de totale blootstelling aan het 
geneesmiddel en voorspelt in onvoldoende mate de effectiviteit (d.w.z. het vrijblijven 
van acute afstoting) en de toxiciteit.
3. De oppervlakte onder de curve van de ciclosporine concentratie uitgezet tegen de tijd (“area 
under the curve”; AUC) gedurende de eerste 4 uur na inname (AUC
0-4
) en de ciclosporine 
C
2
 zijn een betere afspiegeling van de blootstelling aan ciclosporine dan de C
0
.
4. De ciclosporine AUC
0-4
 en C
2
 correleren met het risico op acute afstoting en toxiciteit.
Vanwege het bovenstaande is recentelijk voorgesteld om ciclosporine te doseren op geleide 
van de AUC
0-4
 of C
2
.7 Echter, deze aanbeveling is gebaseerd op onderzoeken welke grotendeels 
werden verricht onder de novo niertransplantaatontvangers. Daarnaast zijn de bijwerkingen 
van ciclosporine, anders dan nefrotoxiciteit, niet uitvoerig onderzocht.8 Bovendien zijn 
er tot op heden geen onderzoeken gepubliceerd die een verbetering van transplantaat- of 
patiëntoverleving hebben aangetoond als ciclosporine werd gedoseerd op geleide van de 
AUC
0-4
 of C
2
.5,6,9 Aangezien het doseren van ciclosporine op geleide van de AUC
0-4
 of C
2
 
duurder en tijdrovender is dan het doseren op geleide van de C
0
 en bovendien aanzienlijke 
logistieke problemen met zich meebrengt, lijkt verder onderzoek naar de (meer)waarde van 
deze nieuwe doseringsstrategieën gerechtvaardigd.10,11
In Hoofdstuk 2.1 onderzochten wij de relatie tussen de blootstelling aan ciclosporine en 
het optreden van ciclosporine-gerelateerde bijwerkingen [nefrotoxiciteit, hypertensie, 
hyperlipidemie, neurotoxiciteit (polyneuropathie en tremor van de handen), en cosmetische 
bijwerkingen (gingiva hyperplasie, hirsutisme en hypertrichose)]. Een totaal van 49 lever-
, 28 hart- en 26 niertransplantatiepatiënten werd geïncludeerd in het onderzoek. Alle 
patiënten waren klinisch stabiel, minstens 6 maanden eerder getransplanteerd en ontvingen 
een onderhoudsbehandeling met ciclosporine. In alle patiënten werd de ciclosporine AUC
0-
4
 gemeten. De blootstelling aan ciclosporine werd vervolgens vergeleken tussen patiënten 
met en patiënten zonder een bepaalde ciclosporine-gerelateerde bijwerking. Daarnaast 
werden de correlatiecoëfficiënten tussen de C
0
, C
2
 en AUC
0-4
 berekend. De correlatie tussen 
de ciclosporine C
0
 en AUC
0-4
 was zwakker dan de correlatie tussen de C
2
 en AUC
0-4
 (r2 van 
respectievelijk 0.59 en 0.84). Echter, de blootstelling aan ciclosporine (gemeten aan de AUC
0-
4
) was niet significant verschillend tussen patiënten met en patiënten zonder ciclosporine-
gerelateerde bijwerkingen. Een ciclosporine concentratie-effect relatie kon dus niet worden 
aangetoond in patiënten die een onderhoudsbehandeling ciclosporine kregen. Mogelijk was 
dit het gevolg van het reeds eerder naar beneden bijstellen van de ciclosporine dosis bij 
patiënten die bijwerkingen hadden.
In Hoofdstuk 2.2 onderzochten wij de gevolgen van ciclosporine dosisreductie, op geleide 
van C
2
 spiegels, op de nierfunctie van stabiele levertransplantatiepatiënten. Hiertoe 
werden C
2
 spiegels gemeten in 60 stabiele levertransplantaatontvangers (>1 jaar na 
levertransplantatie). De ciclosporine dosis werd vervolgens gereduceerd als de C
2
 spiegel 
206
Chapter 6
boven het aanbevolen niveau van 600 ng/mL ± 20% lag.7 Bij 23 patiënten (38%) werd een C
2
 
spiegel boven de bovengrens van het aanbevolen niveau gemeten. In 27% van de gevallen 
lag de C
2
 binnen het aanbevolen niveau. Twintig van de 23 patiënten met een “te hoge” 
blootstelling aan ciclosporine stemden in met het verlagen van de ciclosporine dosis. Het 
aanbevolen C
2
 niveau werd snel bereikt met een gemiddelde ciclosporine dosisreductie van 
25%. Echter, deze dosisreductie leidde na 6 maanden follow-up niet tot een verbetering 
van de nierfunctie, het lipidenspectrum, of de systolische bloeddruk. Met betrekking tot 
de effectiviteit kreeg één patiënt een acute afstoting en bij 3 andere patiënten keerde de 
oorspronkelijke ziekte terug in het transplantaat (2 gevallen van primaire biliaire cirrose 
en 1 geval van autoimmuun hepatitis). Wij concludeerden derhalve dat, uitgaande van de 
huidige aanbevelingen, een te hoge blootstelling aan ciclosporine frequent voorkomt onder 
stabiele levertransplantaatontvangers. Echter, een dosisreductie met als doel het realiseren 
van de aanbevolen C
2
 spiegels, leidt niet tot een verbetering van de nierfunctie en geeft 
mogelijk zelfs een risico op immuunactivatie.
In deel 3 van dit proefschrift werden farmacokinetische interacties tussen calcineurineremmers 
en enkele andere geneesmiddelen onderzocht. De meeste transplantatiepatiënten krijgen 
naast een calcineurineremmer, diverse andere immunosuppressieve geneesmiddelen. 
Het idee achter het gebruik van een “cocktail” van immunosuppressiva is om voldoende 
immunosuppressie te bewerkstelligen (door de synergistische werking van diverse 
geneesmiddelen met een verschillend werkingsmechanisme) en tegelijkertijd de toxiciteit 
van de individuele geneesmiddelen te beperken.1 Aangezien farmacokinetische interacties 
tot verhoogde of verlaagde bloedspiegels van een individueel geneesmiddel kunnen leiden 
(en daarmee mogelijk resulteren in acute afstoting of toxiciteit), zijn dergelijke interacties 
klinisch relevant.
In Hoofdstuk 3.1 bestudeerden wij het effect van glucocorticoïden op de farmacokinetiek 
van tacrolimus. In een gerandomiseerde, gecontroleerde studie werden de novo niertranspl
antaatontvangers behandeld met tacrolimus en mycofenolaat mofetil (MMF) in combinatie 
met ofwel daclizumab (n = 31) of prednison gedurende 3 maanden (n = 34). De voor dosis-
gecorrigeerde tacrolimus dalspiegels tijdens maand 1 t/m 6 na niertransplantatie werden 
vergeleken tussen de 2 groepen. De voor dosis-gecorrigeerde tacrolimus dalspiegels 
tijdens maand 1 t/m 3 waren lager in de met prednison behandelde groep maar het overall 
verschil tussen de 2 groepen was niet statistisch significant verschillend (P = 0.06). Binnen 
de prednison groep was de voor dosis-gecorrigeerde tacrolimus C
0
 tijdens maand 1 en 2 
lager dan tijdens maand 4 t/m 6 (na het staken van prednison). Deze bevindingen tonen 
aan dat de tacrolimus dosisbehoefte hoger is wanneer tacrolimus wordt gecombineerd met 
glucocorticoïden. Veranderingen in de glucocorticoïd dosering kunnen derhalve aanleiding 
geven tot een veranderde blootstelling aan tacrolimus wat mogelijk resulteert in te weinig 
immunosuppressie of toxiciteit. 
Hoofdstuk 3.2 is een overzicht van de literatuur over de farmacokinetische interactie tussen 
calcineurineremmers en mycofenolzuur (mycophenolic acid; MPA), de actieve metaboliet 
van MMF. Er bestaat controverse over het effect van ciclosporine en tacrolimus op de MPA 
concentratie.12-15  Wij concluderen dat gelijktijdig gebruik van ciclosporine en MMF leidt tot 
een verlaging van de MPA concentratie, terwijl tacrolimus geen klinisch belangrijk effect op 
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de MPA concentratie heeft. Daarnaast postuleren we dat ciclosporine de blootstelling aan 
MPA verlaagt door remming van de biliaire excretie van haar metaboliet MPA-glucuronide 
(MPAG).
Het onderzoek naar het mogelijke pathofysiologische mechanisme dat ten grondslag ligt aan 
de interactie tussen ciclosporine en MPA wordt beschreven in Hoofdstuk 3.3. De hypothese 
was dat ciclosporine de biliaire excretie van MPAG remt door inhibitie van het “multidrug 
resistance-associated protein 2” (MRP2). Drie groepen van elk 10 ratten deficiënt voor Mrp2 
werden gedurende 6 dagen behandeld met placebo, ciclosporine, of tacrolimus. Op dag 7 werd 
tevens gestart met behandeling met MMF welke werd voortgezet tot en met dag 14. De 24-
uurs AUC (AUC
0-24
) van MPA en MPAG werd bepaald na een enkele (dag 7) en na meerdere 
giften MMF (dag 14). Op beide tijdstippen werd geen significant verschil in MPA of MPAG 
blootstelling gevonden tussen ratten behandeld met ciclosporine of tacrolimus. In een eerder 
onderzoek met normale ratten (d.w.z. ratten die Mrp2 tot expressie brengen) werden wel 
significante verschillen gevonden in MPA en MPAG blootstelling tussen ratten behandeld 
met of ciclosporine of tacrolimus (de blootstelling aan MPA en MPAG was respectievelijk 
lager en hoger in de met ciclosporine behandelde dieren).16 Onze resultaten suggereren 
derhalve dat ciclosporine-gemedieerde inhibitie van de biliaire excretie van MPAG door 
MRP2 het mechanisme is dat verantwoordelijk is voor de interactie tussen ciclosporine en 
MPA. Desalniettemin kunnen daarnaast ook andere mechanismen een rol spelen. MRP2 
komt tot expressie in de proximale niertubuli en ciclosporine-gemedieerde inhibitie van 
renale MPAG klaring zou de verhoogde MPAG concentraties in met ciclosporine behandelde 
patiënten kunnen verklaren. Een dergelijk mechanisme lijkt echter geen verklaring te bieden 
voor de verlaagde blootstelling aan MPA.17 Daarnaast suggereren recente experimenten in 
Wistar ratten dat ciclosporine wellicht ook de hepatische glucuronidatie van MPA remt.18   
Deel 4 van dit proefschrift handelt over de farmacogenetica van calcineurineremmers. Zoals 
eerder werd opgemerkt is de farmacokinetiek van deze geneesmiddelen sterk variabel tussen 
individuen. Deze verschillen zijn toegeschreven aan interindividuele variatie in de expressie 
van de drug transporter P-glycoproteïne en de cytochroom P450 (CYP) isoenzymen CYP3A4 
en CYP3A5 welke verantwoordelijk zijn voor het metabolisme van calcineurineremmers.19 
Recentelijk zijn verscheidene, zogenaamde “single-nucleotide polymorfismen” (SNPs) 
geïdentificeerd in de genen die coderen voor CYP3A4, CYP3A5 en P-glycoproteïne.20,21 
Wij onderzochten de mogelijkheid dat deze SNPs leiden tot een veranderde CYP3A of 
P-glycoproteïne expressie of activiteit, welke op haar beurt weer resulteert in verschillen in 
de farmacokinetiek van calcineurineremmers. 
Het doel van Hoofdstuk 4.1 was om te bepalen of genetische polymorfismen in CYP3A4, 
CYP3A5, en MDR-1 (het gen dat codeert voor P-glycoproteïne) gerelateerd zijn aan 
interindividuele variabiliteit in ciclosporine en tacrolimus blootstelling. Niertranspla
ntaatontvangers behandeld met ciclosporine (n = 110) of tacrolimus (n = 64) werden 
gegenotypeerd voor CYP3A4*1B en *3, CYP3A5*3 en *6, en MDR-1 3435C→T.  De voor 
dosis-gecorrigeerde C
0
 werd bepaald en vervolgens gecorreleerd met het genotype. De voor 
dosis-gecorrigeerde tacrolimus C
0
 was significant hoger in patiënten met het CYP3A5*3/*3 
genotype in vergelijking tot patiënten met het CYP3A5*1/*3 en *1/*1 genotype. De voor dosis-
gecorrigeerde tacrolimus C
0
 was ongeveer ⅓ hoger in de groep van patiënten die CYP3A5 tot 
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expressie brachten (patiënten met het CYP3A5 *3/*3 genotype). Dragers van een CYP3A4*1B 
allel hadden een lagere, voor dosis-gecorrigeerde tacrolimus C
0
 dan patiënten met het 
CYP3A4 wildtype (*1/*1). Er was geen relatie tussen het MDR-1 3435C→T polymorfisme 
en de tacrolimus dosisbehoefte. Geen van de bestudeerde polymorfismen was gerelateerd 
aan de voor dosis-gecorrigeerde ciclosporine C
0
. Wij concludeerden dat patiënten met het 
CYP3A5 *3/*3 genotype een lagere dosis tacrolimus nodig hebben om de C
0
 streefwaarden 
te bereiken, terwijl dragers van een CYP3A4*1B allel vergeleken met patiënten homozygoot 
voor CYP3A4*1, meer tacrolimus nodig hebben om de C
0
 streefwaarden te bereiken.
In Hoofdstuk 4.2 onderzochten wij waarom er door ons wel een correlatie tussen 
polymorfismen in CYP3A4 en CYP3A5 en de tacrolimus dosisbehoefte werd gevonden, 
terwijl een dergelijke relatie niet kon worden aangetoond voor ciclosporine (de belangrijkste 
bevinding van Hoofdstuk 4.1). Omdat beide CYP isoenzymen een belangrijke rol spelen in 
het metabolisme van zowel ciclosporine als tacrolimus, was onze hypothese was dat deze 
ogenschijnlijk tegenstrijdige bevindingen het gevolg waren van een (te) weinig gedetailleerde 
farmacokinetische analyse (namelijk de voor dosis-gecorrigeerde C
0
) waardoor een eventueel 
effect van het CYP3A genotype op de farmacokinetiek van ciclosporine mogelijkerwijs 
niet was gedetecteerd. Wij beschreven hiertoe de farmacokinetiek van ciclosporine bij 
151 hart- en niertransplantatiepatiënten op een onderhoudsbehandeling met ciclosporine 
met behulp van “non-linear mixed-effects modeling” (NONMEM) uitgaande van een 2-
compartimenten farmacokinetisch model met een eerste-orde absorptie en eliminatie. Alle 
patiënten werden gegenotypeerd voor de CYP3A4*1B en *3, CYP3A5*3 en *6, en MDR-1 
3435C→T polymorfismen. De orale ciclosporine klaring was 9% hoger onder dragers 
van het CYP3A4*1B allel in vergelijking met patiënten homozygoot voor CYP3A4*1. Dit 
effect was statistisch significant en bleek onafhankelijk van etniciteit. Toevoeging van het 
CYP3A4 genotype aan het NONMEM model leidde slechts tot een beperkte daling van de 
variabiliteit in orale ciclosporine klaring, wat impliceert dat het CYP3A4 genotype de sterke 
interindividuele verschillen in ciclosporine farmacokinetiek slechts voor een klein deel 
verklaart. Geen van de andere polymorfismen had een significant effect op de bestudeerde 
farmacokinetische parameters. Wij concludeerden dat dragers van een CYP3A4*1B allel 
een significant lagere orale ciclosporine klaring hebben dan patiënten homozygoot voor 
CYP3A4*1. Dit genetische effect op de farmacokinetiek van ciclosporine was echter beperkt 
en het bepalen van het CYP3A4 genotype bij transplantatiepatiënten lijkt derhalve geen 
toegevoegde waarde te hebben bij het bepalen van de dosis ciclosporine.
In Hoofdstuk 4.3 bediscussiëren wij de huidige status van de farmacogenetica binnen de tran
splantatiegeneeskunde. Farmacotherapie in deze tak van de geneeskunde wordt gekenmerkt 
door het frequent optreden van geneesmiddeleninteracties, toxiciteit en de noodzaak tot het 
nauwgezet controleren van de concentraties van de gebruikte geneesmiddelen om voldoende 
immunosuppressie te waarborgen. Farmacogenetica heeft het nodige enthousiasme onder 
transplantatieartsen gegenereerd aangezien het de potentie heeft om “de juiste dosering 
van het juiste geneesmiddel voor een individuele patiënt” te identificeren. In dit opzicht 
lijken polymorfismen in het MDR-1 en CYP3A5 gen momenteel het meest belovend. De 
MDR-1 3435C→T en 2677G→T polymorfismen lijken weliswaar een beperkte verklaring te 
bieden voor de interindividuele variabiliteit in calcineurineremmer farmacokinetiek, maar 
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zij kunnen mogelijk het risico op het ontwikkelen van calcineurineremmer-gerelateerde 
nefrotoxiciteit voorspellen. Het CYP3A5*3 allel, dat leidt tot de afwezigheid van functioneel 
CYP3A5 eiwit, is sterk gecorreleerd met de dosisbehoefte van tacrolimus maar niet die van 
ciclosporine. Patiënten die CYP3A5 tot expressie brengen (dragers van een *1 allel) hebben 
een hogere dosis tacrolimus nodig om hun streefspiegels te bereiken en hebben, wanneer dit 
niet wordt onderkend, mogelijk een hoger risico op het krijgen van een acute afstoting.   
KLINISCHE GEVOLGEN
Wat zijn de (klinische) gevolgen van onze bevindingen voor de individuele transplantatie 
patiënt? Ten eerste tonen onze resultaten aan dat het na meer dan 20 jaar van klinisch gebruik, 
nog niet duidelijk is wat de optimale strategie voor TDM van ciclosporine is. Ondanks 
het feit dat recentelijk is aanbevolen om ciclosporine op geleide van de C
2
 (of een andere 
“limited sampling” strategie) te doseren,7 zijn de onderzoeken waarop deze aanbeveling is 
gebaseerd sterk bekritiseerd.10,11,22 Het belangrijkste argument tegen het doseren op geleide 
van de C
2
 is dat er tot op heden geen gecontroleerde klinische onderzoeken zijn verricht 
die onomstotelijk hebben aangetoond dat een dergelijke strategie tot betere klinische 
uitkomsten leidt.10,22 In ons onderzoek kon geen ciclosporine concentratie-effect relatie 
worden aangetoond. Echter, vanwege de cross-sectionele opzet van dit onderzoek kan een 
eventueel verband tussen ciclosporine expositie en het optreden van bijwerkingen zijn 
vertroebeld. Patiënten die ciclosporine niet verdroegen werden mogelijkerwijs reeds eerder 
overgezet op een behandeling met tacrolimus of hun ciclosporine dosis werd gereduceerd. 
Het doseren op geleide van de C
2
 leidde niet tot enige klinisch relevante verbetering maar 
resulteerde mogelijk zelfs in immuunactivatie. Ondanks het feit dat de waarde van onze 
bevindingen beperkt wordt door het geringe aantal (geselecteerde) patiënten, suggereren zij 
dat het doseren van ciclosporine op geleide van de C
2
 of AUC
0-4
 geen voordeel biedt boven 
het traditionele doseren op geleide van de C
0
, in ieder geval niet bij stabiele patiënten die een 
onderhoudsbehandeling krijgen. In dit opzicht onderschrijven wij de mening van Campbell 
en Johnson10 dat “er momenteel te weinig wetenschappelijk bewijs is om het gebruik van C
2
 
monitoring te kunnen rechtvaardigen”. 
Ten tweede was tot voor kort het enige bewijs voor het bestaan van een farmacokinetische 
interactie tussen glucocorticoïden en tacrolimus, gebaseerd op in vitro onderzoek en 
dierexperimentele studies. Wij tonen aan dat ook bij de mens, gelijktijdig gebruik van 
deze geneesmiddelen resulteert in een lagere blootstelling aan tacrolimus. Deze bevinding 
is in overeenstemming met de recentelijk gepubliceerde bevindingen van twee andere 
onderzoeksgroepen.25,26 Daarnaast vormt het werk van Lemahieu et al. een bewijs voor het 
door ons geopperde mechanisme achter deze farmacokinetische interactie, namelijk inductie 
van het CYP3A-gemedieerde tacrolimus metabolisme door glucocorticoïden. De interactie 
tussen tacrolimus en glucocorticoïden lijkt klinisch relevant aangezien afbouwen van 
laatstgenoemde (hetgeen tegenwoordig gemeengoed is in de meeste transplantatiecentra) 
tot een verhoogde blootstelling aan tacrolimus kan leiden, mogelijkerwijs resulterend in 
nefrotoxiciteit, die ten onrechte geïnterpreteerd kan worden als een acute afstoting. Vice 
versa, kan een behandeling van een acute afstoting met een hoge dosis glucocorticoïden 
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leiden tot een verlaagde expositie aan tacrolimus welke mogelijkerwijs aanleiding geeft tot 
het onterecht vaststellen van een zogenaamde “glucocorticoïd-resistente” afstoting. Het lijkt 
derhalve geïndiceerd om de tacrolimus concentraties nauwkeurig te controleren gedurende 
het afbouwen van glucocorticoïden of tijdens een episode van acute afstoting.
Ten derde tonen wij aan dat het gelijktijdig gebruik van ciclosporine en MMF aanleiding 
geeft tot een verlaagde blootstelling aan MPA. Er lijkt geen belangrijke farmacokinetische 
interactie tussen MMF en tacrolimus te bestaan. Daarnaast hebben wij het mechanisme 
dat ten grondslag ligt aan deze interactie opgehelderd, namelijk een door ciclosporine-
gemedieerde inhibitie van de transporter MRP2 waardoor de biliaire excretie van MPAG 
wordt geremd. Daarom dient de MMF dosis bij patiënten die gelijktijdig met ciclosporine 
worden behandeld hoger te zijn dan bij patiënten die tacrolimus gebruiken om een voldoende 
hoge blootstelling aan MPA te waarborgen. Het staken van de ciclosporine behandeling of 
een conversie naar een op tacrolimus-gebaseerde immunosuppressieve behandeling kan 
leiden tot een verhoogde expositie aan MPA en daaraan gekoppelde toxiciteit. Ten slotte kan 
remming van MRP2 door ciclosporine ook belangrijke klinische consequenties hebben voor 
het (gelijktijdig) gebruik van andere geneesmiddelen.28
Uit onze farmacogenetische studies blijkt dat deze, zich snel ontwikkelende wetenschap 
behulpzaam kan zijn bij het individualiseren en optimaliseren van de behandeling met 
calcineurineremmers. Genetische screening van (toekomstige) transplantaatontvangers 
kan helpen bij het identificeren van patiënten met een verhoogd risico op het krijgen 
van bijwerkingen of onder-immunosuppressie. Deze hypothese dient echter in klinisch 
onderzoek prospectief te worden getest. Eén mogelijkheid om dit te doen is om patiënten 
op de wachtlijst voor een transplantatie te genotyperen voor CYP3A5 polymorfismen en de 
tacrolimus dosering hierop aan te passen. Op basis van onze data zou de tacrolimus dosering 
tussen de 30% en 50% hoger dienen te zijn in patiënten die CYP3A5 tot expressie brengen 
in vergelijking met patiënten die geen functioneel CYP3A5 eiwit bezitten. Een dergelijke 
strategie zou ertoe kunnen leiden dat de tacrolimus streefspiegels sneller worden bereikt 
en de incidentie van acute afstoting lager wordt. Echter, gezien de lage allelfrequentie van 
deze polymorfismen in Caucasische en Aziatische populaties, en de lage rejectie incidentie 
die met de huidige immunosuppressieve behandelingen wordt gerealiseerd, zou er voor een 
dergelijk onderzoek een groot aantal patiënten nodig zijn om voldoende onderscheidend 
vermogen te hebben. Hopelijk zijn de verschillende transplantatiecentra bereid de krachten 
te bundelen om een dergelijk onderzoek uit te voeren. Tot slot is het op dit moment niet 
duidelijk waarom polymorfismen in CYP3A en MDR-1 wél zijn geassocieerd met de 
farmacokinetiek van tacrolimus maar niet met die van ciclosporine. De relatieve bijdrage 
van de verschillende CYP3A isoenzymen en MDR-1 polymorfismen aan de farmacokinetiek 
van calcineurineremmers, hetgeen tot op heden alleen in vitro en met behulp van lever 
microsomen is bestudeerd, dient derhalve ook te worden onderzocht bij getransplanteerde 
patiënten in de alledaagse praktijk.29-32
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 CONCLUSIES
1. De expositie aan ciclosporine, gemeten met de AUC
0-4
, is niet gecorreleerd met het 
optreden van ciclosporine-gerelateerde bijwerkingen bij ontvangers van een solide 
orgaantransplantaat op een onderhoudsbehandeling met ciclosporine.
2. Het doseren van ciclosporine op geleide van de C
2
 bij stabiele levertransplantatiepatiën
ten leidt niet tot een verbetering van de nierfunctie en is geassocieerd met een risico op 
immuunactivatie.
3. Gelijktijdig gebruik van glucocorticoïden en tacrolimus verlaagt de blootstelling aan 
tacrolimus.
4. Gelijktijdig gebruik van ciclosporine en mycofenolaat mofetil resulteert in een verlaagde 
blootstelling aan mycofenolzuur, terwijl tacrolimus geen klinisch relevant effect heeft 
op de mycofenolzuur concentraties.
5. De interactie tussen ciclosporine en mycofenolzuur wordt veroorzaakt door ciclosporine-
gemedieerde inhibitie van het multidrug resistance-associated protein 2 waardoor de 
biliaire excretie van mycofenolzuur-glucuronide wordt geremd.
6. Patiënten die CYP3A5 tot expressie brengen hebben een hogere dosis tacrolimus nodig 
om de tacrolimus streefspiegels te bereiken in vergelijking met patiënten die CYP3A5 
niet tot expressie brengen. Genetische screening van transplantatiepatiënten op CYP3A5 
expressie kan derhalve behulpzaam zijn bij het vaststellen van de optimale individuele 
tacrolimus dosis.
7. Genetische polymorfismen in CYP3A4, CYP3A5, en MDR-1 hebben geen klinisch 
relevant effect op de farmacokinetiek van ciclosporine. Het genotyperen van 
transplantaatontvangers op CYP3A en MDR-1 is dus niet behulpzaam bij het vaststellen 
van de (start)dosis ciclosporine.
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ABBREVIATIONS
ABC   ATP-binding cassette
ATP  Adenosine triphosphate
AUC  Area-under the concentration versus time-curve
C
0
  Predose concentration
C
max
  Peak concentration
CAN  Chronic allograft nephropathy
Cl  Clearance
CN  Calcineurin
CNI  Calcineurin inhibitor
CV  Coefficient of variation
CYP  Cytochrome P450
F  Bioavailability
FKBP  FK-binding protein
IFN  Interferon
IL  Interleukin
MHC  Major histocompatibility complex
MMF  Mycophenolate mofetil
MPA  Mycophenolic acid
MPAG  Mycophenolic acid-glucuronide
MRP2  Multidrug resistance-associated protein 2
NFAT  Nuclear factor of activated T cell
P-gp  Permeability glycoprotein
PLC  Phospholipase C
PTDM  Post-transplant diabetes mellitus
SNP  Single-nucleotide polymorphism
TCR  T cell receptor
TDM  Therapeutic drug monitoring
TGF-β  Transforming growth factor-β
t½  Half-life
t
max
  Time-to-peak concentration
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een rituele verbranding van de artikelen is het gelukkig niet gekomen en uiteindelijk was er 
witte rook. Dit proefschrift is grotendeels jouw geesteskind. Het belangrijkste bij het doen 
van onderzoek is het stellen van de juiste vraag en ik denk dat jij dit talent in ruime mate 
bezit. Het siert je dat je dat op mij hebt laten afstralen. Ik hoop dat we in de toekomst de 
samenwerking kunnen voortzetten en dat je me daarnaast het transplantatievak bijbrengt. 
Over gemeenschappelijke reisjes en bezoeken aan duistere kroegen zal ik hier nu niet verder 
uitweiden.
Professor Weimar, beste Willem. Je prikkelende cynisme is al eens eerder op deze plaats 
gememoreerd. Mij heeft dat karakter bijgebracht en geleerd om zeer kritisch naar (mijn 
eigen) onderzoeksresultaten te kijken, iets wat veelal te weinig gebeurt. Bovendien denk ik 
dat als jij niet als de spreekwoordelijke rode lap had gefungeerd, mijn publicatielijst een flink 
stuk korter zou zijn geweest. Ik waardeer het zeer dat je akkoord bent gegaan met een boekje 
dat niet over dendrieten maar over spiegels handelt. 
Professor Lindemans, beste Jan. Dank voor de snelle en correcte afhandeling van alle 
administratie en formaliteiten rondom mijn grote dag. Ik ben blij dat jij vandaag achter de 
tafel aanschuift aangezien een belangrijk deel van het hier beschreven werk op het AKC is 
verricht. Maar al te vaak is een goede samenwerking (laat staan synergie) tussen het lab en 
de kliniek ver te zoeken.
Professor IJzermans, beste Jan. Ik ben blij dat ook jij, als een van de steunpilaren van het 
Rotterdamse transplantatieprogramma, je hebt verdiept in mijn “gestolde ijver”. Ik hoop in 
de nabije toekomst het nodige van je te leren.
Professor Smits, beste Paul. Hartelijk dank voor het beoordelen van het proefschrift en je 
deelname aan de oppositie.
Professor Vulto, beste Arnold. Ik ben blij dat jij, als geestdriftig pleitbezorger van de 
geïndividualiseerde farmacotherapie, achter de grote tafel plaats neemt. Verder wil ik je 
danken voor de gastvrije ontvangst in de apotheek. 
Professor Pols, beste Huib. Onze voorgeschiedenis gaat terug tot mijn co-assistenten examen 
toen je me aan de tand voelde over de bezinking en me onderhield over osteoporose bij de 
Komodo varanen in onze diergaarde. Ik waardeer het zeer dat je, na me te hebben toegelaten 
tot de opleiding interne geneeskunde, meermalen hebt toegestemd in het omgooien van 
mijn opleidingsschema zodat ik onderzoek kon doen. 
Professor Kuypers, beste Dirk. De Leuvense groep loopt voorop in de transplantatiewereld 
en ik wil je bedanken voor je komst naar Rotterdam en je deelname aan de oppositie. Laten 
we de goede samenwerking in de toekomst voortzetten. 
Vele anderen hebben de laatste jaren een bijdrage geleverd aan dit boekje en mijn vorming in 
bredere zin. In de eerste plaats wil ik de medewerkers van de diverse transplantatieafdelingen 
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bedanken. Peter Smak Gregoor bedank ik voor het wegwijs maken in de transplantatieg
eneeskunde en de statistiek en vooral voor de vele grappen. Jacqueline Rischen-Vos voor 
het mogen gebruiken van haar computer en de psychotherapie. Michiel Betjes voor de vele 
inspirerende discussies over dendritische cellen en de hogere zaken van het leven. Daarnaast 
de andere nefrologen, staf- en polikliniek medewerk(s)ters voor de hulp bij het includeren 
van niertransplantatiepatiënten en vele hand- en spandiensten. Aggie Balk en de dames 
van de polikliniek harttransplantatie, Herold Metselaar, Lara Elshove, Anneloes Wilschut, 
Thanyalak Tha-In, Huug Tilanus, en vele anderen van het levertransplantieteam, Hien 
Nguyen, Marike Wabbijn,  alsmede Peter van Hal, dank ik eveneens voor het enthousiasmeren 
van de vele patiënten voor deelname aan mijn onderzoek en de prettige samenwerking.
Ik wil op deze plaats de vele patiënten bedanken die vrijwillig instemden met deelname 
aan mijn onderzoek en van heinde en verre afreisden naar Rotterdam. De respons was 
overweldigend. Daarnaast hebben de lange gesprekken tussen het bloedtappen door me 
geleerd dat orgaandonatie een daad van ware liefde is. 
Naast de diverse klinische afdelingen is veel werk gedaan op het AKC en met plezier richt ik een 
speciaal woord van dank aan Ron van Schaik. Beste Ron, regelmatig heb je me tot wanhoop 
gedreven wanneer je een “final version” van een of ander paper plotseling doordrenkt in 
rode inkt en vlak voor de deadline weer op mijn bureau deed belanden. Uiteindelijk zijn de 
stukken daar natuurlijk altijd beter van geworden en hebben we daar beide ons voordeel 
mee gedaan. Het Erasmus MC mag zich gelukkig prijzen met een Pharmacogenetics Core 
Lab. Verder wil ik Marloes van der Werf, Ilse van der Heiden en Marianne van Fessem 
danken voor de vele genotyperingen.
De derde poot van mijn promotieonderzoek is de apotheek geweest en ik ben veel dank 
verschuldigd aan dr. Ron Mathôt. Beste Ron, ik hield al niet van “creatief afronden” maar als 
iemand me heeft geleerd om de analyse van data zo zuiver mogelijk te doen, dan ben jij het 
wel. De klinische farmacologie is naar mijn smaak nog steeds een ondergewaardeerd vak, 
ook binnen de interne geneeskunde. De complexiteit van de farmacokinetiek en -dynamiek 
ben ik mede door jou enorm gaan waarderen (het kopje “interacties” in het Kompas durf ik 
tegenwoordig niet meer over te slaan). 
De meeste onderzoekstijd heb ik doorgebracht op het transplantatielaboratorium. Een 
speciale vermelding ben ik verschuldigd aan Thea van Dam. Lieve Thea, wie had kunnen 
denken dat we jaren na het bekijken van diffjes en sedimentjes op 3 Noord nog eens samen 
achter de Cobas zouden zitten? Anderen die het regelmatig met mijn driftbuien hebben 
moeten stellen waren de roomies van het eerste uur, Cécile, Petros, en Martijn (Tijneman). 
Ik mis het voetbal! Gelukkig heb ik ook veel gelachen met jullie “opvolgers” Esmé, Jeroen en 
Thijs. Carla Baan dank ik voor de leuke uitjes met het lab, de vele monoklonalen en lessen 
over de transplantatieimmunologie. Ik denk nog steeds dat immunomonitoring de juiste 
weg is. Nicole van Besouw, Barbara van der Mast, Len Vaessen en Cees Hesse wil ik vooral 
danken voor de skilessen, calibratiecurves en de monologen over chemokines, CTLps en 
rode wijn. Ronella, Mariska, Joke, Corné, Wenda, Annemiek, Wendy, Nicolle, Sander, en 
Jurjen voor het leren FACSen, kweken (een beetje) en ficollen (not!).
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Jeroen Nauta dank ik voor het in mij gestelde vertrouwen en het geduld waarmee jij en 
Miriam me wegwijs hebben gemaakt in het lab. Het had weinig gescheeld of ik was kinderarts 
geworden. Hopelijk krijg ik in de toekomst ruimte voor wat verdieping in de nier van de 
kleine patiënt. De internisten van het Clara ziekenhuis en in het bijzonder René van den 
Dorpel en Albert Grootendorst, dank ik voor het leren drijven. Op opmerkingen als “even 
logisch nadenken, dokter Dennis” zat ik niet altijd te wachten maar ik heb er uiteindelijk toch 
mijn voordeel mee gedaan. Ik zie er naar uit om in 2009 weer in de leer te komen. Tom Swaak 
dank ik voor het aanwakkeren van de liefde voor de autoimmuunziektes en met name SLE. 
Mentoren die je laten struikelen als dat nodig is maar voorkómen dat je in het ravijn stort 
zijn zeldzaam. In dit opzicht wil ik ook Martin van Hagen bedanken. De internisten van het 
Havenziekenhuis, in het bijzonder Pieter Wismans en Perry van Genderen, dank ik voor de 
warme sfeer, de vele wijze lessen, en het bijbrengen van een diep respect voor Plasmodium 
falciparum. Ik had me geen betere plaats voor mijn klinische come-back kunnen wensen. 
Ron de Bruin en Fred Bonthuis dank ik voor de geweldige tijd in het hol van de leeuw. 
Stefan Sleijfer omdat hij me “groot heeft gemaakt”. Ewout Steyerberg en Wim Hop voor hun 
hulp bij de statistische analyses.
Mijn paardenimf Reinier wil ik bedanken voor zijn kritiek, geduld (hoe vaak heb je me 
niet de definitie van Vd gesouffleerd?) en voor het fungeren als Klaagmuur. Van collega 
ben je vriend geworden. Mark, van “eten en gegeten worden” tot senaatszaal en vandaag 
collegezaal 7. Al meer dan 20 jaar mijn beste vriend. “Salud!”
Mijn ouders en mijn zus kan ik niet genoeg bedanken. Ondanks alle liefde, zag het er een 
aantal jaren geleden -tot vlak voor de spreekwoordelijke schop onder het achterste- niet goed 
uit. Dat ik uiteindelijk toch dokter2 Dennis ben geworden mogen jullie jezelf aanrekenen.
Als laatste dank ik mijn 3 meisjes Judith, Sophie en Juliette. Jullie zijn het belangrijkste in 
mijn leven. Ik hou zielsveel van jullie.
D.H.
Rotterdam, mei 2007
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